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Design and synthesis of peptide and protein-based 
ATRP initiators 
Oluwafemi Atoloye, university of Durham, Durham. 
D.Phil., Sept 2005 
A series of novel hetero-bifimctional linkers fimctionaUsed as ATRP initiators 
and protein and peptide-reactive agents has been prepared using standard 
synthetic teclmiques. A protein-based initiator has been applied to the initiation 
of living polymerisation in the synthesis of a novel bioconjugate. 
The linkers were designed based on the properties of polyethylene glycol and 
short alkyl chains coupled to either amine selective or thiol selective moieties for 
chemoselectivity, and bromoisobutyryl esters to facilitate atom transfer living 
polymerisation. 
The bi-fimctional linkers have also been coupled to short peptides based on the 
RGD bio-recognition sequence synthesised by standard solid phase peptide 
synthesis and the protein. Human Serum Albumin (HSA) using standard 
conditions to prepare peptide/protein-based ATRP initiators. 
Attempts at fimctionaUsing peptides with the N succinimidyl 4-(2-bromo-2-
methylpropionyloxy)butanoate linker were unsuccessful. 
Model test of the protein based ATRP initiators in living polymerisation towards 
a novel strategy for bioconjugate synthesis was inconclusive as premature 
termination of the polymer chain was observed by MALDI analysis. 
V I 
APPENDIX 
Research Conferences Attended 
Sep 2004 Celebration of Organic Chemistry, Warwick University, UK * 
May 2004 3"* Year PhD Presentation, University of Durham, UK * * 
May 2004 Boron Chemistry, University of Durham, UK 
Apr 2004 RSC North East, Organic Division, University of Leeds, UK 
Mar 2004 Avecia Poster Competition, University of Durham, UK 
Mar 2003 Peridn Division, North East, Regional Meeting, University of 
Newcastle upon Tyne, UK 
Dec 2002 Modem Aspects of Stereochemistry, Sheffield University, UK 
Apr' 2002 Pericin Division, North East Regional Meeting, University of York, UK 
Dec 2001 Modem Aspects of Stereochemistry, Sheffield University, UK 
** 
Poster presentation by the author 
Oral presentation by the author 
1 C H A P T E R 1. 
1.1 Introduction 
1.2 Conjugation_ 
13 Bioconjugates . 
1.3 .1 The Principles of Con jugation ' 
1.3.2 Drug conjugation to macromolecules 10 
1.3.3 Peptide/Protein - Polymer Bioconjugates. 11 
1.4 Advantages of Polymer Bioconjugates , 14 
1.41 Introduction — _ 14 
1.4.2 Diagnostic tools and Immunoassays 16 
1.4.3 Gene Therapy 16 
1.4.4 Controlled Release 1* 
1.4.5 Targeted Delivery 20 
1.5 Bioconjugate Assembly (Peptide Conjugation)^ 22 
1.5.1 Strategy for Conjugate Assembly 22 
1.5.2 Biological Hetero-bifunaional Reagents. 24 
1.5.2.1 Types and Examples of Linker Units 24 
1.6 Living Radical Polymerisation and Macromolecules. 28 
1.6.1 Macromolecules as Drug Carriers ] 28 
1.6.2 Living Radical Polymerisation - Classificatioa 30 
1.6.3 Nitroxide-Mediated Radical Polymerisation (NMRP) 33 
1.6.4 Reversible Addition-Fragmentation Transfer (RAFT) 35 
1.7 Atom Transfer Radical Polymerisation (ATRP-), 37 
1.7.1 Introduction 37 
1.7.2 Mechanism _37 
1.7.3 Components and their Influence on ATRP 38 
1.7.3.1 Monomers . _3* 
1.7.3.2 Catalysts (transition metals) and Initiators^ _ _ 4 1 
1.7.3.3 Initiators^ 42 
1.7.3.4 Other Factors (Solvent, Temperature) . 4^5 
1.8 Block Copolymers 46 
1.8.1 Synthesis 46 
1.8.2 Properties of Block Copolymers 4^7 
1.9 Project Strategy 50 
1.9.1 Design and Synthesis of ATRP taitiator/linker reagents 50 
1.9.2 Structure of the Linkers ^  50 
1.9.2.1 Polymerisation 51 
1.10 References 
2 C H A P T E R 2 6^3 
2.1 Introduction 64 
2.1.1 AIMS • 65 
2.2 Synthesis of succinimidyl /amine-reactivc diester - ATRP initiator/linkers 66 
2.2.1 Section A. Attempted synthesis via 3 bromopropionic acid 66 
2.2.2 Attanpted synthesis via 3-hydroxypropionic acid _67 
2.2.2.1 Synthesis of 3-hydoxypropionic acid 68 
2.2.3 Attempted synthesis of 3-(2-bromo-2-methylpropionyloxy)propionic acid 70 
2 J Synthesis of succhiimide substituted n-butyiester 73 
2.3.1 Synthesis ofp-mdhoxybenzyl 4-hydroxybutanoate 73 
2.3.2 Synthesis of 4-methoxybenzyl 4-(2-bromo-2-methylpropionyloxy)birtanoaie 75 
2.3.3 Synthesis of N-succinimidyl 4-(2-bromo-2-methylpropionyloxy)biitanoate 76 
2.4 Section B: Synthesis of a-methosy masiwd diester 78 
2.4.1 Introduction 78 
2.4.2 AIMS _78 
2.4.3 Synthesis of N-Succinimidyl 2-methoxy-2-methylpropionate 79 
2.4.4 Model conversion using organoborane reagents. Part 1 81 
2.4.4.1 Attempted synthesis of a-bromoisobutyry! ester from a-methoxyisobutyryl 
units using organoborane reagents. 81 
2.4.5 Model conversion using organoborane reagents. Part 2. 84 
2.5 References 86 
3 C H A P T E R 3 .87 
3.1 Introduction 88 
3.1.1 AIMS 88 
3.2 Synthesis of carboxymethyl ester substituted PEGs as reagents for ATRP 90 
3.2.1 Synthesis of benzyl diazoacetate (via diazo transfer agent) 90 
3.2.2 Monofunctionalisationof ethyleneglycol 91 
3.2.3 Deprotection of (a-bromoisobutyryl)benzyl decanoate 92 
33 Synthesis of 'butyl diazoacetate (via diazo transfer agent) 95 
3.3.1 Synthesis of the series of ATRP initiators. 96 
3.4 Investigated synthetic strategies as masking substitute for a-bromoisobutyryi unit 
99 
3.4.1 Silyl electrophile based attempts 99 
3.4.2 Sulphuryl based attempts 102 
3.4.2.1 Molecular bromine based bromination strategy 103 
3.4.2.2 N-Bromosuccinimide based bromination strategy 105 
3.4.3 Model functionalisation of isopropyl untt by NBS 106 
3.5 References 109 
4 C H A P T E R 4 110 
4.1 Introduction H I 
4.2 Synthesis of P E G based maleimide/ttiiol-reactive linkers as ATRP initiators linker 
unit 112 
4.2.1 Synthesis of a flinctionalised PEG for dimethylamino substrates 112 
4.2.2 Synthesis of a tertiary amine substituted PEG 114 
4.2.2.1 Synthesis of a tertiary amine via a modified Gabriel reagent 114 
4.2.2.2 Synthesis of a tertiary amine substrate via an altwnative method 118 
4.2.3 Attempted synthesis of dimethylammonium substituted maleimides 119 
4.2.4 Synthesis of aJV-substituted alkyl maleimide . 120 
4.2.5 Synthesis of a biftinctional //-substituted alkyl amino maleimide 126 
4,2.5.1 Model quatemisation reaction 127 
4 J Coupling of selected linkers to peptides and proteins. 134 
4.3.1 Introduction 134 
4,3.1.1 Peptide synthrais 134 
4.3.2 Synthesis of Peptide-initiator complex 135 
4.3.3 Synthesis of Protein (HSA)-initiator complex 136 
4.3.4 Model polymerisation of protein-initiator complex 137 
4.4 Summary 139 
4.5 References _ 1 4 0 
5 C H A P T E R 5 - EXPERIMENTAL 140 
5.1 General Procedures 1'*^  
5.2 Compounds from Chapter 2 
53 Compounds from Chapter 3 . 155 
5.4 Compounds from Chapter 4 167 
5.5 References 1'* 
111 
Chapter 1 
G E N E R A L ESfTRODUCTION 
Introduction 
1.1 Introduction 
Increased bioavailability of active agents in a diseased area w i l l not only 
reduce toxicity in healthy cells; higher drug efficacy w i l l be expected as 
well. Therefore various combinations of means for effective delivery, 
stabilisation and localisation of administered drugs have been 
investigated by scientists. Perhaps the most versatile and modern 
approach involves the use of water-soluble biopolymers with targeted 
interactions. Biopolymers are (in general) polymers conjugated to one or 
more recognition molecules which are usually bioactive (or mimics) for 
targeted delivery - they are sometimes referred to as "smart" conjugates 
when coupled macromolecules synergistically respond to external stimuli 
while exhibiting a particular and/or expected state of readiness, usually 
site-recognition. These bioactive molecules can be proteins, 
oligosaccharides, phospholipids, and other synthetic molecules, which 
because of their large size promote a prolonged half- l i fe and efficient 
accumulation in the affected area. These unique properties of polymeric 
conjugates result in improved efficacy and make them effective tools for 
therapeutic studies. This had already been reviewed by Ringsdorf' in 
relation to polymer-anticancer drug conjugates before the novel 
developments in polymerisation techniques. The components and concept 
of bioconjugation in association with potentially novel therapeutics 
available by l iving polymerisation techniques w i l l hence be explored. 
1.2 Conjugation 
While the focus of traditional approaches to pharmaceutical research is 
on the discovery of new compounds, one of the frequent problems with 
this approach is the almost ubiquitous association with low drug efficacy 
arising from the low molecular weight, low solubility and consequently 
low-bio-distribution, resulting in high toxicity. However, by conjugation 
of drugs to other macromolecules, increased efficacy and inter-entity 
Conjugation 
cooperation can be employed to improve on current drugs. The principle 
of cooperation takes advantage of the ability to design, synthesise and 
modify natural and synthetic macromolecules with the required, perhaps 
novel characteristics (micellisation or hydrogel formation), to improve, 
for example, drug bioavailability within the bloodstream or increased 
half-life of a reporter molecule by introducing better targeting capability. 
A recent illustration is the development of nanocrystal technology, which 
originally had little biomedical value, until conjugated, yet has already 
brought about the development of a new area of biomedical science. 
Quantum Dots^ (Qdot®) are nanoscopic inorganic crystals with cores of 
cadmium sulfide (CdS), cadmium selenide (CdSe), or cadmium telluride 
(CdTe); their bioconjugates are Qdot nanocrystals coupled to small 
biomolecules^ (sugars, proteins, etc) to aid site-specific recognition as a 
replacement for conventional dyes to achieve lower limits of detection, 
greater quantitative results, and more photo-stable samples. Due to their 
remarkable fluorescence-imaging sensitivity and the small quantities 
required, they can have biomedical use. The advantages of 
bioconjugation become more obvious when two different types of 
macromolecules are involved, such as drug conjugates and 
peptide/protein conjugates (further discussed in section 1.3) or 
oligonucleotides with fluorescence dye'*, metal chelates^ photochemical 
6 7 8 
crosslinkers , redox probes or lipids . 
However, as enhanced capabilities are realised in the preparation of 
conjugates of drug and polymeric macromolecules with well defined 
structures, greater directions are being sought from biologically 
compatible systems (or mimetics) leading to the formation of biologically 
active conjugates (bioconjugates). Therefore convenient synthetic 
methods for the preparation of simple organic bioconjugates are of 
importance. They also include chemical tools which can aid the 
amalgamation of two or more complex substrates covalently. 
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The different areas of research into conjugation have contributed 
different specialised reagents to the pool of bioconjugation reagents from 
which certain methods and reagents are generally used or associated e.g. 
radio-labelling, purification, assay development or protein chemistry. 
Due to continued advances in protein chemistry, it has been possible to 
chemically modify proteins and peptides in order to protect or 
functionalise substrates effectively for use in conjugation using a variety 
of reagents. 
Chemically reactive groups have helped to crosslink various compounds 
depending on their eventual use and the associated advantages resulting 
in sequence-selective crosslinking (see section 1.5.2 for definition and 
details) or cleavage of linkages. For the past 15-20 years, there have been 
a plethora of functional groups capable of crosslinking but few have 
become standard reagents. Some examples are shown in (Table 1): 
> Thiol-selective reagents - using i.e. the thiol of cysteine to 
covalently conjugate with either a maleimide or a pyridiyl 
disulphide respectively, iodoacetal being the most active. 
Hence selectivity is highly dependent on the pH of reaction. 
I f no such residues are available i.e. in a native protein, 
thiol group can be incorporated with Traut's reagent (2-
iminothiolane^). 
> Amide bond formation using a primary amine and activated 
carboxylic acids e.g. succinimide and aminooxyacetamide 
esters; or hydrazine/amine with carbonyl (i.e. aldehyde) to 
form a condensation product hydrazone before hydride 
reduction. 
> Biotin / Avirdin - a non covalent coupling (by association) 
using the ligand biotin and avirdin associated to a receptor 
protein, particularly useful in the detection and localisation 
of antigens, glycoconjugates, and nucleic acids by 
employing biotinylated'° antibodies, lectins, or nucleic 
acid" agents. 
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Table 1. Examples of functional groups /reagents for bioconjugation. 
Reagents Selectivity Product Examples/Refs 
lodoacetamide 
Thiol 
0 
12,13,14 
Maleimide 
o 
A 
N R 
R , S ^ \ ^ 
0 
15,16,17,18 
N-hydroxy 
succinimide 
Amine 
0 
19 
Thiol 
Disulphide 
(Cystine) 
20,21,22,23 
Aldehyde 
Aminooxy 
R H 5 
24, 25,26 
Amine R - ' ^ ^ N ^ I ^ 
H ^ 
Hydrazone 
then reduction 
Aldehyde R NH N ' ' ^ ' ^ ^ ^ 
H 
16,27,28 
Notably, various promising gene and protein-related drugs are limited by 
their inability to penetrate the cell membrane and be delivered inside the 
cell. In order to enhance the effectiveness of any drug, an appropriate 
conjugation methodology to improve targeting and the mode for sustained 
release of the active drug are most often considered. 
Conjugation 
Hence the use of linkers has become prevalent for aiding the targeting 
and release mechanisms in drug and diagnostic studies of disease states. 
However, there is still a great demand for more robust methods or 
alternatives, to compensate for problems that arise in the 
biofunctionalisation and subsequent conjugation of polymers. In 
particular, the harsh reaction conditions that are often required tended to 
lead to the degradation and inactivation of sensitive biological 
compounds or drugs. Moreover, the synthesis of stoichiometrically 
defined polymers - macrobiomolecule conjugates - is a challenge, and is 
particularly important from a biomedical point of view to generate well-
defined (architecture and composition) macromolecules, and the methods 
and material to achieve such macromolecules are now more varied and 
better developed - especially with the advent of l iving radical 
polymerisation. 
Bioconju^ates 
1.3 Bioconiuaates 
1.3.1 The Principles of Conjugation 
The rationale for conjugating a drug or other low molecular weight entity 
to a macromolecule for biomedical use is that the resultant increase in 
molecular weight significantly alters the biodistribution of the active 
agents in the conjugate and curtails the indiscriminate uptake of the drug 
into cells, thus achieving targeting at either tissue or cellular levels. This 
not only improves the therapeutic index of an otherwise toxic drug, but 
also obviates the need for repeated high doses (predictable drug strategy, 
drug uptake and activity). The polymer-drug conjugate exhibits 
decreased clearance—this prolonged circulation provides sufficient time 
for the polymer-drug conjugate (better pharmacokinetics and 
biodistribution) to reach and concentrate at its target site^^, a strategy 
already employed in various commercially available drug conjugates 
often associated with the enhanced permeation and retention effect of the 
increased molecular weight. 
Camptothecin (CPT) derivatives^" have advanced to become 
standard components in the treatment of several malignancies. However, 
as a class of anti-cancer compounds, camptothecins pose many challenges 
that need to be overcome before they can be widely used in anticancer 
therapy. One of the principal chemical features of this class of agents is 
the presence of the lactone functionality, which is not only essential for 
anti-cancer activity, but also confers a degree of instability to these 
agents in aqueous solution. 
A variety of different strategies are being investigated to modulate 
the systemic delivery of CPTs, such as the development of prodrugs and 
polymer conjugates^'. Among all the approaches currently under 
investigation, the polymer conjugates have been studied the most since 
they can lead to alterations in biological distribution, longer retention 
times within the body, reduction in systemic toxicity and improvements 
in therapeutic efficacy. There are several types of CPT-Polymer 
conjugates reported in the literature to overcome the delivery challenges 
Bioconjugates 
such as poly-(L-glutamic acid)-CPT^^ HPMA co-polymer-CPT", PEG-
CPT^^ cyclodextrin-CPT^^ and carboxymethyl dextran-CPT^^ The 
immediate goal of these approaches is often focused on the treatment of 
dose-limiting toxicity in tumors^^. Targeted delivery systems to cell 
surface receptors^*'^^ is another approach that could be used in order to 
treat diseased cells but spare healthy ones. One o f the more studied 
approaches utilises macromolecules. In general, conjugation of natural 
(protein, polysaccharides, DNA etc) and synthetic polymer 
macromolecules (which exist in various forms: emulsions, hydrogels, 
adsorbed or grafted on a surface or dissolved in solution) to carefully 
selected biopolymers or drugs provides improved drug stabilisation, 
cytotoxicity, solubility, localisation and controlled release with direct 
implications on efficacy. Bioconjugation approaches'* '^'*' to therapeutic 
studies have therefore recently focussed on the development of 
biocompatible functional polymers of different architecture provided by 
versatile and robust polymerisation techniques. These further allowed 
access to the variety of molecular organisation required to produce 
sophisticated bioconjugates. 
Although scientists have always explored the possibilities that 
macromolecule conjugation can afford, only recently has the term "bio-
conjugation" been introduced to describe the amalgamation (either by 
physiosorption or covalent association) of biological moieties to 
synthetic macromolecules to develop novel polymers'*^ with specific 
biological capabilities"^. In addition, the non-selective nature of many 
drugs and their resulting toxicity has been a major hindrance in 
biomedical approaches to the treatment of various diseases (e.g. cancer). 
As a result, various potential anticancer drugs have now been re-
engineered via conjugation to create novel chemotherapy (i.e. 
immunotoxins'*'*) and tumour-selective cytotoxic conjugates with 
polymeric carriers'*^ and targeted with carbohydrates or antibodies to 
reduce toxicity to non-cancerous cells during chemotherapy. However, 
since polymeric material can be engineered with in-built but predictable 
mechanical properties as necessary for the various biomedical 
requirements by effecting simple principles for conjugation. The various 
Bioconjugates 
combinations of method of conjugation have already been shown to offer 
benefits to potential drug candidates; such as 
1. Esterification of functional groups on drugs'*^ (aspirin, ibuprofen 
with PEG; or CPT) with a simple polymer stabilises some drugs in 
their active state, which may otherwise be hydrolysed under 
physiological conditions leading to inactive or toxic by-products 
2. The use of hydrophilic polymers leads to highly water-soluble 
formulations of conjugates of low/high molecular weight with 
hydrophobic substrates for greater bio-distribution (EPR effect). 
3. Incorporation of spacer/linker units ensures ease of conjugation to 
sites deep below the surface of macromolecules and a controlled 
release o f drug in response to stimulus. 
Despite the sophistication and prominence shown by conjugation 
techniques, inappropriately designed components can often still lead to 
bioconjugates o f insufficient stability or adversely altered antigenic 
properties of substrates (i.e. peptides'*^) due to the inappropriate design 
and method of construction of intended substrates, even with the 
application o f commonly used conjugation components and methods. 
However, as scientists learn more about disease progression and the 
function(s) of specific natural biomolecules in any given process, the 
more prominent the role of bioconjugates as therapeutics and diagnostic 
tools has been in understanding the precise and required design of 
conjugates. However, one of the more prominent hurdles in 
bioconjugation is the high reactivity of some molecules, such as protein 
and nucleic acids, because of their varied reactive sites and the 
difficulties of chemoselectivity'*^ and this has therefore been more 
routinely studied. 
As such, there are only a few classes of compounds that enjoy 
routine use as substrates for conjugation and they include proteins and 
low molecular weight drugs. For this reason, this discussion w i l l focus on 
the conjugation methods and reports pertaining to these classes of 
biologically important molecules. 
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1.3.2 Drug conjugation to macromolecules 
There are more than 200 different types of cancer, but four of them -
breast, lung, large bowel (colorectal) and prostate - account for over half 
of all new cases. 
OMe O Q OH 
HO 
NHR 
OH 
R = H , Doxorubicin (DOX H C I ) 
R = PEG (i.e Doxil) 
Figure l . l : Structure of an anticancer drug already in use but with high toxicity. 
Doxorubicin'" (Adriamycin) is an anthracycline antibiotic with a broad 
spectrum anti-cancer capability used to treat many types of tumour by 
inhibiting cell growth and inducing cell death. Unfortunately, side effects 
from doxorubicin include nausea and vomiting which may last up to 24-
48 hours after treatment, loss of appetite, d i f f icul ty swallowing, thinned 
or brittle hair and skin irritation. 
The poly(ethylene glycol)-modified derivative of doxorubicin 
"DOXIL®" encapsulated with liposomes^°'^' (polymeric carriers) to reduce 
the side effects via non-specific drug delivery has found use in the 
treatment of Kaposi sarcoma (a type of cancer common in HIV victims) 
and is recommended to patients with low tolerance to traditional 
chemotherapy treatments because of side effects. The main side effects 
associated with the modified drug are heart problems and neutropenia 
(low white blood cell count). While liposomal encapsulation was the 
simplest and initially the most widely used form of drug delivery system 
used to improve the pharmacological properties of a variety of drugs, the 
size and charge was thought to hinder their ability to effectively 
distribute and therefore has a limited use. However the use of liposome 
10 
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encapsulation has shown that conjugation with specially designed 
components may be a promising concept to improve efficacy. 
Some other covalent conjugates described the use o f hydrophilic 
polymers (e.g., N-(2-hydroxypropyl) methacrylamide (HPMA) or 
poly(ethylene glycol)"(PEG) conjugates of doxorubicin to reduce 
doxorubicin toxicity^^ when compared with the free doxorubicin drug. 
The same technology has been used to produce diagnostic and therapeutic 
products when polymeric products are conjugated with folates^^'and other 
biomacromolcules. 
1.3.3 Peptide/Protein - Polymer Bioconjugates. 
Several peptide conjugates have been designed to exploit the relative ease 
with which peptides can be recognised and actively transported across 
cell membranes and hence be used as antisense carriers into the cell and 
in targeting/release in a dual functional role. 
OH 
Figure 1.2: DOTA^^, which can be conjugated 
with peptides for use as a metal ion carrier 
DOTA 
Shively et al in 1994^^ conjugated DOTA to achieve high specific activity 
and high chelate stability in radiolabelled immunoconjugates and in 
2001^^ developed a simple, water-soluble procedure for conjugation of 
l,4,7,10-tetraazacyclododecane-//,//',A^",A^"'-tetraacetic acid (DOTA) to 
the human/murine chimeric anti-carcinoembryonic antigen antibody. This 
improved method results in a 6-fold increase in conjugation efficiency, a 
3-7-fold decrease in antibody crosslinking, a more homogeneous 
population of conjugate species, and a 5-fold decrease in the quantities'of 
11 
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reagents needed for conjugation. The DOTA conjugate was labelled to 
high specific activity with ' " i n , ^ " Y , * ^ Y , ^ '*Cu , and ^^Cu, affording near-
quantitative incorporation of the majority of radio-metals. 
This improved conjugation procedure was proposed to facilitate large-
scale production and radio-metal labelling of cT84.66-DOTA for clinical 
radio-immunotherapy. The use of peptides is not restricted to labelling or 
targeting but can also act as a release mechanism in response to a 
predetermined trigger (i.e. pH assisted hydrolysis). 
Dubowchik et al^* utilised the ability of enzymes to recognise and rapidly 
cleave the dipeptide Phe-Lys in their design of an efficient linker and 
targeting moiety. Furthermore, the linker was designed such that the 
enzyme cleaves the amide bond, which attaches the lysine residue^^ to p-
aminobenzyl alcohol (PABA). Such conjugates have shown considerable 
importance in the field of contrast agent carriers, catalytically active 
metal ions and radioactive markers where the use of purely instrumental 
techniques is unsuitable for detection o f low levels o f contrast agent in 
biological matrices. 
The use of peptide sequences as a targeting moiety has a similar 
principle to that involved in most physiological processes, including the 
immune response, cell differentiation, and cell-to-cell interactions. They 
are also involved in the disease state, such as cancer cell 
pro l i fe ra t ion^nd various inflammatory processes like rheumatoid 
arthritis and asthma^'. The specific sequence required, where known, has 
been fu l ly exploited in bioconjugate synthesis. 
The integrins are a superfamily of cell surface proteins (first 
examples described were fibronectin and vitronectin receptors) which 
bind to an RGD (Arg-Gly-Asp) ligand sequence in the protein, the main 
receptor by which cells attach to the extracellular matrix on which their 
subsequent ability to facilitate cellular functions including disease states 
are highly dependent; for these reasons, the proteins and their application 
or influence in therapeutic approaches has been of great interest. 
12 
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Fibronectin type I I I (in the same integrin-receptor family) is a cell 
adhesion protein widely distributed in the tissues of all vertebrates and is 
present as a soluble polymeric fibrillar network in the extracellular 
matrix. 
Figure 1.3. Cartoon representation of the juncttorudly decoupled state^^ 
Fibronectin has two major domains that help with cell adhesion; they 
both have a peptide motif found within fibronectin with a minimal 
peptide sequence of (leucine-aspartic acid-valine) LDV motif. This is 
analogous to the arginine-glycine-aspartic acid ( R G D " ) motif and their 
importance in the adhesion process has been substantiated^^. Vitronectin 
and laminin are two other proteins that use this sequence to induce 
adhesion on surfaces that are otherwise non-adhesive^. The affinity for 
these tripeptides compared with fibronectin is, however, low. Tambunan 
ei af^ had also shown (using cyclic R O D ) that hydrophobic residues 
adjacent to the R O D sequence are important for an improved affinity of 
the sequence^. An elegant but carefully constructed polymeric capsule 
(considering the micellar size and biocompatibility) for improved 
biocompatibility, labelled with the R O D sequence should therefore be a 
viable vehicle for target delivery and thus of therapeutic importance. The 
concept has already been applied and recently Mitra et af^ further 
discussed the application of water-soluble, N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer carrying cyclised 
Bioconjugates 
Arg-Gly-Asp motifs (HPMA copolymer-RGD conjugate) which showed 
greater in vivo accumulation than the control Arg-Gly-Glu (HPMA 
copolymer-RGE conjugate) conjugate, which they proposed to provide a 
foundation that should support targeted delivery of radionucleides and 
drugs to solid tumours for diagnostic and therapeutic applications in 
specific tumor angiogenesis targeting. The above information has 
therefore contributed to the design of short, hydrophilic and unique RGD-
incorporated peptide^^ sequence with the ability to mimic the natural 
protein binding activity hence avoiding all the intrinsic problems 
associated with lengthy chain peptide synthesis. 
1.4 Advantages of Polymer Bioconiuaates 
1.4.1 Introduction 
The use of liposomes, spherical vesicles made of phospholipids 
commonly used in combating cytotoxicity by encapsulation and their 
ability to permeate cell membranes, forms perhaps one of the simplest 
methods of drug delivery and has led the way for other more 
sophisticated methods. 
As Maeda et af^ recently reviewed, the process known as enhanced 
permeability and retention (EPR) usually associated with l ipid and 
macromolecular agents has been exploited to provide the opportunity for 
more selective targeting of lipid or polymer-conjugated drugs. The 
improved permeability and delivery of such macromolecular drugs are 
highly dependent on the choice of polymer macromolecule. These are 
easily obtained either by natural (liposome) or synthetic polymerisation 
methodologies. 
The use of polymer carriers has several advantages over other 
delivery methods, such as liposomes and antibodies. Liposomes, for 
example can be taken up by macrophages or move to the tissue from the 
blood vessels where they are not necessarily wanted and antibodies have 
the disadvantage that most receptors on tumour cells are also present on 
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normal cells making it diff icul t to find ones that are unique to cancer 
cells. 
In contrast, the use of water-soluble polymers of PEG and A^-(2-
hydroxypropyl)methacrylamide allows the use of a simpler molecule 
rather than a large particle while still acting as an effective 
protective/delivery system in vivo. This constitutes a macromolecular 
prodrug. 
Such polymer-biomolecules have formed a group of conjugates 
with applications in varied areas of medicine and biotechnology, which 
has recently been reviewed by Alexander et af^. They explored the 
influence of smart polymers in medicine especially as controlled drug 
release vehicles, the types of stimulus response used in therapeutic 
applications and the main classes of responsive materials developed to 
date. 
> To summarise, polymeric bioconjugation provides 
approaches to deliver intact low molecular weight 
substrates to required sites by: 
> conjugation with polymers to provide a stimulus-sensitive 
coating or targeting with biodegradable polymers 
> embedding biodegradable matrices, micelles and hydrogels 
to provide stealth and hence 
> Via high molecular weight drug development to produce 
enhanced EPR effect. 
There are various reasons why polymer bioconjugation has been vital to 
research especially when specially designed smart polymers^' are 
conjugated. The enhanced permeability and retention (EPR) effect of 
macromolecules in tumors by plasma proteins and their various synthetic 
polymers conjugates have shown accumulation in solid tumors for 
prolonged periods. More recently, the key mechanism for the EPR 
effect^^ for macromolecules in solid tumors was found to be retention, 
whereas low-molecular-weight substances were not retained but were 
returned to circulating blood by diffusion'^. 
The above unique behaviour and the ability to design smart polymers that 
can be manipulated to respond to a predetermined stimulus has 
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revolutionised various aspects of research, for example as biomedical 
tools, illustrated below with some examples. 
1.4.2 Diagnostic tools and Immunoassays 
The wide use of monoclonal antibodies (mAB) as efficient toxin delivery 
agents and their capabilities in antibody-mediated cytotoxicity has 
ensured rejuvenated interest for various cancer therapies as immunotoxin 
bioconjugates''' but, they have shown side effects as a result of processes 
which are di f f icul t to monitor without genetic engineering, hence are not 
as advanced in application. 
The use of fluorescence tagging has a wide-ranging influence both 
in the area o f high throughput screening'^ and as a diagnostic tool in 
biological systems. Simon et af^ reported the use of luminescent 
quantum dot conjugates as an alternative to current organic dyes. The 
new conjugate was biocompatible and allows for simultaneous studies of 
multiple cells over a long period of time. The corresponding conjugates 
can be proteins (synthetic and natural), biocompatible polymers or 
antibodies with high immunoassay stability 
1.4.3 Gene Therapy 
Genetic material is more often optimally transported into host cells by 
naturally evolved vectors, such as viruses and bacteria. While the 
development and use of mimics or alternatives is gaining ground, 
improvement on nature's design still proves to be the most practical. 
They are increasingly sophisticated while remaining non-toxic to the 
host. 
Ideally, vectors should allow efficient gene insertion and prolonged 
transgene expression, absence of viral host integration and excellent 
immune stimulation. By using information collected on the limitations 
and difficulties associated with such technique, reasonable progress has 
been made in recent years. Focusing on a conjugate-related approach, the 
report'* that recombinant adenovirus, non-covalently complexed to 
cationic polymers and cationic lipids with adenovirus have been shown to 
-increase adenovirus uptake and transgene expression in cells that were 
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inefficiently infected by adenovirus, suggested that there are benefits 
from well designed and conjugated novel approach to gene therapy. 
Gene delivery by vector systems, approached by modification of 
adenoviruses with PEG/peptide complexes^^ has also been investigated. 
The bioconjugates serve to partially overcome the barrier of inefficient 
gene transfer associated with gene delivery by vectors, by incorporating 
cell-specific ligands into the virion to aid vector active site recognition. 
The increased aff ini ty of viral receptors on the surface o f cells was 
introduced by incorporating screened peptide recognition sequences. 
The new approach of using non-viral methods (or mimics),-that 
is, cationic lipids and polymers - is catching up on the more traditional 
gene therapy method of using cell-infectious viral RNA/DNA delivered 
into a cell, allowing the cell to develop the therapeutic protein. The 
problem of immunogenic responses associated with gene delivery by the 
virus is thus avoided. Santanu Bhattacharya et al have investigated the 
transfection ability of a number of cytofectins based on cholesterol. They 
fol low on the success of cationic cholesterol derivatives capable of DNA 
transfection in cells with high efficiency; several other groups have also 
prepared poly(ethylene glycol, PEG) and sugars conjugated with 
peptides, some of which have the ability to form a DNA condensate. 
They are receiving attention for their possible use in DNA complexation^^ 
and as gene transfer agents. 
Another emerging strategy uses non-invasive delivery of drugs and 
genes with microbubbles*'* using ultrasound-mediated microbubble 
destruction, encapsulation of drugs in microbubbles induced by 
ultrasound application, and also the direct delivery of substances bound 
to microbubbles^^ in the absence of ultrasound. Different drugs and 
genetic material can be incorporated into the ultrasound contrast agent 
system. 
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1.4.4 Controlled Release 
Controlled release is effected when a required substrate (or drug) is either 
Maximum Dosage Leuel 
Maximum Effective Level 
Dose 
Time 
,(B) 
Maximum Dosage Leuel 
Maximum EffectiveLevei 
Figure 1.4. Schematics for 
the behaviour of drug levels in 
the blood by (a) traditional 
drug dosing and (b) 
controlled-deltvery dosing. 
Time 
covalently bound to a polymer (natural or synthetic) or associated non-
covalently in order to facilitate a predetermined action/release 
mechanism. The release of the drug can be triggered over a period of time 
and the action initiated by a predetermined stimulus. The advantages of 
such controlled-delivery systems can include the maintenance of drug 
levels within a desired range (Figure 1.4), the need for fewer 
administrations to maintain a level of therapeutic effect, and increased 
patient compliance. 
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Many of the approaches to the development of novel material useful for 
controlled release are focused on the preparation o f polymers with 
specially designed features. Such systems include 
> Block copolymers (see section 1.8) 
> Copolymers with desirable amphiphilic interactions 
> Biodegradable polymers 
> New blends of hydrocolloids and polymers (natural and synthetic) 
Block copolymers offer a unique but simple way to address drug release 
and bioavailability o f drugs. Figure 1.5(A) shows a typical basic cationic 
copolymer that swells at pH 5-8 but is soluble at pH 2.5. Figure 1.5(B) 
shows an anionic copolymer resistant to gastric juice yet soluble in water 
in the small intestine, but insoluble and impermeable to water at a pH 
below 6. They therefore can be tailored to provide protection for 
substrates in specific in-vivo environments. 
\ R = H, C H j 
R ' — C H j , C4H9 
Figure 1.5: (A) Typical 
cationic copolymer (B) 
Typical anionic^olymer used 
o in drug release 
Block copolymers of amino acids have been designed to increase the 
residence time at the active site of hydrophilic drugs, and can be designed 
to respond to a thermally induced stimulus (controlled release). The 
controlled release capabilities (over a period o f one month) o f Fmoc-L-
tryptophan-Boc conjugation with a ABA triblock copolymer (of lactic 
acid and glycolic acid, PLGA) was investigated by Park and co-workers 
for PLGA microspheres. 
In recent years, more polymers specially designed for medical 
applications have entered the arena of controlled release. 
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o CI 
CI 
Polyetliylene glycol 
Figure 1.6. Polycarbonate ofbithionol with poly (ethylene) glycol as spacer group 
Many of these materials are designed to degrade within the body. Some 
are based on polylactides (PLA), polyglycolides (PGA), poly(lactide-co-
glycolides) (PLGA), polyanhydrides and polyorthoesters. Vogl and co 
workers^^'^^ have succesfully modulated the solubility of bithionol 
(Figure 1.6) by conjugating an alternating copolycarbonate o fb i th iono l 
and poly (ethylene glycol) of molecular weight 4000 with an inherent 
viscosity of more than 1.2 dl/g. Alternating copolymers of bithionol 
(antibacterial agent) and other hindered bisphenols have been synthesised 
with an antioxidant in the same polymer chain. These polymers have the 
potential to act as very useful materials for the controlled release of 
bithionol (bactericide), as they undergo degradation under physiological 
conditions by hydrolysis. 
1.4.5 Targeted Delivery 
Delivery systems for targeting fal l into two basic categories: drug 
conjugate systems, in which individual drug molecules are chemically 
modified to target them directly to the site of action; and carrier-based 
systems, in which the drug or gene is first packaged non-covalently into a 
synthetic carrier that is then targeted to the tumour. In both cases, the 
objective is to maximise exposure of the target cells to the drug yet 
minimise side effects that may result from non-specific toxicity in normal 
tissues. 
The use of polymeric micelles for targeted delivery has been widely 
studied. Targeted delivery can often be achieved by controlling particle 
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size and incorporating biological, chemical or biochemical selectivity 
mechanisms. As a result, the conjugate should show specificity. When a 
polymer carrier, conjugated to an active drug, is further modified with a 
natural polymer (e.g. polysaccharides and proteins) with known and 
specific properties (including recognition sites) as a targeting component, 
thereby rendering the drug inactive elsewhere in the body, the result 
should be a site directed (targeted) delivery system. 
Active intracellular targeting systems use protein transduction, a 
recently developed technique that enables proteins to be directly 
introduced into cells. The substrate (e.g. peptides, small proteins, f u l l -
length enzymes, DNA oligomers, peptide-nucleic acid oligomers, 
liposomes, and magnetic nanoparticles) of interest can be "transduced" to 
any type of cell and w i l l rapidly enter each cell so that every cell w i l l 
contain an equivalent amount of transduced protein. Protein transduction-
based approaches circumvent many of the obstacles associated with gene 
therapy. It is not d i f f icu l t to envision treatments for cancer, other 
infectious diseases, genetic diseases and the degenerative diseases of 
ageing arising from this new technique. Recent examples of the range of 
potential applications have been reviewed by Kendrick and co-
workers'^and several cell-penetrating peptides that enable the 
intracellular delivery of polar, biologically active compounds in vitro and 
in vivo have been described^'. 
The use of ionic polymers for protein transduction via an ionic 
interaction of specially defined molecules (e.g. sialic acids) with cell 
membranes has also generated interest. Most importantly, such systems 
are capable of internalising hydrophilic cargoes by a receptor-
independent mechanism much like the natural equivalent. 
Polysaccharides are valuable in the recognition by proteins called 
'lectins' on cell surfaces; hence, polymers incorporating sugar residues 
(for example) have been investigated'^ as practical components of 
synthetic target delivery vehicles that may promote i.e. gene transfer 
independently of the classical endocytic pathway.'^'''* 
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1.5 Bioconiuaate Assembly (Peptide Conjugation) 
1.5.1 Strategy for Conjugate Assembly 
In general, bioconjugation is often performed by covalently reacting 
biological moieties with preformed polymer macromolecules, after 
activation or assisted by traditional coupling reagents (DCC, PyBOP etc) 
or by physical interaction (i.e. Van der Waals interaction). However, 
various other strategies'^ for conjugation culminating in more efficient 
release mechanism of material are employed in the design of conjugates. 
In contrast to the synthesis of low molecular weight natural 
products and drugs, which is aided by a plethora of specific reactions and 
protecting group chemistry, site-specific modification of unprotected 
peptides and proteins to prepare well-defined bioconjugates is more 
challenging. 
The demands placed on the synthesis of various conjugates are 
influenced by their intended end use, as extremely stringent requirements 
on the purity and homogeneity apply to the bioconjugates especially 
those intended for use as intravenous polymeric drugs. However, the 
nature of the linkage between the components of conjugates has often 
been critically important in determining the efficacy of the resulting drug 
and indeed the success of conjugation for both random site or site-
specific conjugation. 
For site-specific conjugation, it is desired that only the intended 
site in a peptide or protein be modified in the presence of other functional 
groups, thus leading to the formation of a well-defined bioconjugate 
aided by the different available methods and reagents (see Table 1). This 
is generally achieved by providing favourable covalent conjugation 
conditions (usually pH or temperature) for respective functional groups, 
for thiol (cysteine), which is 100 times more reactive at pH less than 6 
than N-terminal amine or indeed pendant lysine amine. 
Although degradable substrates (i.e. peptide) sequences are often 
incorporated, drug release from macromolecules in many cases is highly 
"inefficient, because the polymeric structure sterically hinders the driig-
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cleavage mechanism. The above problems of site-specific conjugation 
and inefficient release mechanism have prompted an increased interest in 
the use of linkers as a simple but effective medium to enhance efficacy. 
There are two general methods for conjugating macromolecules: 
a) Traditional approach - This process often does not require the 
use of linkers but traditional activating/coupling agents (i.e. 
carbodiimide^^) to form carbonates or carbamates'^. Such conjugation 
approaches to macromolecule synthesis often results in multiple bonds 
and by-product formation, a process that can lead to diminished potency 
Ofi 
of the final bioconjugate , a problem further exacerbated by the fact that 
the site of modification of substrates often dramatically affects 
pharmacokinetics^'. A well-defined structure wil l be difficult but not 
impossible to obtain, often only after further purification. 
b) Linker/Spacer approach - Macromolecules are sterically 
demanding, and ease of accessibility to target sites either for cleavage or 
conjugation is a prerequisite for efficient drug release. The use of linkers 
has been shown to be suitable for creating effective biomacromolecule-
drug conjugates, which ensure efficient drug release characteristics. In 
the design of a suitable linker it has to be taken into account that 
conjugation to active sites (which are often located well below the 
surface of the required bio-macromolecule, due to secondary interactions, 
for example) may require the use of a linker with an appropriate spacer 
length and compatibility to discourage unfavourable interactions with the 
recognition moiety, while at the same time providing direct access to the 
intended conjugation functional group. 
The use of linkers has now become a prerequisite for efficient 
conjugation of chemotherapeutics (where high molecular weight natural 
macromolecules are prevalent i.e. Bovine Serum Albumin and 
Immunoglobulin). 
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While chemotherapeutics and macromolecules can be designed to 
exercise reasonable tolerance using various recent polymerisation 
techniques, a sizeable number of such polymer bioconjugate drugs often 
display reduced potency for reasons that can be attributed to a less than 
efficient conjugation and release mechanism of the potent drug, 
sometimes highly influenced by the type, length and function of the 
linker/spacer used'°°. Kruger et al'°' have already described the influence 
of an appropriately chosen linker length in a complex system. They found 
that potency was dependent on the spacer length used to conjugate 
receptor binding domains and synthetic bivalent antagonists of 
adrenocorticotropic hormone (ACTH), synthesised by coupling the 
terminal carbonyl with the cysteine of synthetic ACTH to form a peptide-
spacer-cysteine conjugate. 
Further studies by other research groups have also shown that efficacy of 
chemotherapeutic drugs, for example Calicheamicin'"^''^^, an anticancer 
agent, already approved by US Food and Drug Administration (FDA) can 
be improved on, mainly by appropriate choice and design of linker 
1.5.2 Biological Hetero-bifunctional Reagents. 
1.5.2.1 Types and Examples of Linker Units 
By definition "linkers" are functional agents consisting of a spacer 
(cleavable or non-cleavable) and two reactive end groups. These reactive 
groups are required for direct, facile and selective access to functional 
groups for anchoring two different entities (e.g. proteins, polymers and 
surfaces). For biomedical applications, linkers with the ability to site 
selectively release compounds (e.g. drug, polymer or peptide) usually by 
hydrolysis from a conjugated polymer via predetermined stimuli (or 
stimulus) in an aqueous environment and predetermined conditions have 
generated greater application. 
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In vivo, this property can be utilised in the controlled release of drugs for 
treating various ailments or in vitro, to study surface receptors of cell 
culture as a model s y s t e m T h e use of cleavable linkers has been 
widely reported in various capacities. However for cancer chemotherapy 
the advantages are more readily exploited. Kukis et al^^^ reported an 
increase in the tumour-to-liver and tumour-to-kidney radiation dose ratios 
in preclinical studies of radiolabelled proteins conjugated to antibodies, 
designed for cleavage in the liver and kidney. 
To crosslink biological (i.e. protein or antigens'^') macromolecules, it is 
necessary to use a bifunctional reagent, which has two functional groups 
linked by a spacer arm. These reagents fall into two classes: 
1) Homo-bifunctional with two identical functional groups. 
2) Hetero-bifunctional with two different functional groups. 
Bifunctional reagents can have varying lengths of spacer and different 
reactive side chains on a protein. The most useful reagents are those that 
possess a cleavable crosslinker to regenerate the subunits, often by 
incorporating disulphide links, which can be cleaved by introducing a 
reducing environment or hydrazine - cleavable in acidic environment. 
,S N S S CH2CH2 
(b)N-Succinimidyl-(4-azidophenyl)-l,3-dithiopropionate 
(a) N-(4-azidopheny)thiopthalitiiide 
NH2CI ( C ) 2-Iminothiolane 
Figure 1.7. Example offunctional reagents: a, Mono functional cysteine specific reagent, b, 
Bifunctional cysteine/lysine specific reagent, c, Traut 's reagent'"^' Hetero-
bifunctional linker that converts the terminal amine of lysine into a thiol derivative 
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Spacers are other vital components of a good linker as the linkage can be 
designed to control where and when substrates are released. Some of the 
shorter linkers are simple to prepare but highly prone to unfavourable 
interaction of the conjugated macromolecules. 
However, the use of polyethylene glycol (PEG^* )^ and other synthetic 
polymeric carriers has recently been realised as almost essential, as more 
and more PEG-conjugates perform better in clinical trials. 
Other advantages of PEG in bioconjugation also include: 
^ Non reactive (relatively) and easily functionalised end 
groups 
^ Cheap and commercially available 
> Water soluble, very stable and can be modified to be 
cleavable. 
^ Renal clearance highly dependent on molecular weight 
(tuneable property) 
> High molecular weight - in vivo degradation by-products 
are non-toxic 
> FDA approved, already been used in food and drugs. 
In spite of all the advantages offered by both PEG and ATRP (especially 
their high tolerance to other functional groups), very few ATRP systems 
have utilised or exploited the concept of hetero-bifunctional linkers as 
initiators for synthesis of biologically active polymer conjugates to 
establish a protocol for large-scale synthesis of peptide/protein polymer 
bioconjugates. It was therefore envisaged that an ideal system would 
consist of bifunctional linkers to take advantage of living polymerisation 
and bioconjugation. 
> A PEG Linker to enable tuneable biological interactions and 
aid hydrophilicity and reduce unfavourable macromolecular 
interaction by reducing steric interaction'" but encouraging 
aggregation where and when expected of the bioconjugate 
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> Two functional groups: Archetype alkyl halide for living 
polymerisation and a stable functional group for sequence 
conjugation to ( - N H 2 ) or (-SH) of RGD-based peptide or 
protein (Human Serum Albumin) (see Table 1). 
F G I | L A A A < Linker w M r e l l A A / ^ ^ Structure typical of the 
• ^ - w M ^ — i ^ ^ ^ I 1 proposed hetero-bifunctional 
Polymer Biomolecule 
Figure 1,8. A representative 
structure typical of the 
 hetero-bifunctic 
linker conjugated system 
The above system would be synthesised and tested under physiological 
conditions with the hope of being utilised in biological systems and, to 
allow for large-scale synthesis, by incorporating a versatile and robust 
macromolecule synthesis method, i.e. living polymerisation. 
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1.6 Living Radical Polymerisation and Macromolecules. 
1.6.1 Macromolecules as Drug Carriers 
The discovery of the ability of macromolecules to localise to subcellular 
compartments known as lysosomes heralded their evolution as drug 
carriers"^. In 1975, Ringsdorf formulated the rationale for targetable 
polymeric drug delivery based on pharmacologically active polymers'. 
Since then, polymers of natural and synthetic origin have been widely 
used for the delivery of low and high molecular weight drugs further 
enhanced by (for instance), the research by R. Duncan et al (1984) into 
the use of synthetic polymers as potential drug carriers to offset the 
extremely rapid biodegradation, immunogenicity and instability towards 
modification with drugs of naturally occurring polymers (e.g., 
oligosaccharides, proteins) 
In a polymeric drug delivery system, the drug is generally but not 
exclusively included either as a unit of the polymer backbone or as a 
pendant group, part of the carrier side chains. The drug can be introduced 
by either copolymerization with a monomeric drug derivative (e.g., N-(4-
aminobenzensulfonyl)butylurea), or by a polymer-analogous reaction 
with side chains carrying functionalised groups, such as active esters. 
Intended for synthetic polymers, such as polyethylene glycol (PEG) and 
biodegradable poly(l-glutamic acid) (PGA), which are currently being 
evaluated in clinical trials, e.g. Pegasys-branched PEG-IFN-a2a, have 
been extensively reviewed 
The synthesis of novel synthetic material with improved properties and 
functionalities is an ever-expanding frontier in science. The increased 
interest in the synthesis of functionalised macromolecules can be 
attributed to the recent advances in polymerisation techniques and the 
need for desirable polymer composites and conjugates of high 
dispersibilty in aqueous systems, and which are highly uniform (in size 
and composition) and reproducible. 
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A notable advance was made in 1995, when Percec et al"^, 
Matyjaszewski and Sawamoto independently reported the use of 
controlled/living radical polymerisation (instead of anionic, cationic, co-
ordination or ring opening methodology) to design different architectural 
polymers, and the subsequent synthesis of an increasingly large number 
of functional synthetic polymers with characteristics similar to natural 
polymers both in complexity and function (recent reviews^'^'"^'"'). 
Chemists can therefore - using the chemistry established by 
Matyjaszewski, Sawamoto and Percec - design macromolecules and 
combine several synthetic macromolecules (conjugation) of predictable 
properties to suit the specific field of research. 
While the developments in polymerisation chemistry may have been 
brought about by the need to synthesise novel biologically responsive 
macromolecules, the need to overcome certain intrinsic drawbacks (e.g. 
solubility, cytotoxicity and low bio-availability) and the availability of 
polymerisation method(s) for well defined polymers, which can mimic 
natural and improve on synthetic polymers, that have revolutionised the 
polymerisation process and the chemistry. However, most research 
conducted on the mechanism and kinetic studies of living polymerisation 
in contrast with conventional radical polymerisation, was inconclusive in 
determining the conventional nature'^"^''^'of the living process (e.g. 
similar rate constant, tacticity, region, stereo and chemoselectivity). The 
indirect/direct influence of the "persistent radical effect" (PRE)'22.123,124 
living radical polymerisation as the predominant (a non self terminating 
by-product) side reaction may also play a vital role in distinguishing 
conventional from living polymerisation. 
The development of the living radical polymerisation technique 
has led to improved polymer technology and to the efficient production 
of different polymer architectures with applications in various areas of 
research. 
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1.6.2 Living Radical Polymerisation - Classification. 
Despite the simplicity, robustness and mechanistic similarities of 
conventional polymerisation - which consequently led to the wide 
industrial usage of conventional radical polymerisation techniques - the 
resulting polymers of ill-defined structure, unpredictable molecular 
weight distribution, all directly linked to lack of control over the 
termination step (by combination or disproportionation) in conventional 
polymerisation has helped encourage the fostering of more efficient 
ahemative techniques. 
Other traditional polymerisation techniques (ionic'^* and group transfer) 
have also played vital roles in industry, but exercise limited monomer 
compatibility and the need for stringent conditions^^ '^^ ^^Figure 1.9). This 
has possibly hindered advances in novel polymer products and other areas 
for which collaboration with polymer chemistry is now vital (i.e. 
synthetic natural polymers and biopolymer science). The last few decades 
have seen the rapid growth in the development and understanding of 
other techniques, especially controlled/living radical polymerisation. 
LMW 
Hybrids 
Env ^ 
Water 
EndFunct 
Blocks 
Mon Range 
ATRP 
- - N M P 
RAFT 
HMW 
Figure 1.9: Schematic shows one interpretation of the relative advantages and 
limitations of A TRP. NMP and RAFT as applied to the synthesis of low (LMW) and 
high molecular weight polymers (HMW), range of polymerisable monomers (Man 
Range), preparation of block copolymers (Blocks), end-functional polymers (End 
Funct), Hybrids , aqueous systems (Water) and some environmental issues (Env). 
http://www.chem.cmu.edu/groups/maty/crp_2001-2005/ 
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The major mechanistic difference between conventional and controlled 
radical polymerisation is the lifetime of the propagating radical species 
during the polymerisation process - attributed to the dynamic equilibrium 
created between the active and inactive radical species in conjunction 
with a radical moderator, which has the net effect of prolonged radical 
half-life of up to hours for a typical living polymerisation system. This is 
unlike the conventional process where the propagating radicals merely 
persist for seconds after the initial radical initiator decomposition-
propagation step resulting in a lack of control over the polymerisation 
process and its polymer product, A living process of an efficient 
polymerisation possesses unique and investigated characteristics'^* 
(experimentally or mechanistically) easily observed in order to predict 
the progress or the outcome of a typical polymerisation i.e. 
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> Narrow molar mass distribution (Mw/Mn < 1.1-1.3'^") 
> Linear plot of ln[ l / ( l -x) ] vs. time through the origin. Where 
x=conversion. Indicative of constant concentration of active 
species. 
> Predictable polymer molar mass/degree of polymerisation. 
DP = [M]o/[initiator]o x conversion 
[M]o = initial concentration of monomer 
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> Linear plot of Mn vs conversion through the origin'^'. 
0 20 40 60 80 too 
<M> Comnersion 
While the favoured system for polymerisation depends highly on the 
requirements of the resulting polymer and the capabilities of such 
techniques (see Figure 1.9, page 30), the types of "living" system 
generated mainly depend on the type of radical transfer agent used to 
assist or maintain the equilibrium generated (i.e. nitroxide or transition 
metal) of the living polymerisation, techniques that can be described 
(with general mechanism) as: 
> Stable free radical polymerisation (SFRP) e.g. Nitroxide-mediated radical 
process (NMRP) 
P-X Dissociation- Combination 
> Degenerative transfer e.g. Reversible addition-fragmentation chain 
transfer (RAFT) 
p.X + Z* ^ P* + x-z Degenerative Transfer 
> Metal-mediated atom transfer radical polymerisation (ATRP). 
P-X + Y ^ 
K H 
P* + XY* Atom Transfer 
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They are easily differentiated by the choice of capping agent (radical 
moderator) employed to maintain the reversible activation process of a 
typical living "equilibrium" system. 
1.6.3 Nitroxide-Mediated Radical Polymerisation (NMRP) 
SFRP processes are conducted under polymerisation conditions 
comprising a radical source (which can be conventional i.e. iodine or 
AIBN), a stable free radical (alkoxyamine-based radical regulator, see 
Fig 1.10 and 1.11) and at an appropriate temperature to provide the 
effective exchange between the active and dormant species. The radical 
source and the stable free radical may be combined in one species. NMRP 
processes are typical of SFRP processes. NMRP processes include the 
initiation of the polymerisation in the presence of a nitroxide, such as, 
2,2,6,6-tetramethyl-l-piperidinyloxyl ("TEMPO")'^ or its derivatives 
(Figure 1.11 A, B-D), or phosphorus-containing nitroxides (designed by 
Gnanou et.aV^^), for acrylate polymerisation, or may employ a preformed 
alkoxyamine as the radical source/control agent. The most popular 
nitroxide used for NMRP in the past has been TEMPO. However, 
TEMPO is limited in the range of compatible monomers, mostly due to 
the stability of the radical. Hawker et. a/"^  discovered that by replacing 
the a-tertiary carbon atom with a secondary carbon atom, the stability of 
the nitroxide radical decreased which lead to an increased effectiveness 
in polymerisation for 
X Ph 
RO N 
\ 
R2 
Ph 
K p 
monomer 
Figure 1.10. General mechanism for NMRP 
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many monomers in which TEMPO was inefficient. This had the net effect 
of increasing the range of moderator (hence reduced operating 
temperature), and monomer (from styrene only to various acrylate, 
acrylamide and acrylonitrile). 
/ OEt 
Figure 1.11. Polymerisation mediators for use in Nitroxide mediated radical polymerisation. 
The use of radical stabilizers (i.e. nitroxide and its derivatives) ensures 
that irreversible terminations and PRE are suppressed while the 
equilibrium can also be activated and propagated (Kp) to maintain the 
essence of living polymerisation. 
Unfortunately, thermally induced polymerisation, especially for a 
bimolecular approach using TEMPO, also means high temperatures are 
often required (>60°C) for the initial dissociation to release nitroxide, a 
highly unfavourable condition for large-scale industrial usage or 
biological substrates. However, the choice of nitroxide moderator 
especially of the second and third generation alicyclic TEMPO design has 
permitted the use of a wider range of monomer with moderate or better 
control of the resulting polymer. The process requires stringent 
conditions and the choice of monomers is still comparatively restricted. 
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1.6.4 Reversible Addition-Fragmentation Transfer (RAFT) 
Degenerative transfer or R A F T ' ^ ' ' '''''''''^ is the newest LRP technique, 
developed in 1998. RAFT polymerisation conditions allow the 
polymerisation of a wide range of monomers including functional 
monomers, such as, but not limited to, styrenes, acrylates, methacrylates, 
acrylic cid, DMAEMA, and HEMA to give functional polymers with a 
wide range of architectures, including block, star, and gradient polymers. 
The mechanism follows the addition of thioesters, (the efficient 
reversible addition-fragmentation chain transfer agent) to conventional 
free-radical polymerisation, subsequently; addition-fragmentation of the 
propagating 
X 
+ R 
R = C H 3 o r P h K p 
monomer 
Figure 1.12: General mechanism for RAFT 
carbon-centred radicals, which is reversibly stabilised by the dithioester, 
and generates the active radical species. The reaction of thioesters with 
initiator-radical species (fast trapping) is faster than the rate of 
propagation and the fragmentation process that generates the active 
radical species, hence, suppressing bimolecular termination. 
In RAFT polymerisation, the molecular weight is predetermined by the 
ratio of consumed monomer to the consumed initiator and the quantity of 
added transfer agent. While the monomer compatibility and the operating 
temperature (approx. 60''C) for RAFT are considerably better than for 
NMRP, the reported work of McCormick et al discussed the use of RAFT 
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as a viable technique for the synthesis of acryloamido water soluble 
polymers since ATRP failed to give controlled molecular weights for 
acrylamides, and NMP methods are usually run in organic solvents with 
nonionic monomers, RAFT was the only valid technique for these types 
of systems 
However, there are limitations. For example: -
1. Some of the RAFT agent can be relatively difficult to synthesise 
2. Reactions can be slow 
3. The process involves sulphur compounds, bad odour. 
4. Polymers tend to be coloured. 
5. Efficient (fast) fragmentation i.e. good choice of thioesters is 
essential 
6. The end-group (i.e. thioether) after polymerisation tends to lead to 
toxicity and displacement usually requires further polymerisation. 
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1.7 Atom Transfer Radical Polymerisation (ATRR'' 
1.7.1 Introduction 
The performance of any polymer is largely determined by the 
composition and architecture (e.g. micelle forming block copolymer). 
Therefore the ability of any living polymerisation system to afford the 
wide variety of scientifically interesting materials is highly dependent on 
the ease of access to sophisticated architecture. The process can easily be 
approached by using living radical polymerisation to directly effect the: 
> Copolymerisation of new material with predictable properties 
(e.g. micelle-forming block copolymer) 
> Accommodation of novel initiators/monomer to facilitate new 
architecture (e.g. functionalised''" or bio-macroinitiators) 
> Control over the architecture (e.g. grafted or statistical 
copolymer) 
> Post-polymerisation (e.g. with functional groups) 
1.7.2 Mechanism 
ATRP is more complex than other living polymerisation method because 
it involves a complex, often heterogeneous catalytic system. The 
solubility and structure of the catalyst in solution may change not only 
the catalyst composition but also the compatibility of each monomer, 
solvent, and temperature conditions with the process of living 
polymerisation. Various groups have studied (recently Fischer 2001) the 
kinetics and mechanics'"^ involved to understand the fundamental 
>Br-li Cu(l)Br ^ = ^ - . B r C u ( l ) B r ^=±s \ - '4 Cu(ll)Br2 
Polymerisation 
Figure 1.13: A general schematic mechanism of ATRP 
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chemistry, scope, and limitations of A T R P ( l iving polymerisation and 
PRE' ' ' ^ ) , which has formed the basis for the rapid advance in the 
development of the technique. They showed that it follows first-order 
kinetics with respect to monomer concentration, indicating a l iving 
process. Fakuda et al^'^ also recently produced a more comprehensive 
literature based on an experimental and theoretical approach to the study 
of the kinetics of l iving radical polymerisation. A T R P is based on the 
ability of the metal complex to efficiently maintain the radical species' 
transformation and concentration via a fast and reversible redox from 
active to dormant (and vice versa) at any given time and temperature 
1.7.3 Components and their Influence on ATRP. 
ATRP is probably the most versatile l iving radical polymerisation 
technique that can easily afford all of the above conditions. It is the most 
conducive to producing biopolymers with biomedical applications by 
virtue of its tolerance to different monomers and homopolymer 
properties. 
1.7.3.1 Monomers 
The prerequisite for a plausible monomer is the ability to produce the 
active radical species fast f rom the capped growing polymer chain 
a, b 
T B D M S a 
TBDMSO 
TBDMSG" OTBDMS 
a . CuBr, Toluene, T R E N b. Bromoisobutyric ethyl ester 
No of monomer (Mn) = 3,400; Molecular Weight (Mw) = 4,600; 
Polydispersity (PD) = 1.35 
Figure 1.14:.An example of adenosine derived monomer used in living polymerisation 
developed by Andrew Marsh, Warwick'^^ 
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effected by using a phenyl or carbonyl (stabilising) alkyl halide adjacent 
to a carbon radical complexed to a metal centre. This process is, however, 
less accessible in systems like acrylates (in general), except dienes and 
carboxylic acids as they possess acidic protons, which can lead to 
poisoning o f the metal c a t a l y s t H o w e v e r , the ATRP o f M M A using 2-
bromoisobutyric acid has been demonstrated''*^. With the appropriate 
monomer (acrylate or methacrylate) regardless of the tandem structures 
(except acrylamido etc) for example, nucleoside (Figure 1.14) or PEG, 
can undergo polymerisation. 
PEG 
Et 
^ ^ ^ ^ 
H(? "OH 
Figure 1.15. Example of functional monomers in ATRP. a. Adenine methyl methacrylates, b. 
Poly(ethyleneglycol) methacrylate, c(Diethylamino)ethyl methacrylate, d. 
Dihydroxymethylmethacrylate ande. Adenosine acrylate. 
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The practical advantages of ATRP can be ascribed to: 
> The ability to accommodate many varied monomer 
structures and functionalities to create functional polymers. 
These monomers include methacrylates'""(examples, Figure 
1.15 a-d), acrylates"'^'"'^ (Figure 1.15e), styrenes'^^-'^'-'", 
acrylonitrile'^^, hydroxyls, amines, and ethers. 
> Operational at temperatures as low as room temperature'^'*. 
> I t can be carried out in the presence of water'^ ^*'^ ^ or other 
protogenic reagents. 
> Its livingness can lead to novel polymer architectures (block 
copolymers etc) 
Most significant is the ability to optimise and modify any of the reagents 
to suit the purpose of polymerisation (i.e. the design of novel materials) 
and the efficiency o f the systems. The optimal operational conditions that 
best satisfy a specific atom transfer radical polymerisation system are 
affected by various factors, such as reagents, solvents systems and 
catalyst. Careful studies have been carried out on the roles of the 
components in the polymerisation process. It is known that, for example, 
while various monomer/initiator combinations have been used 
successfully in ATRP, each monomer exhibits particular rate behaviour 
even at the same reaction conditions. 
Kd=10'M-iS-* \ ^ 
Metal/Ligand catalyst 
Dormant Species Active Radical Species 
Figure 1.16. Showing the equilibrium between dormant and active system 
As a result, only components with a predictable and manageable 
influence are manipulated to ensure efficient polymerisation, which often 
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involves the transition metal catalyst. Perhaps the more interesting 
component for the purpose of this project and as a synthetic chemist (in 
general) is the ease o f manipulation and the range of initiators applicable 
in producing biopolymers. 
1.7.3.2 Catalysts (transition metals) and Initiators 
ATRP utilises a transition metal as radical initiator via a halogen transfer 
(usually bromide) cycle; deactivation of the chain is by reversible 
transfer of the halogen, and reactivation by halogen abstraction. 
The inherent stability of a carbon halide initiator helps to control 
the equilibrium constants involving the initiation and propagation step on 
which the concept of "livingness" depend with the basic requirement for 
a transition metal catalyst for use in ATRP being the access to an empty 
d-orbital, the ability to accommodate coordination expansion to form a 
stable complex with ligands and display no Lewis acid characteristics. 
While a number of group V I - X transition metal catalysts have been 
applied in ATRP (they include, molybdenum, chromium, rhenium, 
ruthenium, iron, rhodium, nickel, palladium and copper), copper catalysts 
have been the most successful and widely used because of their relative 
low cost and versatility. 
N N 
N R 
Y 
Matyjaszewski 
b. 
Haddleton 
J 
Figure 1.17. a. Substituted bipy andb. TREN ligands developed by Matyjaszewski. c Pyridyl 
methanimine ligand developed by Handdleton for use in ATRP. 
An efficient catalyst (for ATRP) depends on the use of an appropriate 
Jigand to give the complex a more reducing property and therefore make 
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it more active. The ligands help to form soluble catalysts, which greatly 
increases the rate of polymerisation while maintaining good control. 
These Schiff base ligands are easily prepared, amine-based, bi-or 
multidentate, which lends itself to modification by changing the R group 
as required (Figure 1.17. a-c). 
N Polyethylene 
Figure 1.18 
The disadvantages o f using these catalysts are due to the catalyst not 
being often recycled, and copper contamination in products does occur. 
Some publications have shown the removal of contaminant effectively 
performed with the use of the polyethylene-segmented pyridinimine 
ligand (A) in the polymerisation of methylmethacrylate and CuBr'^^. 
Similarly, 2-(2'-pyridyl)-4,5-dihydro-oxazole (B) in the CuCl-mediated 
polymerisation of methacrylates'^^ 
1.7.3.3 Initiators 
Living polymerisations are well known for their ability to accommodate 
various functional groups. Hence, by using specifically derivatised 
initiators, l iving polymerisation can produce functionalised'^' end-group 
polymers tailored to particular requirements, and therefore offers one of 
the best routes to biologically active conjugates. For example, polymeric 
vectors for the delivery of bio-agents (bioconjugates) or the delivery of 
oligonucleotide conjugates and the synthesis o f polymers coupled directly 
to drugs and pro-drugs (therapeutic agents) or simply functionalised with 
antibiotics, cholesterol, sugars and other biologically important 
functionalities, have received increased interest as means of generating 
^structures capable of recognition, binding and intelligent delivery of 
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materials, hence directly affecting drug administration'^*', methodology 
and increasing the pool of research tools. 
While any alkyl halide can potentially be an initiator provided it can 
reasonably stabilise the radical species to minimise side reactions, the 
need for copolymerisation and polymerisation of functional 
macromolecules meant that alkyl halides have been substituted (using 
synthetic organic chemistry) with more useful functionalities like mono 
and oligosaccharides, cholesterol, benzylic halides, nucleosides, 
miscellaneous initiators and dendritic initiators for ATRP (Figure 1.19 a-
h). Haddleton et al'*' successfully transformed P-cyclodextrin into an 
initiator for polymerisation with various methacrylate-based monomers 
The main role of the initiator is to determine the number of propagating 
polymer species with the initial concentration of initiator in a l iving 
polymerisation determining the theoretical molecular weight or degree of 
polymerisation (DP) which increases reciprocally. I f initiation is fast and 
transfer and termination negligible, then the number of growing chains is 
constant and equal to the initial initiator concentration. 
DP = [M]o/[initiator]o x conversion 
[M]o = initial concentration of monomer 
In ATRP, alkyl halides are typically used as the initiator and the rate of 
the polymerization is first order with respect to the concentration of alkyl 
halides. To obtain well defined polymers with narrow molecular weight 
distributions, the halide group must rapidly and selectively migrate 
between the growing chain and the transition-metal complex. Thus far, 
when halide is either bromine or chlorine, the molecular weight control is 
the best. Iodine works well for acrylate polymerisations in copper-
mediated ATRP and has been found to lead to controlled polymerisation 
of styrene in rhenium-based ATRP. 
The use of macroinitiators (in-situ or isolated) is crucial in the synthesis 
of block copolymers of various topologies or composition (see block 
copolymer synthesis). 
43 
Atom Transfer Radical Polymerisation (ATRP..) 
Br 
„,«\0H 
H O ^ « " " ' \ ^ " " " ' O H 
OH 
NaO 
Br 
Br 
HO OH 
NH2 
^ T 
Br 
O f 
J 
.0 
NH 
HO OH 
Figure 1.19: Showing the diversity in ATRP initiators under current usage a .monosaccharides 
b. oligosaccharides c. cholesterol d. benzylic halide e. adenosine'", 
/.uridine'", g. miscellaneous h dendritic '^^ 
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A l l y l bromide as an initiator offered a narrower molecular weight 
distribution than the chloride counterpart in the polymerisation of 
styrene. This is due to the stability offered by electronic conjugation of 
the radical to the v i n y l H o w e v e r , the irreversible activation of the 
carbon-chlorine bond in C C I 4 with Fe(0Ac)2 to generate the C C I 3 radical 
has been used to induce polymerisation of less conjugated vinyl 
a c e t a t e T h e diversity in the initiators tolerated by ATRP has helped to 
generate a renewed interest in areas of collaboration between polymer 
and biomedical scientists. The versatility of ATRP has also led to novel 
polymeric systems with applications in existing areas of research, as well 
as allowing the development of new branches of polymer science, such as 
the collaboration between polymer scientists and biological chemists in 
the development of biopolymer conjugates. 
1.7.3.4 Other Factors (Solvent, Temperature) 
Solution polymerisations are slower than bulk polymerisation due to the 
reaction order of each component except at high temperatures (90° C -
130° C) where a proportional increase in the level of side reaction can 
also be observed i.e. the evolution of aqueous HCl from the propagating 
species accompanied by unsaturated substrates and the oxidation of 
copper (I) to inactive copper ( I I ) by oxidants (i.e. oxygen). 
In general, protic solvents'^^ can poison the catalyst. However, most 
chain transfer inert solvents with the ability to solvate the 
initiator/catalyst complex can be suitable. Some researches have also 
shown water to accelerate the rate'^^''^^ of l iving polymerisation. Also, in 
solution, the behaviour of the l iving process differs in both heterogeneous 
and homogeneous mixtures, which are in-turn greatly influenced by the 
ligand used to complex the metal. 
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1.8 Block Copolymers 
Block copolymers are one of the macromolecular architectures possible 
from the polymerisation of monomers. They can be presented in different 
forms, such as d i - , t r i - , four-arm, graft, star-block and random multi-
block copolymers. 
Block copolymer 
B. 
Branched / graft block 
copolymer 
Tri-block copolymer 
Figure 1.20. A representation of three different polymer architecture based on block copolymers 
1.8.1 Synthesis 
Block copolymers can be synthesised'^°from a monofunctionalised 
radical initiator (or macroinitiator) by sequential homopolymerisation of 
its constituent monomers. However, when bifunctional initiators are used, 
A B A or ABC triblock'"" copolymers are formed, the best known example 
being the PEO-PPO-PEO triblock copolymer (pluronics). 
Multifunctionalised initiators are required for multi-arm and star block 
copolymers'^'. Polymers with similarities to natural polymers (for 
example, polyelectrolytic polymers as substitute for DNA, RNA and 
some proteins) can be designed with this process. Zwitterionic block'''^ 
copolymers are similar electronically to proteins and may therefore be 
useful as synthetic polymeric substitutes for proteins. 
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1.8.2 Properties of Block Copolymers 
As one of the best-known smart functional block copolymers, micelles 
containing a specific hydrophobic block have been found to be more 
effective as carriers of some specific drug. Some of the other sought after 
properties of block copolymers are: -
> Solubilisation; The ability to solubilise an otherwise insoluble 
substance into an incompatible environment 
> It is possible to synthesise block copolymers with high structural 
definition and predictable properties, using l iving radical 
polymerisation. This is useful for defining the quality and 
subsequent use of the polymer produced. 
> Synthesis of block copolymer conjugates with dual solubility 
(amphipathic) and micellisation capability under predetermined 
biochemical conditions (e.g. pH and temperature). 
> Possibilities for reverse micelles, ionic micelles and hydrophilic -
hydrophobic block copolymer formation 
In studies, various groups have investigated many of the physico-
chemical parameters of block copolymer micelles in a very systematic 
way '" . Several reviews have also (indirectly or directly) resulted from 
this work. 
They are typically polymers that respond reversibly or irreversibly to 
changes in biological, physical or chemical stimuli, a property often 
exploited in block copolymer design (usually from hydrophilic-
hydrophilic or hydrophilic - hydrophobic block copolymers) for 
biomedical applications. 
The polybasic hydrophilic-hydrophilic (AB) block copolymer of 
N , N'(dimethylaminoethyl) methacrylate and N , N'(diethylaminoethyl) 
methacrylate has already been synthesised where the resulting polymer 
micellised under pH-induced condition 
Two properties for characterising the phase behaviour of block 
copolymers in solution are micellisation and gelation. 
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Stimulus 
'm 
DMAEMA-DEAEMA 
block copolymer 
Figure 1.21. Shows a general schematic for a smart polymer sensitive to stimulus and 
forming micelles (Chem. Comm., 1997,671-2) 
Upon aggregation'^'* or association of block copolymers in solution 
beyond a certain critical point termed critical micelle concentration, 
micelles'^^ are formed. The aggregation usually forms spherical micelles 
(sometimes elongated) with two distinct regions, the corona (or shell), 
and the hydrophobic core in aqueous solution, which can incorporate a 
hydrophobic substance. 
Attention has been attracted by the development of unique 
hydrophilic-hydrophobic micelle forming combinations with possible 
applications in biological systems under physiological conditions. Armes 
and co-workers have described the properties and characterisations of 
micelles/ micellization in a range of copolymers. 
\ / 
/ \ 
I.OMNa2S04 zero salt 
pH6 7 / \ pH8 
MEMA DEAEMA 
block block 
\ / /V 
Figure 1.22: Schematic representation of the formation of micelles and reverse micelles for an 
AB diblock copolymer. 
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They have also described the synthesis o f micelles with an 
interchangeable (with temperature) core/corona using a partially 
quaternised D M A E M A - M E M A block copolymer'^^Optimum biopolymer 
mimetics capabilities are strongly related to the balance in polymer 
compositions, size and shape. Allen et al '^^ has reviewed the determinant 
for the ability of micelles to deliver various drugs, and factors that 
influence or control each of these individual properties, i.e. loading 
capacity, release kinetics, circulation time, biodistribution, size, size 
population distribution and stability, and morphology of block copolymer 
aggregates as another potential performance related parameter. Micelles 
of amphiphillic block copolymers in aqueous solutions at room 
temperature have been synthesised by a number of research groups, 
which can precipitate at elevated temperature due to the relative 
solubility of the constituent homopolymers. For polyelectrolytic block 
c o p o l y m e r s t h e efficient distribution o f electric charges, which 
consequently contributes to their biocompatibility, defines their ability to 
accurately and efficiently participate in various gene transfer processes. 
Further investigations into these properties should ensure that block 
copolymers are at the forefront of biologically useful materials 
development, perhaps most significantly as delivery systems. 
Unfortunately, the synthesis and manipulation of many of the 
biocompatible block copolymers is d i f f icul t . For this reason, few 
systematic studies have been performed whereby one parameter (e.g. core 
block length) is varied and the effect of this variation on the micelle's 
characteristics is measured due to the fact that there are such a large 
number of variables, which influence micelle properties. Haddleton and 
co-workers'^^ recently polymerised D M A E M A with macroinitiators to 
yield n-BMA and D M A E M A (60-80 mol % ) blocks of different 
architectures (diblock, triblock and star block copolymers). They 
investigated by different techniques as a function of the composition and 
architecture of the compound, the micellization behaviour of the 
amphiphilic block copolymers in acidic water. However, the PPO-PEO-
based block copolymers are available commercially, and for this reason 
many studies have been done on this system. 
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1.9 Project Strategy 
1.9.1 Design and Synthesis of ATRP initiator/linker reagents 
The aims of the above project are to design and synthesise hetero 
bifunctional linkers for functionalising bioactive substrates with ATRP 
initiators for polymerisation to form water-soluble biocompatible 
bioconjugates. Attachment of a chemoselective group (See Table 1) and 
an ATRP initiator unit to either end of a medium length polyethylene 
glycol (PEG) spacer w i l l give a suitable reagent for such a purpose. 
The anchored hetero-bifunctionality on the PEG w i l l possess a 
functionality (a-bromoisobutyryl ester) for ATRP polymerisation and 
maleimide or succinimide selective towards amines or thiols in proteins 
and peptides; they can also, in the absence of the primary target groups, 
be used with others, functionalities (e.g. phenols). These reagents w i l l be 
soluble and stable in a wide range of synthetic and aqueous conditions. 
After the desired protein/peptide-ATRP initiator synthesis has been 
achieved, they w i l l be subjected to bioconjugate synthesis by exploiting 
the reactivity of the tert-alkyl halide in a metal assisted living 
polymerisation process as previously discussed. 
The project was envisaged to apply established methodology 
(Merrified's Fmoc peptide synthesis and ATRP etc) in the development 
of a standard protocol, for the preparation of bioconjugates. 
1.9.2 Structure of the Linkers 
Two classes o f novel hetero-bifunctional reagents, containing thiol or 
amine chemoselective groups as targeting moiety tethered to an alkyl or 
(tri , tetra and penta) ethylene glycol spacer functionalised with an ATRP 
initiator of the isobutyryl bromide variety were intended. The masking of 
the ATRP moieties to prevent deleterious side reactions would be 
investigated. The medium length ethyleneglycol was expected to provide 
increased aqueous solubility for the reagent and the conjugates; and 
where the bioconjugate is a complex macromolecule (i.e. proteins^, Jhe 
spacer should improve access'^° of the targeting moiety to the protein 
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receptor and in some case suppress non-specific binding'^'. A shorter 
length linker would also be synthesised with a minimum length of alkyl 
spacer to reduce the hydrophobicity of the resulting linker/initiator. 
These two groups of biocompatible ATRP initiator/ linker were intended 
to be further amenable to encompass a variable number of available 
targeting moieties (i.e. RGD, HSA etc) in order to develop a simple 
protocol for encouraging large-scale synthesis of ATRP polymer 
bioconjugates. 
1.9.2.1 Polymerisation 
The block copolymerisation and the subsequent conjugated 
macromonomers using the uniquely developed initiators to satisfy certain 
technological or biomedical requirements w i l l also posses the ability to 
form micelles on exposure to appropriate conditions. These initiator 
labelled substrates (of amino acid, peptide or protein) would be subjected 
to ATRP conditions according to published procedure to construct the 
final peptide/protein polymer bioconjugates. 
Functionalised 
Peptide/Protein 
1. LRP,20°C 
2. DMAEMA 
3. MEMA 
2 
Figure 1.23. 
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Synthesis of succinimidyl/amine-reactive diester -ATRP initiator/linkers 
2.1 Introduction 
The main focus of our synthetic strategy to succinimidyl ester 1 is the 
construction of the diester in an activated form suitable for selective 
functionalisation of substrates in a mild environment thereby avoiding 
complications associated with conditions intolerable to biological substrates. The 
synthesis relies on the successive coupling/condensation reaction based on 
standard reagents and conditions to give 1, Scheme 2.1. The retrosynthetic 
analysis in Scheme 2.1 shows the key intermediate 3, and the early introduction 
of the succinimide ester to 3 wil l also ensure easy access to the required final 
substrate in a single step. The final compound would then be loaded onto a pre-
prepared and appropriately fianctionalised amino acid residue (i.e. lysine) to 
produce the required ATRP initiator-labelled peptide (or protein) for use in living 
polymerisation. 
AA = Amino acid 
Peptide with free lysine residue 
1. X = Br 
2. X = O M e 
Br O H 
Scheme 2.1: Suggestedretrosynthesis ofN-alkyl succinimidyl-based ATRP reagent 1 
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Synthesis ofsuccinimidyl/amine-reactive diester-ATRP initiator/linkers 
2.1.1 AIMS 
The main aim of this work was to undertake a model study based on our strategy 
to afford a unique ATRP initiator with minimum hydrophobic or contributive 
hydrophilic properties to the constructed bioconjugate consisting of, for example, 
a peptide/protein coupled to ATRP generated polymer. Our first synthetic target 
was the diester 1 with the initial retrosynthetic procedure proposed shown in 
Scheme 2.1. The succinimide 3 would be prepared by reacting the commercially 
available 3-bromopropionic acid 4 with iV-hydroxysuccinimide. The resulting 
activated ester would be condensed with an appropriately a-substituted 
isobutyric acid (Scheme 2.2) to produce the diester 1. The reagent 1 was 
designed to incorporate a minimum length of hydrophobic alkyl chain to reduce 
hydrophobicity. Also, preparation of the a-methoxy 2 equivalent to a-bromo 
compound 1 when urmiasked (Scheme 2.2) was also investigated to provide an 
alternative route to functionalisation with 2 in enviroimients less conducive to the 
halogenated equivalent. Consequently, this report wil l be in two sections 
describing the synthetic approaches to 1 and 2 and the attempted interconversion. 
NaOMe/MeOH 
Bromocatechol borane, DCM 
Scheme 2.2:Interconversion of the masked halogen under mild conditions. 
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2.2 Synthesis of succinimidvl/amine-reactive diester-
ATRP initiator/iinkers 
2.2.1 Section A: Attempted synthesis via 3 bromopropionic 
acid 
Starting from commercially available 3-bromopropionic acid 4, the synthesis of 
the key succinimidyl intermediate 3 would be expected to be approached in 
several simple and sequential condensation reactions as shown in Scheme 2.1. 
The attempted coupling of unprotected 3-bromopropionic acid was 
carried out using standard coupling reagents, that is, treatment of 4 with 1.4 
equivalents of N-hydroxysuccinimide in the presence of E D C I with or without a 
catalytic amount of N,N-dimethylaminopyridine in dry dichloromethane at room 
temperature. After complete consumption of the acid, the mixture was subjected 
to aqueous workup and in vacuo removal of solvent to give a crude compound. 
Upon analysis of the crude compound by ' H N M R , the presence of at least three 
different compounds was observed. The mixture was fiirther subjected to either 
distillation or column chromatography both of which resulted in the degradation 
of the mixture. 
The mixture was then triturated in methanol to give the acrylate 5 as a colourless 
solid in 33 % yield. This was confirmed by the characteristic broad four-proton 
signal in the ' H N M R corresponding to the (CH2CH2) of //-succinimide at 6 2.88 
ppm suggesting the incorporation of succinimide in the product, while the 
presence of three sets of 
Su 
SuOH. EDCI . D M A P ^ 
Br ^ 
DCM, rt. 
S u O 
33% 
Br 
Q 5 
S u O ' 
Scheme 2.3 
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doublets of doublets at 5 6.3 ppm, 5 6.5 ppm and at 5 6.7 ppm corresponding to a 
vicinal proton adjacent to a pair of geminal protons were also observed, 
suggesting that the acrylate 5 had been formed. However, the expected product, 
succinimidyl 3-bromopropionate 3 which had been observed as two triplets at 6 
2.9 ppm and 6 3.5 ppm (CH2CH2Br) in the ' H N M R of the crude product (with 
other by-products) during preliminary analysis was not identifiable thereafter 
either in the methanol triturate or after column chromatography. The presence 
and identity of the acrylate was fiirther confirmed by comparing the observed 
melting point 67 - 69 ° C and other data with the data published' for N -
succinimidyl acrylate 3 to further confirm the identity of the unexpected 
elimination product. The elimination product via the loss of HBr was thought to 
be facilitated by the tertiary amine present on E D C I , which may have 
deprotonated the highly base labile a-proton to the carbonyl and fiirther 
accelerated by the potential to form a stable conjugate after such elimination. 
Therefore, the use of a substrate with less potential as a leaving group than 
bromide anion was investigated. 
2.2.2 Attempted synthesis via 3-hydroxypropionic acid 
The retrosynthesis below was therefore proposed to incorporate the fimctional 
X = Br, OMe 
H O ' - B r 
4 
O 
H O ' ^ - O H 
6 
Scheme 2.4. New retrosynthetic procedure to target compound 1 
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group interconversion to an hydroxy substrate 6 (Scheme 2.4) with a poorer 
leaving group than alkyl halide 4 necessary to give the new key intermediate 7. 
Discussed below are the attempts to synthesise the intermediate 7 and to 
proceed to the target compound 1. The proposed approach for the new strategy 
was based on modified published^ methodology for the conversion of various 
haloalkyl carboxylic acids into the equivalent hydroxypropionic acids in 
moderate to good yields. 
2.2.2.1 Synthesis of 3-hydoxypropionic acid 
Using the method of Kowski and Lossen^, 3-bromopropionic acid was refluxed 
in water for 6.5 h. Scheme 2.5. Upon completion, as determined by TLC, the 
reaction mixture was extracted with ethyl acetate and concentrated under reduced 
pressure. Unfortunately, analysis of the reaction mixture by mass spectroscopy 
showed that it consisted of several products. The product resulting from 
dehydration was detected as an ion at m/z (-ES) 73, and at m/z (-ES) 45, a 
H2O, reflux, 6.5 h; 
H O ^ ^ B r HO^ ^ " O H 
Scheme 2.5 
product resulting fi-om decarboxylation. A signal at m/z 89 (M - H^) 
corresponding to the expected product was also seen in the mass spectrum. 
Attempts at precipitation of the crude mixture or column chromatography almost 
always resulted in accelerated process of elimination to give acrylic acid and 
subsequent formation of polymer by-products. The reaction mixture was instead 
subjected to kugelrohr distillation, giving the product 3-hydroxypropionic acid 6 
in 30 % yield as an orange/pink oil which solidified on standing. The presence of 
the expected new methylene group of hydroxyl methylene (CH?OH ) was 
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observed as a ' H N M R signal at 5 4.37 ppm with the expected characteristic 
infrared signal at 3264 cm"' for the hydroxyl group. 
To synthesise the key intermediate 7, synthesis of the required bromoisobutyryl 
ester 8 activated with //-hydroxysuccinimide was necessary to reduce reaction 
time and consequently reduce exposure to a possibly deleterious environment. 
O 
H O ^ ' ^ N < ^ (i) SuOH, EDCI, DMAP, DCM, 8 h, 55 % 
Br • 
20 
Scheme 2.6 
Using traditional coupling reagents to produce the aqueous soluble urea, 1.2 
equivalents of EDCI, N,N-dimethylaminopyridine (catalytic) in dichloromethane 
and a-bromoisobutyric acid 20 was then stirred with 1.2 equivalents of A'-
hydroxysuccinimide in dry dichloromethane at room temperature and the 
reaction was monitored by TLC until complete consumption of the investigated 
carboxylic acid occurred, after 8 hours. After aqueous workup and removal of the 
solvent in vacuo, further purification gave the desired product 8 in 55 % yield, 
Scheme 2.6. The structure of the product was further identified by the presence 
of the characteristic ' H N M R signals for succinimide and substituted isobutyryl 
units. The structure of a - bromosuccinimide ester 8 was confirmed by the 
presence of the unperturbed signal for a six-proton singlet at 5 2.08 ppm and a 
broad four-proton singlet signal at 5 2.86 ppm in the ' H N M R spectrum 
corresponding to a-bromodimethyl and //-substituted succinimidyl group 
respectively. A molecular ion for (M*) at m/z 263 in the mass spectrum was also 
observed. 
The lower yield for the formation of 8 was thought to be due to the formation of 
the elimination product, hydrogen bromide, exacerbated by a lengthy reaction 
time, although, only the unreacted acid 20 (20 %) was identifiable (total 
recovered reactant mass was less than expected) as the by-product. 
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2.2.3 Attempted synthesis of 3-(2-bromo-2-
methylpropionyloxy)propionic acid 
The next stage of the proposed strategy, and with both activated a-substituted 
isobutyryi and the hydroxyethyl carboxyiic acid reagents in hand, is the synthesis 
of the key intermediates (Scheme 2.7) by the coupling of an isobutyryi to the free 
hydroxyl group. With the use of succinimide 8, it was hoped that the milder 
environment would discourage or reduce the formation of elimination products. 
HO 0 
7 (X = Br) 
Scheme 2.7 
To form the 3-(2-methoxy-2-methylpropionyloxy) carboxyiic acid 7, a solution 
of 3-hydroxypropiomc acid 6 was stirred with 1.2 equivalents of succinimidyl 2-
bromo-2-methylpropionate 8 and a catalytic amount of N,N-
dimethylaminopyridine. Scheme 2.8. Unfortunately, the resulting elimination 
H O ' ^ OH 
6 
(i) or (ii) or (iii) 
RO R O ' ^ OH 
6 
R = H, N-Succinimidyl 
HO 
(i) SuOH, DMAP, EDCI; (iia) PhjCCl, TEA; (b) 8 (c) Dioxane/HjO (1:1); 
(iii) PMBCl, Nal, DMF, TEA 
Scheme 2.8. Schematic of attempts to synthesise the key intermediate 7. 
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compound 5 was the only isolated product in 30 % yield after purification. This 
was increased to 40% yield whenever D M A P is used in the reaction. The by-
product 5 was further confirmed by comparing with previously isolated acrylate 
product, Scheme 2.3. The crude reaction mixture, after interpretation of the 
spectral data showed the presence of a hydroxyethyl group, which differed from 
that in the starting carboxylic acid 6 although with a higher proportion of the 
characteristic A B X coupling pattern in the ' H N M R signal attributed to a proton 
adjacent to germinal alkenes. A number of other unsuccessftil (Scheme 2.8) 
attempts were made at synthesising the key intermediate, some of which included 
in-situ protection/deprotection of the carboxylic acid prior to hydroxyethyl 
fiinctionalisation and changes in reaction time and temperature. The observed by-
product was proposed to be due to the highly acidic proton (pKa ~ 20) adjacent 
0 H 
B L G = OH" and Br' Conjugate base intermediate 
Scheme 2.9. The stabilised elimination reaction mechanism 
to a carbonyl and the influence of a conjugated potential leaving group in the p-
position, which could have facilitated the elimination via enolate intermediate 
formation to produce an a, p - unsaturated carbonyl compound. Scheme 2.9. 
Hence, to reduce the potential for leaving group conjugation assisted elimination 
(EICB), an extension of the alkyl chain from 3-hydroxypropionyl to its 
hydroxybutyl equivalent was proposed. The hydroxybutyl should disfavour the 
formation of a,P-unsaturated carbonyl even if a conjugate base intermediate (via 
enolisation) was formed. Due to our unsuccessful attempts to efficiently 
synthesise succinimidyl ester of 7 or 3, the approach starting from 3-
hydroxypropanoic acid was now abandoned in favour of the newly proposed 
strategy below based on hydroxybutanoic acid. 
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2.3 Synthesis of succinimide substituted n-butvlester 
2.3.1 Synthesis of p-methoxybenzyl 4-hydroxybutanoate 
The synthesis of the alkyl succinimide reagent 12 was attempted based on the 
procedure outlined below (Scheme 2.10). The new approach would employ the 
commercially available sodium salt of 4-hydroxybutanoate 9 to synthesise its 
o 
SuO 
12 
NaO 
.Br 
O 
OH 
SuO = A'-succinimidyl, PMB = p-methoxybenzyl 
Ro-
l l , R = PMB 
llb,R = H 
PMBO 
10 
OH 
Scheme 2,10 
4-methoxybenzyl ester 10 by reacting with 4-methoxybenzyl halide based on 
general^  methodologies for benzylation of carboxylic acids. 
The reaction of /?-methoxybenzyl chloride (1.2 eqv) with the sodium salt 
of 4-hydroxybutanoate in dry DMF and a catalytic amount of sodium iodide with 
activated powdered sieves was monitored by TLC, the level of reactant 
consumption was the same after the first 4 h as after 72 h (5% MeOH/ 
dichloromethane, Rf 0.35). The presence of two different ' H N M R signals 
(MeOPhCH?, 6 5.07 ppm and 6 4.86 ppm) for the same benzyl methylene proton 
were thought to represent both the product and /7-methoxybenzyl hydroxide from 
the incomplete reaction, accompanied by other unassigned signals. On workup, 
the low yield of 40 % for 10 was attributed to the ease of hydrolysis of p-
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methoxybenzyl iodide and also could have resulted from the choice of solvent 
(DMF) and the consequent decomposition of the highly reactive p-
methoxybenzyl iodide. 
.OH PMB-CI(1.2eqv.) 
NaO PMBO 
OH 
Scheme 2.11 
Reaction 
No 
Reagents 
& 
Solvent 
Condition(s) Yields 
% 
Comment(s)/ Others (%) 
01 Nal, 
DMF 
25 °C, 72 h 40 * *Decomposition 
02 TBAB, 
DCM 
25 °C, 72 h 51 4-hydroxybutanoic acid 
40 % 
03 TBAB, 
THF 
25 °C, 72 h 66 4-hydroxybutanoic acid 
30% 
04* TBAI, 
acetone 
Reflux, 24 h 80-92 ••Decomposition 
•Literature''' ** including 4-hydroxybutanoic acid amongst the products 
Table 2.1 
The solvent system (DMF) was therefore substituted with THF and 
dichloromethane respectively in subsequent reactions (Table 2.1) without sodium 
iodide in order to reduce possible hydrolysis. However in both cases after 72 h 
only a limited reaction was observed without Nal. When a catalytic amount of 
tetrabutylammonium bromide (phase transfer agent) was added and Nal was 
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omitted from the reaction mixture for a 72 hours (monitored by TLC) reaction 
period, the reaction gave 10 as a colourless oil in 51 % in dry dichloromethane 
and 66 % in dry tetrahydrofiiran with 40 % and 34 % of 4-hydroxybutanoic acid 
recovered respectively from the resulting brown oil after chromatography. It was 
noted that on addition of catalytic Nal to the reaction, the yields were 
significantly reduced and increased decomposition that is, increased quantity of 
by-products were observed. 
The above observations suggested that while increased solubility of 
reagents/reactants increased the rate of reaction, the increased reactivity 
associated with introducing a more reactive substituent (Table 1) also increases 
the rate of side reactions including hydrolysis. The process leading to the 
decomposition material was not comprehensively investigated but minimised by 
avoiding Nal. 
During the course of our attempt to efficiently use /?-methoxybenzyl chloride in 
alkylating sodium 4-hydroxybutanoate, a different and successfiil approach was 
reported"* involving the reflux of p-methoxybenzyl chloride and sodium 4-
hydroxybutanoate in acetone to afford the protected carboxylic acid in good 
yield. We therefore attempted the reaction in accordance with literature, 1.2 
equivalents of p-methoxybenzyl chloride was stirred with the 4-
hydroxybutanoate salt in acetone before adding a catalytic amount of 
tetrabutylammonium iodide and stirred for 24 hours. The reaction mixture was 
then filtered, concentrated and diluted with dichloromethane before being 
washed with water. The resulting brown oil was dried and purified by flash 
column chromatography to give 10 in 92 % yield - a result that was further 
reproduced on multigram scale synthesis. 
2.3.2 Synthesis of 4-methoxybenzyl 4-(2-bromo-2-
methylpropionyloxy)butanoate 
Introduction of the ATRP initiator moiety on to the linker was achieved by 
converting the free 4-hydroxyl group on 4-methoxybenzyl 4-hydroxybutanoate 
10 to the key intermediate 11 by reacting respectively with bromoisobutyryl 
bromide 21 and N,N-dimethylaminopyridine (cat.) at room temperature 
overnight. The progress was monitored by TLC and column chromatography 
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gave the product (11) 54 % yield. When 8 was used instead of bromoisobutyryl 
bromide 21 to react with 4-methoxybenzyl 4- hydroxybutanoate 10, the yield was 
improved by 20 % (to 72 %) of 11, Scheme 2.12. 
PMBO 
10 
Br, T E A , D C M PMBO-
11 
Br 
X = Br (21), 54%, 
X = oxy succinimidyl ester (8), 72 % 
Scheme 2.12 
The increased yield can be attributed to the mildness of the liberated spectator 
molecules and their influence on the system (product and reagents). The 
liberation of hydrogen bromide (strong acid) when a-bromoisobutyryl bromide 
was used with the absence of an adequate quantity of triethylamine to neutralise 
the reaction mixture, had the probable effect of deprotecting the p-
methoxybenzyl esters 10 and 11 to their carboxylic acids. The problem can be 
overcome by using a greater number of equivalents of more hindered base (i.e. 
DBU) or as proven above. Scheme 2.12, the use of 8 that produces a less 
hazardous spectator species - A^-hydroxysuccinimide. 
2.3.3 Synthesis of N-succinimidyl 4-(2-bromo-2-
methylpropionyloxy)butanoate 
The final stage for the synthesis of the described alkyl linker was 
approached as shown below, using standard deprotection and coupling 
methodology. The /?-methoxybenzyl protected bromoalkyl spacer 11 was treated 
with 10 % TFA/ dichloromethane (1:1, v/v) for approximately 4 hours at room 
temperature during which a dark red colouration was observed. The consumption 
of 11 was monitored by TLC. Upon completion, the mixture was quenched with 
water and saturated NaHCOa - fiirther treatment of the aqueous extract gave the 
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intermediate carboxylic acid l i b in 90 % yield confirmed by molecular ions at 
m/z 274.9912/276.9894 in high resolution mass spectroscopy which was in 
agreement with the calculated value of m/z 275.000/276.998 for C8Hi3Br04Na. 
The free carboxylic acid l i b was treated under standard coupling conditions 
with 1.2 equivalents of DIC, 1.2 equivalents of N-hydroxysuccinimide and 2.0 
equivalents of triethylamine in dry dichloromethane. 
PMBO 
(i) 10 % TFA/ DCM, 4 h, 98 % 
(ii) DIC, SuOH, TEA, DCM, 16 h, 75 % 
lib 
Scheme 2.13 
The mixture was stirred for 16 h at room temperature, monitoring of the reaction 
by TLC showed the appearance of a new spot and further investigation by 
observing the ' H NMR spectrum also showed a new four-proton succinimidyl 
signal at 6 2.85 ppm after 12 h. Purification by column chromatography gave the 
target succinimidyl product 12 in 75 % yield (Scheme 2.13), this was confirmed 
by HRMS which agreed with the calculated values. 
No Reagents/Condition Duration (h) Analysis ('H NMR & ES/MS) | 
1 20% Piperidine/ DMF 0.5 No decomposition 
2 TFA/ Water/ TIS 4 No decomposition | 
3 TFA/ Water/ TIS/ EDT 4 No decomposition 
32 : 2 : 2 : 1 (ratio) 
Table 2.2 
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However, our model test (Table 2.2) to determine the stability of the bifunctional 
linker 12 in a peptide synthesis environment, showed the substrate to be 
unaffected within a specific period of time representative of the intended solid 
phase peptide synthesis (SPPS) protocol in Table 2. 
2.4 Section B: Synthesis of a-methoxv masked diester 
2.4.1 Introduction 
As demonstrated during the synthesis of 8 (Scheme 2.6) and 11 (Scheme 2.10) of 
Section A, the a-bromoisobutyryl unit was sensitive and therefore susceptible to 
deleterious reactions induced by either the reaction enviroimient or by co-
reagents involved in a transformation. Although the model test above eliminated 
the need for such action during solid phase peptide synthesis (SPPS) for short 
duration based on the conditions above however, the examples in Section A 
proved otherwise especially with time. The investigation would hence focus on a 
simple but routinely effective method of interconverting masked a-halide 
functionality for use in (for example) prolonged and potentially detrimental 
transformation/functionalisation processes. 
2.4.2 AIMS 
This is to synthesise 15 (Scheme 2.16) and perform an efficient functional group 
interconversion of the more stable masked substrate 15 to its active species 12 
based on Scheme 2.2. The masking functional group would be of the form of an 
Nucleophilic Boron intermediate 
Scheme 2.14 
77 
Section B: Synthesis of a-methoxy masked diester 
alkyl ether synthesised as shown in Scheme 2.2 (and elaborated on later), and 
transformed using agents based on Lewis acidic organoboranes. Monoftinctional 
organoboranes of the general formula R2BBr were envisaged to be suitable 
halogenating agents because of their steric and electronic nature (Figure 2), 
which should influence the SNI VS SN2 reactivity of an appropriate ether-type 
substrates and consequently the expected transformation. The attempts are 
discussed in the next section. 
2.4.3 Synthesis of N-Succinimidyl 2-methoxy-2-
methylpropionate 
Starting from the commercially available 2-bromo-2-methylpropionyl bromide 
21, the syntheses of N-succinimidyl 2-methoxy-2-methylpropionate 14 (Scheme 
2.15) would be established from its carboxylic acid based on modified literature 
procedure.^  The masking group (a-methoxy) was expected to form a more stable 
substrate but easily convertible to its corresponding alkylbromo moiety under 
mild conditions^ using a simple procedure proposed to involve a nucleophilic 
boronic intermediate species (Figure 2), thus a-methoxy was chosen as a suitable 
substitute. 
H O - ^ ^ (i) H O ' ^ < ^ „ (ii) 
~Br ^ I^OMe 
21 13 
(iii) 
(i) NaOMe, MeOH, 40 °C, 24 h, 77 %; 
(ii) SuOH, EDCI, DMAP, DCM, 4 h, 73 %; 
(iii) SuOH, EDCI, DMAP, DCM, 8 h, 55% 
* see Section A for details 
Scheme 2.15 
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The nucleophilic substitution of the bromide in the commercial 2-bromo-
2-methylpropionic acid was achieved by stirring with freshly prepared NaOMe 
(2.2 eqv) in methanol at 40°C, and the resulting mixture was monitored by TLC 
over a period of 24 h, and the diminishing ' H NMR signal at 5 1.92 ppm for the a 
substituted tertiary halide was monitored. The reaction was then acidified to pH 
1, filtered and the methanolic filtrate concentrated and subjected to further 
workup to give 13 in 77% yield, Scheme 2.15. The structure was observed in 
NMR spectrum as signal for six proton singlet at 6 1.4 ppm and three proton 
singlet at 5 3.3 ppm corresponding to the dimethyl and methoxy respectively, 
adjacent to the carboxylic acid. The structure was further confirmed by the 
presence of a molecular ion [M+Na"^ ] at m/z 141 in the mass spectrum. 
Attempts at increasing the yield by varying time and temperature proved 
unsuccessful, often resulting mainly in reduced yield and the recovery of the 
bromoisobutyric acid especially at temperatures below 40 °C, while 
decomposition products became more prominent at temperatures above 60 °C. 
The carboxylic acid obtained was then treated with standard coupling reagents as 
described for 8 (Scheme 2.6) in Section A with N-hydroxysuccinimide to yield 
the activated ester 14 in 73% yield. The compound was confirmed by the 
presence of the new four-proton singlet 
p 
9 14 
OMe 
0 
0 ^ 0 M e 
^ TEA. DCM, rt, 6 h, 90 % 
O 
PMBO' 
O H 
PMBO 
10 
Scheme 2.16 
signal at 8 2.8 ppm corresponding to CH2CH2 of succinimide in the ' H NMR 
spectrum and the presence of a molecular ion [M+Na^] at m/z 238 in the mass 
spectrum. 
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The synthesis of 15 was easily accomplished by reacting 1.1 equivalents 
of 14 with 10 in 90% yield following the procedure described for 11 (Scheme 
2.13). The replacement of the two proton multiplet at 5 3.6 ppm for CH2OH with 
two proton triplets at 6 3.8 ppm corresponding to the acylated hydroxyl group in 
the ' H NMR was used to monitor the reaction progress and the structure was 
fiirther confirmed by presence of the molecular ion [M+Na^] at m/z 347 in the 
mass spectrum. With the substrate 15 in hand, the next section discusses the 
attempts at the proposed interconversion with organoborane reagents. 
2.4.4 ly/lodel conversion using organoborane reagents, Part 1 
2.4.4.1 Attempted synthesis of a-bromoisobutyryl ester from a-
methoxyisobutyryl units using organoborane reagents. 
.6 The use of boron in synthesis often takes advantage of their high selectivity 
(especially monofiinctionalised organoborane) in the cleavage of carbon -
oxygen bond, and their method of reactivity (SNI VS SN2) can be modified based 
on electronic 
R O R ' + B - B r B - O R + R Br 
H2O 
OH 
+ H3BO3 + R O H 
OH 
Scheme 2.17 
and steric control of the boron/ligand composition. Diphenylboron bromide and 
dimethylboron bromide'are the most prominent boron reagents for such studies. 
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Other literature had already described how with or without a co-reagent 
(BFa.OEti), various commonly used ethers on azo dyes have been converted into 
bromides using catecholboron bromide at room temperature based on the 
mechanism shovra below. Scheme 2.17. Published data showed catecholboron 
bromide to represent an even milder but equally efficient reagent with reactions 
often completed in one to two hours (but varies from 5 min, 0.5 h to 36 h), which 
after an aqueous workup gives the products in excellent yields (84 - 95 %). 
The unmasking via borane-assisted functional group interconversion 
(FGI) of the masked ATRP substrate 15 to its bromoalkyl ATRP fiinctional 
group in 11 (Scheme 2.13) was intended to occur under mild conditions to 
protect the surrounding potentially sensitive biomacromolecule (e.g. peptide, 
protein). The a-methoxy alkyl 15 was therefore subjected to the literature 
conditions by the treatment with 1.1 equivalents of bromocatechol borane at 0°C 
in dry dichloromethane. 
PMBO 
OMe 
Bromocatecholborane 
PMBO-
11 
Scheme 2.18 
However, no reaction was observed by TLC analysis after a period of 4 hour. 
The reaction was then allowed to stir at room temperature for a further 4 hour, 
during which several new spots not corresponding to the expected product were 
observed as major components of the crude mixture, hence the reaction was 
quenched with water and aqueous NaHCOa, After an aqueous workup, the 
column chromatography gave unreacted 15 in 60 % with other unassigned by-
products. 
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15 
OMe 
Bromocatechol borane 
room temperature, 2 h © OMe 
Aqueous 
work-up 
HO' 
16 
i^OMe 
O 
Scheme 2.19 
When the reaction temperature was reduced to -78 °C for 6 h, analysis by TLC 
showed patterns similar to that described above with 50 % of 15 and 25 % 
unassigned by-products recovered after workup. The observed results were 
proposed to have been facilitated by the high affinity for electrons by 
catecholborane in the neutral environment that aided the facile removal of the p-
methoxybenzyl ester instead of the other ester or indeed the desired ether. 
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Hence, attempts to reduce the electronic contributions from the potential 
conjugating system present in the p-methoxybenzyl ester (Scheme 2.19) were 
NaO-
(i) 
BnO 
OH 
BnO-
(i) BnBr (1.2 eqv.), DMF, rt, 48 h, 97 %; (ii) 2-methoxy-2-niethylpropionic acid 
(1.2 eqv.), EDCI (1.2 eqv.), DMAP (1.2 eqv), DCM, 51 %; (iii) 2-bromo-2-
methylpropionyl bromide (1.2 eqv), TEA, DCM, 5 h, 56 %.; (iv) Bromo catechol 
borane. 
Scheme 2.20 
proposed. They would ensure the adjacent carbonylate was preferentially and 
adversely transformed. A benzyl-protected alkyl ester was therefore proposed 
and synthesised using standard methodology. 
The phenyl protecting group without electron donating substituents would be a 
less labile protecting group and therefore avoid intramolecular hydrolysis even in 
the presence of species capable of hydrolysis. 
The benzyl ester was synthesised by treating the sodium salt of 4-
hydroxybutanoic acid 9 in dry DMF with tetrabutylammonium bromide (cat.) 
and 1.2 equivalents of benzyl bromide for 48 hours at room temperature. The 
crude mixture was subjected to in vacuo removal of DMF before being subjected 
to an aqueous workup and column chromatography. This gave 17 in 97% yield. 
The identity of the compound was fiirther confirmed by the presence of a two-
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proton singlet at 5 5.15 ppm for benzyl methylene in the'H NMR spectrum and 
by the molecular ion at 217 (M + Na*), which agreed with calculated value of 
217 for CnHnBrOsNa (Scheme 2.14). Subsequent treatment with 1.2 
equivalents of 2-methoxy-2-methylproionic acid 13 or 1.2 equivalents of a-
bromoisobutyryl bromide 21 was carried out according to previously described 
methods for 11 and 15 to give 18 in 51 % yield and 19 in 56 % yield respectively 
with high recovery of 17 in both cases. The yield could possibly be improved by 
using a greater excess of reagents relative to 17. However, as the aforementioned 
compounds 18 and 19 were only initially required in milligram quantities for test 
conversion purposes, it was not considered necessary to attempt to improve the 
yield. 
2.4.5 Model conversion using organoborane reagents, Part 2. 
Compared with the standard approaches that used strong acid or base cleavage 
methodology, the mildness and neutral nature of the above methodologies 
therefore made catecholboron bromide our first choice as a reagent for 
converting a-methoxyether into its a-bromo equivalent. One equivalent of 
bromocatecholborane was stirred in dry dichloromethane containing 18 at room 
temperature. The reaction was monitored by TLC over a period of 24 hours but 
Q 
BnO' 
0 
L--OMe Organoborane Jl ^ o 1^^' 
BnO 
O O 
18 19 
Scheme 2.21: Some of the attempt at unmasking using mild organo-boron based reagents 
unfortimately showed no change. The same result was observed when the ratio of 
borane to substrate was increased to 4:1 in order to compensate for the necessity 
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for coordination. The above approach also showed no reaction over a period of 
24 hours in dry dichloromethane as judged by TLC with the substrate recovered 
quantitatively. While the temperature was kept constant at room temperature and 
the duration maintained at 24 hours, three different boron reagents and conditions 
were employed to no avail. They included the use of boron tribromide (one and 
four equivalents), dimethylboron bromide (one and four equivalents) in toluene, 
acetonitrile or dry dichloromethane. 
Due to time constraints the required transformation was not realised. 
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3.1 Introduction 
Our target linker reagent, inspired by the synthesis of zwitterionic (or Huisgen 
ylid) intermediates of carboxymethyl esters, is a succinimidyl ester that 
incorporates a medium length polyethylene glycol (of the tri, tetra and penta 
series) unit as spacer in the developed potential ATRP initiators. Polyethylene 
glycols are degradable by both enzymatic and chemical hydrolysis, and have 
been described' as effective component of bioconjugation strategy as observed to 
also enhance half life, solubility and biocompatibility (and consequently 
biodistribution) of, for example, drug bioconjugates^ than the drug's native form 
e.g. pegylated recombinant interferon^ 
The pre-requisite a-bromoisobutyryl unit has already been utilised by various 
groups in the presence of polyethylene glycol for living polymerisation; 
furthermore, Matyjazewski and Armes for example, have both independently 
described the effect of aqueous media on living polymerisation with favourable 
effect on polymerisation and resulting polymer properties i.e. narrow 
polydispersity index (see Section 1.4). 
3.1.1 AIMS 
In this chapter we are concentrating on the development and synthesis of N -
succinimidyl fiinctionalised polyethylene glycol of the a-bromoisobutyryl 
substrate, a precursor of potential ATRP initiators unit for polymerisation. 
9 ?^ (i) o 
R O ' \ R o - - -^"^ 
(i) R' Nj, Base, DCM 
Scheme 3.1: Proposed alternative to haloacetate approach. 
The synthesis of the linker reagents (1 - 3) was based on the Lewis acid assisted 
insertion of carbene into OH a-bond using diazonium transfer agents. Scheme 
3.1, R = Bn, tert-B\x, R'=Me, Tol. 
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This approach provides access to the carboxymethyl unit under milder reaction 
conditions and better yield than the alternative methodology''"'that (for example) 
utilises bromoacetic acid. The protecting group prevents complication with the 
monofiinctionalised PEG while the preferred benzyloxycarbonyl protecting 
group of the diazo is ideally suited to our goal, being stable to the reaction 
condition employed and easily removed in near neutral conditions. Access to the 
key intermediate (4 - 6) was expected to be via the condensation of an 
appropriately activated a-substituted isobutyryl substrate with the free hydroxyl 
group to yield (7 - 9) prior to debenzylation. The applicaton of a traditional 
coupling technique to the key intermediate should then afford the target 
compoimd. Scheme 3.2. 
Br 
HO 
1, n = 2 
2, n = 3 
3, n = 4 
OSu 
10-12 
OBn 
O 
R = Benzyl, t-Butyl. 
Br 
OH 
O 
Br 
Key Intermediates 
4-6 
OBn 
7 - 9 
HO-
13, n = 2 
„0" 14, n = 3 
15,n = 4 
Scheme 3.2: Retrosynthesis of the carboxymethyl of N-Succinimidyl ester (1-3). 
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This methodology would allow the fast and convenient large-scale synthesis of a 
series of compounds for the chemoselective labelling of biomacromolecules for 
use in living polymerisation of bioconjugates. 
3.2 Synthesis of carboxymethyl ester substituted PEGs 
as reagents for ATRP 
The basic design principle of 12, (chapter 2) was extended to the synthesis of a 
more hydrophilic and more flexible ATRP agent utilising the intrinsic advantages 
(discussed above) offered by medium length polyethylene glycol groups, namely 
- ease of fiinctionalisation and aqueous solubility^. One such functionalisation 
technique utilises a diazonium-based transfer approach to create a new carbon -
carbon bonds or carbon - oxygen bonds via a carbene insertion reaction. To this 
end the first intermediate to be synthesised was benzyl 1 l-hydroxy-3,6,9-
trioxaundecanoate 10. We therefore first needed to synthesise the required diazo 
transfer agent, benzyl diazoacetate - which was achieved according to literature 
methods^. 
3.2.1 Synthesis of benzyl diazoacetate (via diazo transfer 
agent) 
The diazo sources (methyl and p-toluenesulphonyl azide) were preptired 
according to literature method^ by treating 1.4 equivalents of sodium azide with 
methanesulphonyl chloride 16 in acetone at room temperature over a period of 
NaNi Benzylacetoacetate 
R-SO2CI 1 • R-SO2N3 
TEA(1 eqv.), 3 h. 
16. R = Methyl 18. R = Methyl 
OBn 
17. R = p-Tol'uene 19. R = p-Toluene "^ 2 
20 
H 
21 
O 
OBn 
32 M NaOH, 12 h 
Scheme 3.3 
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2.5 hours to give the azide 18 in quantitative yield. This was confirmed by 
characteristic infrared signals at 2146 cm'' (N=N). Alternatively, 1.5 equivalents 
of sodium azide in a mixture of water and ethanol solution was added to the 
solution of /?-toluenesulphonyl chloride 17 in ethanol maintained at 45°C, after 
twelve hours gave the tosylazide 19 in quantitative yield confirmed by infra red 
signals at 2132 cm"' (N=N, str) The azide 18 or 19, was treated with 
triethylamine and benzyl acetoacetate in anhydrous acetonitrile for three hours at 
room temperature before adding potassium hydroxide, and stirred for a further 
twelve hours. After purification by silica gel chromatography, the reaction gave 
21 in quantitative yield. The intermediate 20 was often recovered after adding 
and stirring with triethylamine but before the addition of KOH in attempt to 
initially improve the yield of 21. However, it was observed that the prolonged 
one-pot reaction (described) with KOH had similar effects (similar yields) 
thereby negating the need for additional isolation-purification step. The 
diazoacetate was further confirmed by ' H N M R spectroscopy and characteristic 
diazo infrared stretch at 2115 cm"' corresponding to nitrogen (N=N). 
3.2.2 Monofunctionalisation of ethyleneglycol 
With the diazo at hand, we next attempted to functionalise the polyethylene 
glycol by Lewis acid assisted degradation and the subsequent carbene sigma 
bond insertion. 
Benzyl diazoacetate 21 in dichloromethane was treated with three equivalents of 
triethylene glycol under Lewis acid catalyst condition and at room temperature to 
BFjOEtj (cat.) 
10, n = 88% 
Scheme 3.4 
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yield the monobenzylacetyl substituted triethylene glycol 10 in 8 8 % yield after 
flash chromatography. Scheme 3 . 1 . The product was confirmed by the presence 
of the distinctive two proton singlet and the five proton multiplet N M R 
signals at 5 5.2 ppm and 7.3 ppm in the spectrum corresponding to the benzyl 
methylene (CHiPh) and phenyl protons (CH2Ph) respectively. The observed [M 
+ Na"^ ] ion at m/z 3 2 1 in the low resolution mass spectroscopy was in agreement 
with calculated value of m/z 3 2 1 for Ci5H22Br06Na. 
3.2.3 Deprotection of (a-bromoisobutyryl)benzyl decanoate 
Having fiinctionalised the polyethylene glycol, we then chose a route that 
involved simple deprotection and condensation steps to introduce the desired a-
bromoisobutyryl and N-succinimidyl ester functionality for A T R P initiation onto 
the proposed water- soluble substrate 1, Scheme 3.5. 
^ o 
10 1 
Scheme 3.5 
The key intermediate, carboxylic acid 4 was attempted from the corresponding 
alcohol 10 by treating with 1.2 equivalents of 2-bromo-2-methylpropionyl 
bromide and triethylamine in dichloromethane, initially at 0°C but then allowed 
to warm up to room temperature and stirred for eight hours. After workup and 
silica gel chromatography the benzyl diester 7 was obtained in 7 8 % yield. 
Formation of the benzyl diester was confirmed by the presence of a new six-
proton singlet 
Br 
10 
Scheme 3.6 
92 
Synthesis of carboxymethyl ester substituted PEGs as reagents for A TRP initiator 
at 6 1.9 ppm corresponding to the isobutyryl unit and by the presence of the 
molecular ion [M+Na^] at 469.0940/471.0920 in HRMS, which was in 
agreement with the calculated value of 469 .0843/471.0826 for Ci9H27'''*'Br07Na. 
However, the reaction of benzyl diester 7 with a combination of 10% palladium 
on charcoal, atmosphere of hydrogen gas and in methanol showed an incomplete 
level of consumption (as judged by TLC) which remained even after stirring 
overnight at room temperature. After removal of the insoluble/solid materials by 
filtration, the filtrate was concentrated and dried in vacuo. 
O o 
10%Pd(0), C, H2gas 
Oxidative addition 
RO 
22 
Reductive elimination 
R = H, Bn 24 
47, R = B n 
48, R = H 
Scheme 3.7 
Observed in the resulting N M R spectrum of the crude product was the lack of 
a-bromo substituted product (a common feature for two of the three possible 
components of 4 and 7 ) as judged by the distinctively absent signal for the 
-associated six proton singlet at 8 1.9 ppm but the appearance of a doublet at 5 1.2 
ppm corresponding to an isopropyl unit in addition to the presence of a one 
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proton multiplet at 5 2.6 ppm. Further analysis by mass spectrometry proved 
difficult due to presence of large quantities of by-products. However, the infrared 
spectrum showed the presence of both carboxylic acid (OH) at 3208 cm"' and 
carboxylate carbonyl at 1735 cm"'. The presence of two of the components was 
identified by comparing with prepared authentic samples of 47 and 48. 
Conceivably, the oxidative addition of the alkyl halide onto palladium (0) may 
have resulted in the reductive elimination product 22, and where the 
concentration of dissolved hydrogen is low, a P-hydrogen abstraction may ensue 
to reveal the methacrylate 24, although such process usually proceed or 
accelerated in the presence of base, Scheme 3.7. Methacrylates are highly 
reactive polymerisation monomer hence, once formed, could have contributed to 
the level of by-product observed. Attention was therefore turned to exploring 
processes of protecting the a-halide by masking with substitutes prior to 
debenzylation. The various processes of investigations into substitutes for a-
bromoisobutyryl subtrate has been described in section 3.4; and discussed below 
is the actual altemative procedure followed to accomplish the synthesis of target 
compounds 1 -3 . 
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3.3 Synthesis of*butyl diazoacetate (via diazo transfer 
agent) 
Our next approach relies on the ability to form the tert-hutyl diazoacetate via the 
methodology used to prepare the benzyl equivalent (Scheme 3.3) although the 
prepared tert-huXy\ diazo compound may also be incompatible with our intended 
target compound. 
tert-Butylacetoacetate 
18 or 19 
TEA(1 eqv.), 0°C, 5 h. 
' ^O'Bu ^ 
26 II 
N2 
Q o 
NaOMe, 0°C, 
0.75 h, 83% 
O'Bu 
N2 
25 
Scheme 3.8 
'Butyl diazoacetate 25 was prepared according to the published method^ via a 
diazo transfer fi-om an azide onto an active methylene of tert-butylacetoacetate to 
obtain the diazoacetoacetate in 80% yield, with further decomposition by base 
assisted deacetylation in acetonitrile at 0°C and distillation at reduced pressure to 
give the diazoacetate 26 in 83% yield. Scheme 3.8. The formation of the 
diazoacetate was verified by the presence of a one-proton singlet in the ' H N M R 
spectrum at 5 2.5 ppm corresponding to the a-hydrogen and a nine-proton singlet 
27, n = 2(7I %) 
28, n = 3 (87%) 
29, n = 4 (70 %) 
Scheme 3.9 
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at 5 1.5 ppm corresponding to the tertiary butyl protons. The structure was 
further confirmed by observation in the infrared spectrum that revealed a 
nitrogen and carbonyl stretch at 2132 cm"' and 1714cm"' respectively. 
We then attempted to monoflinctionalise the free hydroxyl group of the 
selected series of polyethylene glycol with the diazo 26 according to the 
previously described method for 10 (Scheme 3.4) to give the carboxymethyl of 
tri, tetra and penta ethylene glycol. The procedure was therefore repeated on tri, 
tetra and penta ethylene glycol until after 3 hours, the reaction was judged 
complete, as observed by TLC and subjected the reaction mixture to flash 
chromatography to give the expected compounds in good yields. The structure of 
the compounds were confirmed in the ' H NMR spectrum by the appearance of a 
new two proton singlet signal at 6 4.0 ppm corresponding to carboxy methylene 
protons and twelve proton multiplet (for n = 2) at 6 3.6 - 3.7 ppm confirming the 
presence of the protons of oxyethylene repeating units. The [M+Na^] molecular 
ions were also observed at m/z 287 (27, 71% yield), 331 (28, 87% yield) and 375 
(29, 70% yield) for tri, tetra and pentaethylene glycol respectively in the mass 
spectrum. 
3.3.1 Synthesis of the series of ATRP initiators. 
Proceeding via a series of general deprotection and condensation conditions of 
the robust tertiary butyl ester protecting the required substrates, the title 
compound was therefore obtained with the desired functionalities and in good 
yield as described below. 
I o o 
X X ^ ° K " o ) ; ^ ° ^ (i) X^°K^o');;^°Yk" 
0 
27, n = 2 30,n = 2(94%) 
28, n = 3 31,n = 3(94%) 
29, n = 4 32,n = 4(80%) 
(i) Bromoisobulyryl bromide (1.2 eqv.), 
TEA (1.2 eqv), DMAP (cat.), 8 h 
Scheme 3.10 
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The next step towards the synthesis of diester (1 - 3) was the conversion of the 
free hydroxyl esters to the corresponding substituted isobutyryl ester. 
The isobutyryl ester 30 was obtained in quantitative yield by reacting the 
hydroxy ester 27 with 1.2 equivalents of triethylamine, N,N-
dimethylaminopyridine for one hour at room temperature then reaction was 
stirred at 0° C for eight hours with a-bromoisobutyryl bromide. Scheme 3.10. 
Purification of the crude by flash chromatography after workup gave the 
expected diester 30 in 94% yield. The procedure was then repeated on substrates 
28 and 29 to give their esters in 94% and 80% yields respectively. The structure 
of the compounds were confirmed in the ' H NMR spectrum by the appearance of 
a new six proton singlet at 6 1.9 ppm and a nine proton singlet at 5 1.5 ppm 
corresponding to a-bromodimethyl and tert-hntyl respectively. The compounds 
were further confirmed by the presence of the [M+Na^] ion in the HRMS 
spectrum corresponding to Ci6H29^^^*'Br07Na, CigHjs'^^^'BrOgNa and 
C2oH37''^ ^ '^Br09Na, which were in agreement with the expected values 
Deprotection of the tert-hutyl ester 31 (n=2) using a solution of 
trifluoroacetic acid (30%) in dichloromethane gave the acid 33 in quantitative 
yield after flash column chromatography. The ' H NMR spectrum no longer 
exhibited the nine proton singlet for the tert-butyl diester, instead showed the 
presence of the free carboxylic acid proton as a broad singlet at 5 4.6 ppm. 
Ov. J^°' (i), (ii) 
3 0 - 3 2 V l ,n = 2(62%) 
2, n = 3 (80%) 
3, n = 4 (75%) 
O 
HO 
OJ > v . ^o. ' 
O' 
2 
33 o 
(i), 30% TFA/DCM, 3 h, rt, 95% (n = 2), (ii), SuOH (1.2 eqv), EDC (1.2 eqv), TEA, DMAP, 16 h, DCM. 
Scheme 3.11 
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Coupling of the intermediate carboxylic acid 4 with A'-hydroxysuccinimide gave 
the succinimide ester 1 (n=2) in 62 % yield. We observed in the ' H N M R 
spectroscopic analysis the presence of a new (broad) four proton signal at 5 2.8 
ppm corresponding to the succinimidyl cyclic ethylene protons. The compound 
was further confirmed by the presence of the [M+Na"*^] ion in the H R M S at m/z 
476.0493/478.0553 corresponding to Ci6H24^^^^'Br09Na, which was in 
agreement with the expected value m/z 476.0634/478.0614 for the succinimidyl 
diester 1. 
The same procedure as for 1 (except for the isolation of the intermediate 
carboxylic acids) was applied to the synthesis of the succinimidyl esters 2 and 3 
in 80% and 75% yields respectively. Their structures were also observed and 
confirmed by ' H N M R and H R M S analysis to be corresponding to expected 
signals and calculated values. 
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3.4 Investigated synthetic strategies as masking 
substitutes for a-bromoisobutyryl unit 
3.4.1 Silyl electrophile based attempts 
In an attempt to develop masked substitutes for the a-bromoisobutyryl unit 
during the deprotection of benzyl ester 7 (Scheme 3.7) we therefore focussed on 
commonly used hetero-atoms in order to eliminate or reduce any side reactions 
i.e. evoked by palladium. 
The range and ease with which silyl ethers can be displaced by nucleophilic 
substitution^ made this approach attractive and hereafter discussed are our 
attempts to a-substitute isobutyryl unit, first by exploring silyl compounds. 
The ambidental nature of enamide and enol nucleophiles has been exploited in 
various syntheses to prepare enolates of electrophiles of silyl chloride and 
derivatives of sulphonic acid where 0-silylations are readily formed as the 
preferred regio-isomeric product of silylation. However, except via an 
alkylhalide, the possibilities and application of silyl chloride in forming C-Si has 
comparatively rarely been exploited and so initial work concentrated in this area. 
Discussed below are the attempts made to synthesise a-silylated ester by 
enolisation with hindered, non-nucleophilic base of firstly an in-situ prepared 
o 
BnO " 
1, A or B or C 
2. T M S C l , T H F , - 7 8 C . 
, S i (OH3)3 
B n O ' ~ ' 
A. 'PraNH, BuLi , B. KHMDS, C . 'BuOK 
37 38 
Scheme 3.12 
lithiumdiisipropylethylamine quenched with trimethylsilylchloride at various 
number of equilvalents. Unfortunately, observed in the ' H N M R of the crude 
mixture was the one proton sextet, before only isolating the hydrolysis product 
after chromatography. Similar results were observed when potassium 
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hexamethyldisilisane or potassium rerr-butoxide was employed in the process 
under the same conditions. The observed resuhs were thought to be due to the 
unstable nature of the electrophile to form the more stable substrate (C-Si) hence, 
during aqueous workup, the preferred reversible kinetic product (0-Si) 
decomposed. We therefore turned our attention to a more stable silyl 
electrophile. 
However, studies'^''' (Scheme 3.13) have shown that the influence of the 
alkyl/aryl substituents on the silyl electrophile can be exploited to preferentially 
prepare C-silylation or 0-siIylation; and that the process is independent of 
sterics, rather the basicity induced on silylchloride by its substituents; a phenyl 
substituent renders the silyl center softer thereby reactive towards the 
corresponding site on the substrate. As a result, diphenylmethylsilylchloride 
proved to be the suitable silyl electrophile. Scheme 3.13. 
C H 3 C 0 0 E t '^^ ^^ '^^ "^ •-X^  
(ii) RjSiCl 
RjSi = MejSi 
RjSi = PhMejSi 
RjSi = PhjMeSi 
PSiRa 
OEt 
Major 
50% 
0% 
R,Si 
Minor 
50% 
100% 
OEt 
Scheme 3.13: Literature precedence for C-silylation. 
We proceeded to attempt the synthesis of dimethylsilylbenzyl ester 38 by 
reacting isopropylbenzyl ester 37 with lithium diisopropylethylamine at -78° C, 
quenched the lithium enolate with diphenylmethylsilyl chloride and worked the 
reaction up according to literattire procedure however, only the starting benzyl 
ester and hydrolysed silyl reagent was recovered. Attempts at silylating n-
propionylbenzyl ester with diphenylmethylsilylchloride were also unsuccessful 
as observed by LC/MS-MS analysis. Other variables were also investigated but 
proved unsuccessful. 
Having established literature precedence for the viability of C-silylation, 
i t was reasoned that the required dimetiiyl substituents provided steric hinderance 
at the a-carbon centre that could have prevented such reaction. We therefore 
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proposed the use of the Reformatsky reaction because of the different site of 
attack (on carbonyl oxygen) utiUsed, which as a result negates the need for initial 
steric considerations. Reformatsky methodology'^'*'' was therefore attempted, in 
order to prepare a zinc enolate from the a-bromoester 39 and zinc at reflux based 
on literature procedure''* 
o 
Eto 
39 
-Br 
1, Zn (1.2 eqv)., C2H4Br2 
2, PhjMeSiCl 
Eto -S iPh jMe 
40 
Scheme 3.14 
The mixture of 39 and freshly prepared zinc solid was quenched with the 
diphenylmethylsilyl chloride in order to yield 40 from 39 based on modified 
literature procedure. On work-up, the unreacted zinc was filtered and the filtrate 
freated to recover the a-bromoester as identified by ' H N M R . The reaction was 
then repeated with dibromoethane as catalyst for zinc and after 3 hours refluxing 
in DMF the zinc had dissolved. The reaction was then quenched with 
diphenylmethylsilyl chloride to recover the hydrolysed silyl products after 
aqueous workup and chromatography as the only recognisable material. As all 
the observations may have suggested, the formation and subsequent 
decomposition of the enol without the formation of the expected stable C-silyl 
adduct can be due to the incompabtibility of the electrophile-nucleophile 
substrate combination. Although with fiirther investigation, greater compatibility 
can be developed however a different electrophilic heteroatom approach was 
pursued. 
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3.4.2 Sulphury! based attempts 
We had described our unsuccessful attempt to synthesise the a-silyl substituted 
isobutyryl substrates based on literature procedures with the conclusion that 
incompatibility of electrophile was the probable reason. The formation of a-
substituted thiol ether was attractive because of the stability to palladium 
transformation processes of thiol derivatives and the variety of sulphur-based 
compounds already employed in synthesis demonstrating versatility. 
Furthermore, the inter-conversion of Boc-a-ethylthioglycinate to the 
corresponding bromo derivatives (Scheme 3.15) had already been described'^ so, 
initial work concentrated on methodologies based on this strategy 
l .NEtj, THF,-78C 
2. HSEt 
I. B r j . C C U Reflux 
BocHN C02Me BocHN XOzMe 
2. -EtSBr 
Scheme 3.15 
This chemistry was repeated on our a-thioether substrate 42, which was prepared 
by treating the corresponding a-bromo propionate 41 with triethylamine before 
adding ethanethiol based on literature methods'^, Scheme 3.15. The mixture was 
then monitored with TLC, which showed no reaction after 24 h at room 
EtO 
41 
l . N a O E t ( l M) 
2. HSEt, 65 C, 1.5 h, 30% 
EtO 
S E t 
42 
Scheme 3.16 
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temperature while, on subjecting the reaction mixture to refluxing condition 
resulted in the recovery of unacceptable level of by-products. The reaction was 
unsuccessfully repeated under the same conditions with different solvents (THF 
and DMF) and base (TEA and pyridine). The substitution reaction was then 
repeated based on the method developed for the synthesis of a-methoxy 8 
equivalent (Chapter 2) by stirring with 1.2 equivalents of ethanethiol and one 
mole of freshly prepared sodium ethoxide. After stirring for 1.5 hours at 65°C, 
the reaction showed the complete consumption of the ethyl ester as judged by 
TLC. The precipitates formed were then removed by filtration, concentrated the 
mother liquor before distillation to give the ethylthio propionate 42 in 31% yield. 
This was confirmed by the presence of the six-proton singlet at 5 1.6 ppm 
corresponding to the thioisobutyl units in the ' H N M R spectrum of the product 
and a carbonyl stretch at 1728 cm"' in the infrared spectrum. 
3.4.2.1 Molecular bromine based bromination strategy 
However, treatment of a-ethylthioisobutyrate 42 with excess bromine solution in 
carbon tetrachloride under reflux conditions to evoke the conversion to the a-
bromo derivative. After three hours, the conditions resulted in the observation of 
various halogenated mixtures (Scheme 3.18) as judged by the isotopic 
O 
EtO > C Brj , CCI4, Reflux 
^ S E t 
42 
NBS (1 eqv.), DCM, Reflux 
-EtSBr 
Scheme 3.17 
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composition and observed by positive electrospray mass spectroscopy. The 
solvent was replaced with a less reactive dichloromethane but similar results 
were observed at reflux. The halogenating agent (bromine) was replaced with 
bromocatechol borane or boron tribromide in carbon tetrachloride or 
dichloromethane, none of which yielded the expected a-halogenated isobutyryl 
ester 41 but rather resulted in hydrolysis and degradation products at elevated 
temperatures. The observed isotopic composition of the mixture using reactive 
solvents with multiple halogens (i.e. carbon tetrachloride, bromine, 
dichloromethane) was proposed to have instigated the multiple halogenation 
process that was fiirther exacerbated by the harsh reaction conditions. 
-EtSBr Br2, CCI4 p n 
R = Et 
B r C C l 
Scheme 3.18 
The high temperature could have resulted in the homolytic cleavage of bromine 
bond, which fiirther cleaved the C-Cl bond of the solvent to result in a multitude 
of interactions via radical chain reaction. Scheme 3.18. Since reactions were only 
observed at reflux, it was then decided to attempt the conversion with milder, 
mono-halogenated reagent, for example A'-bromosuccunimide in carbon 
tetrachloride. 
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3.4.2.2 N-Bromosuccinimide based bromination strategy 
The use of A'^-bromosuccunimide (NBS) as a highly selective allylic bromination 
agent in carbon tetrachloride has been documented,'^ fiirthermore, the 
substitution of a carbon-hydrogen bond with a carbon-bromide bond has also 
been discussed. ' Other factors contributing to the selectivity of bond 
formation process were concluded'^ to include the chain carrier property of the 
imidyl radical, often resulting in a ring opened imidyl radical accounting for up 
to 6 0 % of by-product, and hydrogen abstraction by imidyl radical with high 
selectivity. 
Our initial strategy was to derive the a-bromoisobutyryl substrate by 
coupling the cheap and commercially available isobutyric acid using standard 
techniques to the free hydroxyl on a monoftinctionalised PEG before introducing 
the a-halogen to the isopropyl unit post debenzylation depending on conditions 
and substrate tolerance. 
In order to determine the feasibility of the strategy, the radical reaction of one 
equivalent of NBS with isobutyric acid was carried out in dry, argon degassed 
CCI4 under either reflux or radiation conditions under an atmosphere of argon. 
The reaction was then monitored with TLC to show complete consumption of the 
acid. Unfortimately the crude material was impossible to identify by ' H NMR, 
and electrospray mass spectroscopy showed the presence of multiple halogenated 
products (combinations of chlorine and bromine isotopes, Scheme 3.18. To 
reduce deleterious influence of the reactive solvent (i.e. CCI4) on the process, a 
less reactive solvent (methylene chloride) was therefore proposed. The reaction 
was then repeated in freshly distilled dichloromethane with one equivalent of 
NBS and monitored with TLC until complete consumption was observed. The 
reaction mixture, after aqueous workup and drying in vacuo was examined by 
electrospray spectroscopy to reveal little or no halogenated isotopes. It was 
speculated that the observation was due to the relative low solubility and ring 
opening potential of NBS that has proven more favourable to the formation of 
NBS open ring adducts with the isopropyl unit as evident by the presence of m/z 
2 1 4 (M+H*) corresponding to ethyl 2-methyl-2-(N-succinimidyl) propionate 44 
(Scheme 3 .17) and four proton singlet at 6 2.8 ppm corresponding to 
succinimidyl proton in ' H NMR of the crude sample. Attempts at purification 
proved difficult. 
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We therefore decided to increase the ratio of NBS to increase the rate of 
hydrogen abstraction^^ and/or the bromine radical concentration and perhaps 
consequentially reduce unwanted succinimidyl adducts formation. By evaluation 
with authentic commercial sample, a-bromoisobutyric acid 21 was observed as 
the product of the reaction of 2.5 equivalents of NBS with isopropionic acid in 
dry dichloromethane under an argon atmosphere after refluxing for 18 hours or 
UV radiation for 5 hours as judged by TLC. After filtration, aqueous workup and 
drying in vacuo, the crude product 21 was obtained in yields of 97% (by reflux) 
and 80% (by UV) respectively. Analysis without further purification of the 
compound by ' H NMR showed a six-proton singlet at 6 1.9 ppm for the a-
bromoisobutyryl unit that compared favourably with an authentic sample. With 
the model conversion procedure of C-H to C-Br established, we therefore 
attempted to repeat the process of bromination on the intended PEG substrate in 
order to further access the viability of the strategy. 
3.4.3 Model functionalisation of isopropyl unit by NBS 
We were able to demonstrate with a simple model, the efficient bromination of 
an isopropyl unit under two different conditions. This chemistry was expected to 
be repeated on the intended substrate 48, to obtain the expected product 4 in 
O 
HO 
45 
Method A NBS (2.5 eqv ), 
DCM, UV , 5 h., 80% 
\ 
0 
HO , 
Br 
Methods NBS (2.5 eqv.), D C M / 21 
Reflux. 18h.,97% 
Scheme 3.19 
good yield. First, the precursor benzyl isopropyl diester 47 was prepared by 
coupling the free hydroxyl group on the monofrinctionalised 10 with two 
106 
Investigated synthetic strategies as masking substitutes for a-bromoisobutyryl unit 
equivalents of isobutyric acid in dry dichloromethane with N,N-
dimethylaminopyridine and EDCI. The isopropyl diester 47 was obtained in 89% 
yield after column chromatography. The product was confirmed by molecular 
ion at m/z 391 in the mass spectrum, which was in agreement with the calculated 
value of 391 for Ci9H2807Na and ' H N M R . Treatment of the isopropyl 47 with 
10% palladium on carbon in methanol under an atmosphere of hydrogen at room 
temperature gave a quantitative conversion to the carboxylic acid 48, as observed 
by the disappearance of the five proton multiplet at 5 7.4 ppm corresponding to 
the phenyl protons and the appearance of an infra red stretch at 3208 cm'' in the 
spectrum for O H corresponding to the liberated carboxylic acid 
o 9 ^ 
3 ^ q A ^ 0 ^ ^ , ^ 0 H Isobutyric acid, E D C , ^ B n O ^ ° ^ - ^ 0 ^ ° 
^ DMAP, DCM, 89 % O 
10 47 
Pd/C, H 2 , 97%. 
9 I .Br 
HO' 
O DCM, 6 h, UV. 33 % 2 I 
4 
O 
48 
Scheme 3.20 
With the carboxylic acid at hand, we therefore attempted the model 
bromination reaction (Scheme 3.20) on the key intermediate 48 to produce the 
final product after activation with N-hydroxysuccinimide. Using the exact 
concentration as determined from the model system above, 2.5 equivalents of 
NBS in dry dichloromethane was reacted with 1 l-(2-methylpropionyloxy)3,6,9-
trioxalmdecanoic acid 48 under radiation condition. After 8 h, no further 
consumption was observed of the acid and the crude reaction was filtered and 
analysed. ' H N M R showed the presence of a mixture of isopropyl and substituted 
a-bromoisobutyryl unit (3:1) as determined fi-om the relative integral of the 
corresponding dimethyl unit at 6 1.1 ppm and 5 1.9 ppm respectively. 
Unfortunately, even after changing the variables for example, time, glassware 
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(silicate or borate) and distance of UV source, the reaction showed no significant 
improvement. When the reflux strategy established above was applied, 
uidiscriminate/multiple bromination product was observed by mass spectroscopy. 
The route was therefore not pursued fiirther. 
It was expected that generating a-bromo isobutyryl unit from the more stable 
isobutyric acid would be, as demonstrated above, more practical and stable to 
palladium assisted debenzylation and this was achieved however, in a poor 3 3 % 
yield. 
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CHAPTER 4 
S Y N T H E T I C A P P R O A C H E S T O M E D I U M 
L E N G T H P O L Y E T H Y L E N E G L Y C O L M A L E I M I D E B A S E D 
A T R P I N I T I A T O R S 
(Thiol-Selective Hetero-bifunctional Linker) 
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4.1 Introduction 
In this chapter our target ATRP initiators consist of a series of medium length 
PEG imits, which incorporate a quaternary ammonium centre introduced by 
either one of two dimethylamino-functionalised substituents as determined by 
substrate compatibility. The synthetic objectives involved the coupling of one 
end of a PEG (previously protected as a tetrahydropyranyl) to an a-
bromoisobutyryl unit, a required ATRP functionality; the second free hydroxyl 
group would be functionalised with appropriately reactive group to facilitate an 
SN2 displacement 
Br 
Br 
1, n = l 
2, n = 2 
3, n = 3 
Br 
4-6 
/n 
10-12 
13-15 
HO 
7-9 
16-18 R = OMs, I 
22, n = 1 
23, n = 2 H 
24, n = 3 
.OH .OH 
19-21 
Scheme 4.1 
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reaction with a labile leaving group (i.e. iodo or pseudohalide functionalities) on 
an A/^ -alkyl substituted maleimide. Scheme 4.1. The simplest approach to the key 
intermediates (4 - 6) was by selective coupling of isobutyryl bromide to the fi-ee 
hydroxyl and then of substituted A'^-alkylmaleimide to the hydroxylamine 
precursor (7 - 9) prepared by a modified Gabriel synthesis. The use of an acid 
labile protecting group (i.e. tetrahydropyran) was expected to reduce 
complication of homo-bifunctionalised PEG formation and encourage region-
and chemoselectivety during the application of a modified Gabriel synthesis. 
4.2 Synthesis of PEG based maleimide/thiol-reactive 
linkers as ATRP initiators linlter unit 
4.2.1 Synthesis of a functionalised P E G for dimethylamino 
substrates 
Formation of the tetrahydropyranyl 19 was achieved by treating 
dihydropyran with /7-toluenesulphonic acid and three equivalents of 
azeotropically treated triethylene glycol at 70° C for 2 hours. 
HO' ^ ^OH ^CT ^O-^ > / - ^ ^OH 
19, n = 2 (69 %) 
20, n = 3 (64%) 
21, n = 4 (52%) 
Scheme 4.2 
Removal of the solvent in vacuo gave the mono functionalised product 19 in 
6 9 % yield after column chromatography. This was confirmed by the presence of 
six_p.roton multiplets at 8 1.4 - 1.8 ppm in the ' H NMR spectrum corresponding 
to the T H P methylene and the molecular [M+Na"^] ion at m/z 257 in the mass 
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spectrum. The procedure was employed to also synthesise the tetra and 
pentaethylene glycol in yields of 64% and 52% respectively. The typical signal 
for cyclic methylene (as for triethylene glycol) was observed by ' H NMR 
analysis for both 20 and 21. The respective molecular [M+Na^] ion at m/z 301 
and m/z 345 of the mass spectrum was observed. Examination by mass 
spectroscopy of the samples from column chromatography showed the exclusive 
formation of di-substituted polyethylene glycol as the only by-product in the 
above reaction, hence the low yield. 
The free hydroxyl on monofianctionalised triethylene glycol 16 was then stirred 
overnight with 1.5 equivalents of methanesulphonyl chloride and after the 
removal of the solvent in vacuo, aqueous workup and purification by flash 
column chromatography, and the desired mesylate 16 was obtained in 89% yield. 
MsCI (15 eqv.), TEA (1.5 eqv.), DMAP (Ml ) 
OH • ^o^ > ^ ' ^ ^om 
16, n = 2 (89%) 
17, n = 3 (77%) 
18, n = 4 (67%) 
Scheme 4.3 
The structure of the product was confirmed by the presence of a three proton 
singlet at 5 3.0 ppm in the ' H NMR spectrum corresponding to the 
methanesulphonyl group and an ion for [M+Na*] at m/z 335 in the mass 
spectrum. The procedure was repeated in the synthesis of the mesylates of tefra 
and pentaethylene glycol in yields of 17 and 18. They were confirmed by ' H 
NMR spectrum and the molecular [M+Na"*^ ] ion at m/z 379 and m/z 423 in the 
mass spectrum. 
Further attempts were made to improve the yield for pentaethylene glycol 
mesylate 18 by conducting the reaction in the presence of freshly activated sieves 
suspension. Unfortunately, the approach tended to evoke a side reaction, which 
resulted in an increased level of by-products being isolated after column 
chromatography. Flash chromatography was-also employed to reduce the effect 
of the acidic silica gel. The workup that only involved neutralisation with 
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aqueous sodium bicarbonate before extraction to avoid solvent induced 
complications was also unable to consistently increase the yield. 
4.2.2 Synthesis of a tertiary amine substituted P E G 
4.2.2.1 Synthesis of a tertiary amine via a modified Gabriel 
reagent 
The introduction of tertiary amine was first envisaged to exploit the modification 
of a known procedure for the formation of primary amines via an N-
alkylphthalimide by substituting the base hydrolysis to reveal the primary amine 
(Gabriel synthesis') with a different process (i.e. hydride reduction) to expectedly 
liberate a dimethyl tertiary amine and eventually afford a quaternary ammoniimi 
salt after SN2 displacement of an alkylhalide functionalised maleimide. 
a P Na I, DMF or Butanone, reflux 
Sodium salt of diformylamide. 
Butanone or DMF, reflux 
25 
Diformylamide 
sodium salt, reflux, 
DMF. 
N. H 
1. LiAlHi 
2. 50% AcOH/Water. 
Scheme 4.4 
However, a reported literature^ had applied a convenient and modified Gabriel 
synthesis reagent substitute employing sodium diformylamides to N-alkylate 
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halides or sulphonates, and after hydrolysis this gave the primary amine. We 
therefore developed a strategy based on this approach, Scheme 4.4. 
We attempted the SN2 reaction described above by treating the mesylate 16 under 
reflux conditions with two equivalents of diformylamide sodium salt in 
butanone. The reaction was monitored by TLC until complete consumption of 
the mesylate (after 48 h) was observed which upon analysis of the crude, 
observed a mixture of products. The rrtixture proved difficult to separate cleanly 
by column chromatography however, during ' H N M R analysis of the crude and 
the several fractions, mono and diformylated products and diminished 
tetrahydropyranyl constituents as mixtures were observed. This was also evident 
in the crude TLC analysis as muhiple spots, and the observation of one-proton 
broad singlet at 6 1.9 ppm of the crude N M R spectrum corresponding to the 
new, free hydroxyl group. The monoformylated products were also observed as a 
significant component in the N M R spectrum with broad singlet signal at 5 8.9 
ppm in the spectrum for the secondary amine. A similar result was observed 
when butanone was replaced with D M F . 
We assumed that the spectator ion, the mesylate, became more active in the 
deformylation process by acting as the source of acidity (protonation of 
0 OMs 
16 
O ' "0 
:oH, 
hydrolysis 
i 
n N " " ^ H + Methanesulphonic acid 
H 
+ Formic acid 
Scheme 4.5 
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carbonyl) and due to the forceful hydrolysis conditions induced by the prolonged, 
high reaction temperature, resulted in several by-products, Scheme 4.5. To 
reduce the forceful nature of the reaction condition (i.e. 24/48 h and reflux), it 
was proposed that the synthesis of the intermediate 25 consisting of primary 
iodoalkyl would accelerate the rate of reaction thereby reducing monoformylated 
products probably originating from hydrolysis. The iodide was then prepared by 
treating 1.5 equivalents of sodium iodide with the mesylate 16 in butanone 
overnight. The crude reaction mixture was then examined by TLC and confirmed 
by ' H N M R only, to exhibit the expected two proton triplet at 5 3.2 ppm 
corresponding to the CH2I of 25 (Scheme 4.4) having replaced the two proton 
multiplet signal at 6 4.2 ppm corresponding to CH2OMS of the starting mesylate. 
Unfortunately, attempts at further analysis of the intermediate iodide resulted in 
hydrolysis product; and therefore we filtered the reaction mixture to remove the 
solids or salt content (with syringe through cotton wool plug) before adding 1.5 
equivalents of diformylamide (assuming quantitative yield) in portions and 
heating at 70° C for 18 hours in D M F or butanone. The crude mixture by TLC 
showed multiple spots and the attempted column chromatography resulted in the 
recovery of material difficult to identify by mass spectroscopy or ' H N M R . 
The reaction of diformylamide with the iodide intermediate 25 was repeated with 
commercial or freshly prepared diformylamide in butanone or D M F but yielded 
0 ' ^0 
25 
Sodium salt of diformylamide 
Products from various other 
reactions i.e. cleavage of THP, 
polymerisation, Michael addition 
or hydrolysis e.t.c. 
0 ' 
0 
e - \ H 
N 
o 
R 
H 
R = Iodide, imide 
0 
+ H N ^ H 
O' ^ O 
+ HI 
H 
Scheme 4.6 
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results similar to described above; as did varying the reaction temperatures. The 
speculated method of degradation was envisaged to involve the reductive 
elimination of the alkyl diformylamide to give an aza-enolate (amide tautomer) 
and the resulting acidic environment (via elimination of H I ) further degrades the 
substrate, Scheme 4.6. At this stage it was apparent that the simple 
diformylamide unit is inherently sensitive to the employed reaction conditions. 
We therefore proposed the introduction of tertiary amine via a more practical 
source of dimethylamine. To avoid the use of gaseous dimethylamine, which is 
difficult to handle, or the hydrochloride salt of dimethylamine, which may be 
deleterious to the substrate i f a reflux condition is required. The use of 
dimethylamine dissolved in water would take advantage of the dual solubility of 
polyethylene glycol in both aqueous and organic solvents and avoid the use of 
gaseous amino compounds. The work generated in this area is discussed in the 
next section. 
4.2.2.2 Synthesis of a tertiary amine substrate via an alternative 
method 
The nucleophilic substitution of mesylate 17 in dichloromethane was effected by 
treating with dimethylamine (40% in water) initially at 0° C then by stirring at 
room temperature. The reaction was monitored by ' H N M R spectroscopy and 
quantitative conversion was observed by the replacement of the methylene and 
methyl of CH20S02Me with the two proton triplet at 5 2.5 ppm and six proton 
singlet at 5 2.2 ppm corresponding with methylene and the new dimethyl of 
CH2NMe2 respectively. 
1. 40%HNMe2/H2O,4h,rt . 
•Ov 
I 7 , n = 3 
10, n = 2 (60 %) 
U , n = 3 (45%) 
12,n = 4 (71 %) 
Scheme 4.7 
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The reaction mixture, after aqueous treatment was subjected to column 
chromatography to reveal the tertiary amine 11 in 45% yield with the structure 
fiirther confirmed by a molecular ion at 306.2202 in the HRMS which was in 
agreement with the expected value of 306.2297 for CoHssNOsNa. The procedure 
was also repeated for the mesylate of 16 and 18 to reveal their equivalent tertiary 
amine in yields of 60% and 71% respectively, which were confirmed by ' H 
NMR and mass spectroscopy. 
Treatment of the tertiary amines with an acid catalysed deprotection condition 
for tetrahydropyran to liberate the hydroxyl amine 8, Scheme 4.8, was observed 
as the replacement of the six-proton multiplet signal at 5 1.4 - 1.8 ppm 
corresponding to tetrahydropyran with two proton multiplet signal at 6 3.8 ppm 
corresponding to the new CH2OH in the ' H N M R spectrum was used to confirm 
the conversion. 
50% AcOH/Water. 50° C, 4 h. H O v . J ^ 
\ 
7, n = 2 (66 %) 
8, n = 3 (94%) 
9, n = 4 (92 %) 
Scheme 4.8 
The amino tetrahydropyranal 10 was reacted either with 30% hydrochloric acid 
in diethyl ether or 50% acetic acid in water and heated at 50° C for 4 hours. The 
resulting mixture was either filtered and washed with cold ether or passed 
through a plug of neutral alumina before drying in vacuo and over phosphorus 
pentoxide to give the hydroxyamine 7 in 66% yield. The structure was further 
confirmed by the hydroxy (OH) absoption at 3409 cm'' in the IR spectrum and a 
molecular ion [M+Na*] at m/z 178 in the mass spectrum. 
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4.2.3 Attempted synthesis of dimethylammonium substituted 
maleimldes 
We now envisaged a bilateral approach to the preparation of the target 
ammonium salt. The process would involve the nucleophilic displacement 
reaction of a suitably fianctionalised //-alkylmaleimide (i.e. halide or 
pseudohalide) relying on both sterics and the relative nucleophilicity of tertiary 
Route A 
7 -9 
Route B 
Br 
4 - 6 
n = 2, 3, 4. 
26 
Br- \ / 
•0" r - S ^ N ' 
1-3 
Scheme 4.9 
amine before or after affording the condensation product with a -
bromoisobutyryl bromide to obtain the target molecule via route A or route B, 
Scheme 4.9. Unfortunately, the various attempts made to prepare the 
bromoisobutyryl amine (4 - 6) via route A had resulted in decomposition product 
being recovered. The reaction was performed in the presence of N,N-
dimethylaminopyridine or potassium carbonate then bromoisobutyryl bromide in 
different solvents (i.e. MeCN, DCM, DMF and THF) and at different 
temperatures (0° C and rt only) while been monitored with TLC. As observed in 
the mass spectroscopy and ' H NMR, the crude reaction mixture was unassigned 
and so attention turned to route B. In order to explore the possibilities of 
fimctionalising the spacer units (7 - 9) by coupling to appropriately configured 
maleimide substrate, it was essential before reacting with a-bromoisobutyryl 
filnctionalities to test the possible condition to ensure the generation of the 
119 
Attempted synthesis of dimethylammonium substituted maleimide 
required ammonium salt. The preparation of the required and varied A^-alkyl 
substituted maleimide was therefore attempted and discussed below. 
4.2.4 Synthesis of a A/-substituted alkyi maleimide 
Direct alkylation of maleimide represents a convenient procedure for the 
synthesis of N-alkylmaleimides under mild or neutral condition as represented by 
Mitsunobu^ reaction. However, some reports have demonstrated the process to be 
low yielding and deleterious to certain substrates, i.e. substituted polyethylene 
PPhj or PBuj/ DIAD, THF 
n = 3 (37 %) 
n = 6 (31 %), polymer bound PPh, 
One example as modified and 
applied by Kratz ei al. 
Scheme 4.10. Low yields from Mitsunobu as demonstrated by Kratz et af 
I' 
PPhj, DEAD, Maleimide, -78° C 
R = R, = CHjCOjtBu. X = H. DEAD (mono anion) 
Via reversible 
intermediates 
-C02tBu 
Scheme 4.11. Stevens rearrangement as a possible side reaction as reported by Walker et al'. 
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glycol^ and for tertiaryamino butanol^ because of the various competing 
reactions and reagents present. Scheme 4.10 and 4.11. 
Another method towards the synthesis of bifimctional A^-substituted maleimide 
involves the condensation cyclisation of the corresponding maleamic acid under 
various conditions^'^'^''° which generally proceed in modest yield for N-
arylmaleimide but less satisfactorily for N-alkyl maleimide"''•^ 
Based on the literature precedents, in order to realise the successful 
construction of the target ammonium salts (1 - 3) we therefore pursued the 
requirement to establish an efficient means to prepare A^-alkylmaleimides 
compatible with our substrates and in good yields. 
^ " - ^ (i), (ii) 
27 
(i) . 2-bromoethylamine .HCl, NaHCOj, Water, 2 h, 77%. 
(ii) . AC2O, NaOAc, 80°C, 10 min, 85°C. 10 min, 14%. 
Scheme 4.12 
Other literature'^preparation had already shown that haloalkyl maleimide 
could be prepared in moderate yields in a two stage cyclo-condensation process 
of the maleamic acid - by treating with a combination of NaOAc and acetic 
anhydride at 80° C for 15 min. However, our attempt at repeating the procedure 
resulted in a poor yields (14%, after two steps) after further purification of the 
maleimide 28, Scheme 4.12. The maleimide was confirmed by the presence of a 
two-proton singlet signal at 5 6.7 ppm and two proton triplet signal at 6 3.5 ppm 
Corresponding to (CH=CH) and CHiBr respectively in the ' H NMR spectrum; 
and by carbonyl stretch at 1770 cm'' in the IR spectrum. 
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HO. 
7,n = 2 
2-Bromoethyl maleimide \ / H 
© 
Br O 
26 
Scheme 4.13 
We proceeded to examine the compatibility of the two substrates by stirring the 
maleimide (1.1 eqv.) with the tertiary amine 7 in dry diethylether at room 
temperature overnight. The resuhing precipitate was filtered, concentrated and 
dried in vacuo to yield an unidentified product possessing no recognisable signal 
observable by ' H NMR and mass spectrum. The reaction was repeated with or 
without SchifFs base; and varying the solvents (THF and MeCN) was 
unsuccessful. 
© 
O ^ 
RHN 
H O . 
RHN 
Polymerisation e.t.c. 
Heating 
0: 0 
R H ^ N J 
-RNH2 
Scheme 4.14 
The attempted synthesis at elevated temperature of the quaternary ammonium 
salt using maleimide 28 could not be attempted due to the unsuccessfial attempt 
at synthesising 2-bromoethyl maleimide by the method above; and various other 
acid catalysed cyclo-condensation based on literature methodology i.e. pTsOH, 
PhMe, reflux, 8 h or polyphosphoric acid, PhMe, reflux, 18 h or ethanol/HCl, 
reflux - as they all gave unidentified white polymeric solids, as observed by 
mass spectrum and ' H NMR. The observed results can be attributed to 
polymerisation product at high temperature of maleic anhydride or maleic 
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anhydride reformed from the maleamates via intramolecular cleavage of the 
amide bond at low pH, Scheme 4.14*''. Unfortunately, when the cyclo-
condensation reaction was attempted in the presence of a varied amount of 
triethylamine (catalytic or stoichiometric amount) in toluene to obtain polymeric 
material attributed to the probable formation of an allylic product, which would 
have polymerised. Similar results were observed irrespective of the PEG 
substrate subjected to the conditions as described above. 
To reduce the rate of formation of the proposed elimination product 
during attempted cyclisation, consequently increasing the yield for the 
maleimide, a pseudohalide (i.e. triflate or mesylate) was proposed as a substitute 
for the highly labile bromine and reactive hydrolysis product (aq. HCl) as a 
practical alternative and work in this area will be discussed next. 
Recent literature by Kratz et al'^ showed precedence for the base assisted cyclo-
condensation of maleimide via an amidoacid intermediate. They were able to 
1 Ethanolamine. Acetone, 0°C, 5 h. 
2. Dean Stark, T E A . 2 h , 14%. 
27 
Scheme 4.15 
couple ethanolamine to maleic anhydride to give the expected hydroxyethyl 
amidoacid in moderate yields before condensation to give A'^-(2-hydroxyethyl) 
maleimide. This chemistry was repeated and ethanolamine was treated with 
TfCl, (7 eqv ), DMAP (cat )^ 
0°C,2hthen rt, 8 h, 63% 
Scheme 4.16 
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maleic anhydride 27 in acetone at 0° C for 4 h and the zwitterionic acid 
precipitated at 4 ° C in quantitative yield. This was confirmed by melting point 
value of 99° C which agrees with the expected value 98° C'^. Without further 
purification, the amidoacid was allowed to dissolve in hot toluene before 
refluxing for 2 hours with one equivalent of triethylamine in a Dean Stark setup. 
The bifimctional maleimide 29 was obtained in 14% yield after silica column 
chromatography. The ' H NMR spectrum showed the appearance of a two-proton 
triplet signal at 5 3.7 ppm and a two proton singlet at 6 6.7 ppm corresponding to 
the signal for CH2OH and CH=CH respectively; and the molecular ion 
[M+NH4^] at m/z 158 as viewed with mass spectroscopy. Treatment of the 
hydroxy maleimide 29 with seven equivalents of trifluoromethanesulphonyl 
chloride in the presence of a catalytic amount of N,N-dimethylaminopyridine for 
2 h at 0° C then at room temperature for 8 h gave the triflate 30 in 63% yield. 
This was observed by the shift in the ' H NMR signal fi-om 5 3.7 ppm to 5 3.9 
ppm corresponding to the formation of CHiOTf from CH2OH and the molecular 
ion [M+H^] at m/z 274 in the mass spectrum. At lower equivalents of 
trifluoromethanesulphonyl chloride (i.e. less than 2.5 eqv.) the reaction was 
observed to be very slow at room temperature (as observed by TLC) and after 24 
h, resulted in the recovery of the expected triflate in less than 30% yield. 
o 
H * / H3O+ °'=Y'''N^-.^'^N'''"^"^°^* 
^ ^ _ H , 
© O 
31 
Scheme 4.17 
The use of triflic anhydride was less successfiil than all comparable equivalents. 
The acidic environment exacerbated by prolonged reaction time had probably 
encouraged the generation of an intramolecularly cleaved zwitterionic amidoacid 
31, Scheme 4.17. With the triflate at hand, attention was then turned to the 
"proposed quartemisation via an SN2 displacerherit of the triflate with the required 
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tertiary amine. This was attempted by stirring two equivalents of the 
hydroxyamine 7 with the triflate 30 in dichloromethane at room temperature over 
five days during which observations by ' H NMR showed minimal reaction. 
Refluxing the reaction resulted in disappearance of the unsaturation of the 
maleimide in the ' H NMR spectrum. The reaction was further attempted by 
conducting the reaction in methanol or ethanol at room temperature or at reflux 
based on published procedures'^''^ for the formation of alkyl ammonium chloride 
and alkyl ammonium tosylate respectively. Unfortunately, the above and further 
attempts remained unsuccessful as the halide and pseudohalide alkylmaleimide 
proved to be unstable and so easily decompose before the substitution reaction 
was effected. Although these reactions demonstrated a stability problem, 
quartemisation is an established chemistry and was therefore suggested as an 
approach using a different combination of bifunctional quatemising agents of N ' -
(N-dimethyl)ethyl maleimide. The dimethylamino on maleimide was considered 
an attractive alternative approach as this provides an inherent stabilizing agent 
for the maleimide by maintaining a basic environment (high pKa) in solution 
(Scheme 4.14), while exhibiting less lability towards elimination reaction 
(relative to halides or pseudohalides). Progress with dimethylethyl maleimide is 
described in the next section. 
4.2.5 Synthesis of a bifunctional A/-substituted alltyl amino 
maleimide 
Several procedures had been published'^for the condensation of various 
alkylamines with aryl substituted maleic anhydride. They also showed that the 
reaction of phthalic acids with dialkylaminoalkyl amines in the presence of 
dicyclohexaycarbodiimide (DCC) in THE could be used to synthesise their 
corresponding phthalimides in high yields. We therefore applied the procedure to 
our substrate by refluxing the mixture of maleic anhydride in THE with an 
equivalent amount of MA^-dimethylethylenediamine. 
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N'-2-(N,N dimethylamino) ethylamine 
THF, DCC, Reflux 
N'-2-(N,N dimethytamino) ethylamine 
C C , THF, 4 h 
TEA (1.5 eq), THF, 
TMSCl{1.5eq), 5h 
80% 
Scheme 4.18 
After two hours refluxing, the urea formed was filtered and the organic phase 
subjected to precipitation with warm ether. Although total consumption of the 
diamine was observed during the reaction by TLC, three other distinct types of 
diamine products including the expected diamine (as a minor content) had been 
formed as observed in the ' H NMR. We suspected the formation of acyclic 
diimide. We therefore decided to prepare and isolate the intermediate amidoacid 
prior to cyclo-condensation to ensure efficient cyclo-condensation. The addition 
of an equimolar amount of dimethylethylenediamine to maleic anhydride to give 
the expected intermediate 32 in quantitative yield after drying in vacuo. No 
fiirther purification was required to confirm the compound by the two one-proton 
doublets at 6 5.9 ppm and 6 6.1 ppm corresponding to C H A = C H and C H = C H B 
respectively, and a two proton triplet at 5 3.2 for CH2NMe2 in the ' H NMR 
spectrum and a molecular ion [M+H^] at m/z 187 in the mass spectrum. When 
the amidoacid 32 was subjected to triethylamine assisted Dean Stark 
condensation procedure, a very poor yield of the expected compound 33 was 
observed in ' H NMR. However, on changing the solvent fi-om toluene to THF, a 
significant reduction in the amount of unidentifiable constituents was seen by ' H 
NMR. When DCC was added to the condensation mixture to accelerate the 
process, decomposition product was observed as the main component by ' H 
NMR. However employing trimethylsilyl chloride resulted in a significantly 
improved yield. Hence, the maleimide 33 was prepared by stirring the suspended 
mixture of amidoacid 32 and 1.2 equivalents of triethylamine in THF for half an 
hour under reflux conditions before treating the mixture with 1.2 equivalents of 
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trimethylsilyl chloride at reflux for 5 hours. The supernatant was concentrated in 
vacuo to obtain an orange powder that was recrystalised from dichloromethane in 
80% yield. The maleimide was confirmed by a two-proton singlet at 5 6.7 ppm 
and a six proton singlet at 5 2.2 ppm, corresponding to C H = C H and 
dimethylamino units respectively, in the ' H N M R spectrum, and the presence of 
a molecular ion [M+H^] at m/z 169 in the mass spectrum. 
4.2.5.1 Model quaternisation reaction 
As the synthesis of maleimide 33 was expected to allow access to the generation 
of a quaternary ammonium salt, it was desirable to establish condition(s) 
conducive to fiinctionalised tetraethylene glycol with stable but SN2 labile groups 
(i.e. mesylates). The strategy was to subject the maleimide to quartemisation 
, TEA,MsCl,DCM, 18h. 
61% \ ^ ^ 0 ' 
22 35 
Scheme 4.19 
conditions based on a modified procedure'^ with mesylated tetraethylene glycol 
35. The mono-mesylated tetraethylene glycol 35 was synthesised by stirring 
methanesulphonyl chloride with one equivalent of triethylamine and five 
equivalents of tetraethylene glycol in dichloromethane and after flash column 
chromatography obtained the mono-mesylate 35 in 61% yield as seen in ' H 
NMR spectrum as a three proton singlet at 6 3.1 ppm corresponding to the 
methyl of mesylate and a molecular ion [M+Na^] at m/z 295 in the mass 
spectrum. However, treatment of mesylate 35 with maleimide 33 under several 
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,OMs Microwave irradiation 
170 Watts, 100 psi, 150°C, 1 h 
30% 
35 
Scheme 4.20 
room temperature conditions and reagents showed only unreacted, hydrolysed 
maleimide or at reflux, showed no recognisable material and none of the 
expected ammonium salt. 
We therefore applied microwave irradiation chemistry to attempt to 
obtain the ammonium salt. The expected hydroxyammonium salt 36 was 
obtained in 30% yield by dissolving tetraethylene glycol monomesylate 35 in a 
solution of N'-(N,N-dimethylamino)ethyl maleimide 33 in dry THF under argon. 
The mixture was subjected to microwave irradiation (superheating) for one hour. 
Scheme 4.20. 
36 
(i) 
(i), Bromoisobutyryl bromide, TEA, DMAP, MeCN 
Scheme 4.21 
The precipitate formed was collected and washed with cold THF, and dried in 
vacuo before being characterised. The salt was observed in the ' H NMR 
spectrum with signals at 6 3.6-3.9 ppm corresponding to the twelve-proton 
multiplet of tetraethylene glycol and the molecular ion at 345.2020 in the HRMS, 
which was in agreement with the expected value of 345.2007 for Ci6H29N206Na. 
To improve on the yield, numerous attempts were carried out, altering the 
conditions (i.e. wattage, pressure, time) and reagents (i.e. organic/inorganic base 
and various stoichiometric ratios) but all were unsuccessfial and were unable to 
improve the yield. We therefore preceded to the reaction of hydroxy ammonium 
128 
Synthesis of a bifunctional N-substituted alkyl amino maleimide 
sah 36 with bromoisobutyryl bromide in acetonitrile as observed by ' H NMR, 
which showed none of the expected bromoisobutyryl ammonium sah 2. 
At this stage it was apparent that reacting the isobutyryl unit with the free 
hydroxy of ethylene glycol post any other modification was incompatible, we 
therefore decide to install the isobutyryl unit prior to mesylation (or other 
equivalents) and then quatemisation. Hence, we proceeded by stirring 2-bromo-
2-methylpropionyl bromide with triethylamine and triethylene glycol in 
dichloromethane to obtain the functionalised PEG 37 after flash chromatography, 
in 70% yield. The compound was observed by ' H NMR spectrum as a six-proton 
singlet at 5 1.9 ppm and a ten-proton multiplet at 6 3.7-3.8 ppm corresponding to 
the a-bromo dimethyl unit and ethylene glycol repeating unit respectively. 
HO. OH (i) 
(i) , . Bromoisobutyryl bromide, TEA (1 eq.), 9 h. 
(ii) . MsCI (1.2 eq ), diisopropylethylamine (1.2 eq), 6 h. 
(ii) 
37, n = 2(70%) 
OH 38, n = 3(76%) 
39, n = 4(95%) 
40, n = 2(78%) 
41, n = 3(78%) 
OMs « , n = 4(70%) 
Scheme 4.22 
The structure was further confirmed by the observed [M+Na*] molecular ion at 
321/323 in the mass spectrum. The procedure was also repeated for 
tetraethyleneglycol of 38 and pentaethylene glycol 39 to give their equivalent 
isobutyrate esters in yields of 76% and 95% respectively, which were also 
observed by ' H NMR and mass spectroscopy and confirmed to be in agreement 
with expected data. The condensation to produce the mesylate 41 was achieved 
in 78% by treating with methanesulphonyl chloride according to the previously 
described procedure. The mesylate was confirmed in the ' H NMR spectrum by a 
six proton singlet signal at 6 1.9 ppm and a three proton singlet at 3.0 ppm 
corresponding to the a-bromo dimethyl unit and the methanesulphonyl unit 
respectively. 
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O OMs 
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Scheme 4.23 
Further clarification was observed in the mass spectrum for the molecular ion 
[M+Na^] at m/z 399/401. The procedure was repeated for tetraethylene glycol 38 
and pentaethylene glycol 39 to reveal their equivalent mesylates 41 and 42 in 
yields of 78% and 70% respectively, which were also observed by ' H NMR and 
mass spectroscopy and confirmed to be in agreement with expected data. With 
the mesylates at hand, attention was therefore turned to the microwave reaction 
with N'-(N,N-dimethylamino)ethyl maleimide 33 according to the previously 
successfully attempted procedure and conditions described above in order to 
afford the ammonium salts (1 - 3) as the final product. However, treatment of the 
mesylates under microwave conditions with maleimide 33 did not yield expected 
ammonium salt (1 -3 ) but rather a mixture of products possessing degraded 
mixtures of substrates and hydrolysed maleimide signal observed in the ' H NMR 
spectrum but unidentified by mass spectroscopy. 
It was speculated that the weak C-Br bond of the isobutyryl unit was also 
unstable to the microwave irradiation conditions and therefore resulted in 
unwanted side reactions and the eventual degradation of the reagents. 
A different strategy was consequently proposed based on substituting the 
methanesulphonate with its triflate equivalent as a more labile moiety for SN2 
displacement with dimethylaminoethylmaleimide; and relying on the steric 
hindrance aroimd a-bromoisobutyryl to prevent a parallel nucleophilic 
substitution at room temperature at this centre. We therefore proceeded to 
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^ TfCI(2eqv).Pyr(leqv.), 0°C. 2 h " > ^ " ^ 0 ' ' r ^ ° ' M ^ "^OTf 
n = 2,3,4 
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44, n = 3(63%) 
45, n = 4(45%) 
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46, n = 4 (58%) 
Scheme 4.24 
synthesise the triflates by treating the free hydroxyl of the propionate 37 with 
two equivalents of trifluoromethanesulphonyl chloride and one equivalent of 
pyridine to obtain the triflate 43 in 95% yield as seen by '^F NMR spectrum at 5 
-78 ppm corresponding to CF3 unit and further confirmed by the observed 
molecular ion [M+Na"^] at m/z 453/455 in the mass spectrum. The procedure was 
repeated for tetraethylene glycol to obtain their equivalent triflates 44 and 45 in 
yields of 63% and 45% respectively, which were also observed by ' H NMR and 
mass spectroscopy and confirmed to be in agreement with expected data 
although it was not possible to confirm the triflates by HRMS. The lower yield 
for 45 was attributed to relatively greater hygroscopic nature of pentaethylene 
glycol. In order to improve the yields, different conditions were attempted 
without much improvement, however whenever trifluoromethanesulphonyl 
anhydride was used instead of trifluoromethanesulphonyl chloride under similar 
conditions, the pyridinium salt 46 was isolated in 58% yield as seen in the ' H 
NMR spectrum by the signal at 5 8.0 ppm (two proton triplet), 6 8.5 ppm (one 
proton triplet) and 6 9.0 ppm (two proton triplet) corresponding to the pyridinium 
protons (Ph-H) and the molecular ion [M+Na^] for 404/406 in the mass spectrum 
(Scheme 4.24). 
The triflate 43 (1.1 equivalents) was then stirred with dimethylamino 
maleimide 33 in dry THF at room temperature for 48 hours. Scheme 4.25. The 
reaction mixture was monitored by ' H N M R to reveal the replacement, of the 
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CH20Tf signal at 5 4.6 ppm with a (CH2N^) signal as overlapping multiplet at 5 
3.7-4.1 ppm in the spectrum. 
+ THF.48h.rt B r ^ ^ ^ ' / ® \ 
Br 
O 
O. 
n = 2,3 
1, n = 2(43%) 
OTf 2, n = 3 (82%) 
O 
Scheme 4.25 
The supernatant was then filtered, washed with ice-cold ethylacetate or ether and 
dried in vacuo over phosphorus pentoxide to obtain the triflate ammonium salt 1 
as brown syrup in 43% yield. The salt was further confirmed by a molecular ion 
at 449.1320/451.1312 in HRMS, which was in agreement with the calculated 
value of 449.1287/451.1267 for Ci8H3o '^'*'BrN206Na. The procedure was 
repeated for tetraethylene glycol triflate to give the ammonium salt 2 in 82% 
yield, which was also observed by ' H N M R and as molecular ion [M^] at m/z 
493/495 in the mass spectrum. The hetero-bifiinctional-polymerisation initiators 
1 and 2 are stable brown syrups stored at -4 °C for several weeks. 
The initial attempts to prepare the ammonium salt of pentaethylene glycol 3 were 
unsuccessful and due to time constraints we were unable to explore the 
preparation attempts further. 
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4.3 Couolina of selected linkers to peptides and proteins. 
4.3.1 introduction 
This section discusses the attempts to functionahse the pre-prepared biological 
entities (RGD-based peptide and the protein, HSA) with some of the previously 
prepared initiators (from chapters two, three and four) to give ATRP initiators 
with bio-recognition properties. They (the bio-initiators) will then be subjected to 
polymerisation process according to pubUshed methodology, and after 
purification would produce peptides and protein-based water-soluble 
bioconjugates. 
The peptide was designed based on the ubiquitous RGD sequence modified with 
strategically chosen and positioned amino acid residue (see introduction chapter 
1) to aid bio-recognition. 
4.3.1.1 Peptide synthesis 
The polypeptide 52 (Figure 4.1) was prepared by standard sohd phase Fmoc 
chemistry on TentaGel-S RAM Fmoc resin. (0.1 g, 0.2-0.3 mmol/g substitution). 
The last Fmoc deprotection was performed as a bench reaction with 20% 
piperidine/DMF and a small sample of the resin-bound polypeptide 51 was 
cleaved from the resin (95% TFA) and the polypeptide precipitated vnth ice-cold 
ether overnight. The polypeptide 52 was confirmed by the presence of molecular 
ion [M^] at m/z 745 in the mass specfroscopy corresponding to the calculated 
value. The initial design involved infroducing protected lysine residue 
strategically in the sequence during synthesis. 
EaEsnLPsEJiis G R G D S P A S TentaGel Resin 
Analogue 1 X R G D S P A S TentaGel Resin 
X = Glycine(NH)-- ATRP initiators 
Figure 4.1 
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The lysine residue was then deprotected and coupling attempted with the 
succinimidyl-based initiators using standard coupling techniques and the terminal 
Fmoc left intact to reduce complications. However, on analysis, we were unable 
to recover any molecular ion corresponding to the calculated values but based on 
the isotopic distribution, we were able to propose that the unexpected 
deprotection of the terminal Fmoc might have resulted in di or multiple 
fiinctionalisation of the peptide. 
4.3.2 Synthesis of Peptide-initiator complex 
The peptide-initiator was prepared from the condensation reaction of the parent 
polypolypeptide below (O.lg, free -NH2, -25%) with succinimidyl 17-(2-bromo-
2-methylpropionyloxy)-3, 6, 9, 12, 15-pentaoxaheptadecanoate 3.3 (Compound 
3, Chapter 3) (62 mg, 4 eq) to give the analogue peptide (Figure 4.1) after TFA 
cleavage and precipitation with cold ether. The resulting initiator was fiirther 
analysed by mass spectroscopy as observed by the presence of [M^] at m/z 
1171/1173 corresponding to expected values. Attempted coupling of N -
succinimidyl 4-(2-bromo-2-methylpropionyloxy)butanoate 12 (chapter 2) with 
the polypeptide using the strategy stated above was unsuccessful, only the 
unmodified polypeptide was observed by mass spectroscopy 
RGDSPAS 
(i),(ii) / O O 
GRGDSPAS • 
Protected side-chains 
51 
48 
95% TFA 
(Global deprotection) 
RGDSPAS 
GRGDSPAS 
52 
(i) Diisopropylethylamine, 3 (chapter 3; 4 eqv.) or 12 (chapter 2; 4 eqv.) 
(ii) 95% TFA, 5% TISAVater. 
Scheme 4.26 
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4.3.3 Synthesis of Protein (HSA)-initiator complex 
The protein-initiator complex 50 was prepared by first treating the protein 
Human Serum Albumin (HSA) with ten molar equivalents of ethanethiol to 
cleave disulphide bonds after 24 hours at 4° C. By observing the Ellman's anion 
in the UV-VIS, the concentration of the free thiol was determined (0.6 - 0.8 
SH/HSA) after being purified by gel filteration on Sephadex PD-10 against a 
phosphate buffer eluent. The protein was further observed by TOF mass 
spectroscopy to show the molecular ion (M + 50H) at m/z 1328, which was 
comparable with expected value of m/z 1331. The protein was then treated with 
the maleimide functionalised initiator 1.4 (compovind 1, chapter 4) in PBS 
solution at room temperature. After completion of the reaction as adjudged by 
observing Ellman's anion, the reaction was subjected to gel filtration and the 
fractions collected analysed after PBS elution. The protein-based initiator 50 was 
further observed by TOF mass spectroscopy to show the molecular ion (M + 
47H)'*''^at m/z 1425, which was comparable with expected value of m/z 1423. 
SH 
Protein 0 OTf 
1.4 (Compound 1, Chapter 4) 
(i) PBS, pH 7.4, rt 
OTf 
50 
Scheme 4.27 
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4.3.4 Model polymerisation of protein-initiator complex 
The model polymerisation with the monomer monomethoxy capped 
oligo(ethylene oxide) methacrylate initiated by the initiator 50 was attempted 
based on the literature procedure^". The initiator 50 (0.01 mM) in PBS was 
dissolved in doubly distilled de-ionised water (2 mL) before adding bipyridine 
Ugand (2.2 eqv. of Cu^) followed by CuBr (15 mg) and the monomer (0.02 g, 
100 eqv. of initiator). The reaction was vortexed under a stream of nitrogen at 
room temperature and the progress of the reaction was observed as the mixture 
became dark brown and viscous. The reaction was then purified with Sephadex 
PD 10 eluted with water to yield a colourless liquid. Attempts to analyse by GPC 
(aqueous or organic solvent based) proved difficult, while analysis by MALDl 
was more productive (Figure 4.2) in giving the m/z signals at 33628 and 67541 
which did not correspond to the expected value(s) but were indicative of 
premature termination. 
Figure 4 J 
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4.4 Summary 
We have demonstrated that three different classes of bio-macromolecule linker 
can be prepared that incorporate the ability to initiate living polymerisation 
process with reactivity to biomolecules. 
^ , ^ . 0 . A .RGDSPAS 
U H 
48 
Br-
O 
RGDSPAS 
N 
H 
O 
49 (Unsuccessful) 
Figure 4.3 
They were designed to facilitate chemoselectivity for peptide and protein 
residues; unfortunately, compound 49 proved to be unstable in an aqueous 
environment and as such polymerisation with 49 was not realised. Compound 50 
on the other hand, after initial attempts, showed promising living polymerisation 
properties (initiation and limited propagation). These wil l be improved upon in 
further studies. Compound 48 was successfully prepared but due to time 
constraints was not investigated as an ATRP initiator. 
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5.1 General Procedures 
Reactions were carried out under an atmosphere of argon in dry glassware unless 
otherwise stated. 
Reagents 
Reagents were used as supplied unless otherwise stated. 
Melting Points 
Recorded using Cambridge Instrument Gallen^"^ I I I Kofler melting point 
apparatus and were uncorrected. 
Solvents 
Dry DMF was obtained from the Aldrich Chemical Company and used as 
received. THF was distilled from sodium benzophenone ketyl and dry DCM was 
distilled over calcium hydride under an atmosphere of nitrogen. 40-60 
Pefroleum-ether refers to the fraction of petroleum ether, which boils between 40 
and 60 °C and was redistilled prior to use. A l l other solvents were used as 
received. In the cases where mixtures of solvents were used, ratios given refer to 
volumes used. 
Solvents were dried according to standard procedures: diethyl ether and 
tetrahydrofiiran were distilled under N2 over Na, immediately prior to use. A l l 
solvents were removed by evaporation under reduced pressure. 
Chromatography 
Flash chromatography was carried out using silica gel (Fluorochem 60A, 40-
60|x). Analytical thin layer chromatography (TLC) was performed using 
aluminium plates precoated with silica gel (60 F254), and materials were 
visualized by UV radiation at 254 nm, or by staining with pot£issium 
permanganate in aqueous sodium carbonate or phosphomolybdic acid in ethanol. 
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\R Spectroscopy 
IR spectra were recorded on a Perkin-Elmer FT-IR 1600 spectrometer. Liquids 
were recorded as thin layers (neat) between KBr plates and solids were recorded 
as compression formed discs made using KBr unless otherwise specified. 
NIMR Spectroscopy 
' H N M R spectra were analysed in D2O, CDCI3 or CD3OD on Varian Oxford 
200, Bruker AM250, Varian Unity 300, Varian VXR 400 or Varian Inova 500 
spectrometers and are reported as follows: chemical shift 5 (ppm) (number of 
protons, multiplicity, coupling constant J (Hz), assigrmient). '^C NMR spectra 
were recorded at 63 MHz on the Bruker AM250 spectrometer or 126 MHz on the 
Varian Inova 500 spectrometer. The central resonance of CDCI3 (6c = 77.00 
ppm) was used as an internal reference. '^F NMR spectra were analysed in 
CDCI3 at 188 MHz on the Varian Oxford 200 spectrometer. '^F spectral data are 
referenced to CFCI3 (5F = 0 ppm). Chemical shifts are quoted in parts per 
million relative to tetramethylsilane (6H = 0 ppm) and coupling constants are 
quoted in Hertz. 
iViass Spectrometry 
Low-resolution mass spectra were obtained on VG Analytical 7070E or VG 
Autospec Organic Mass Spectrometer. High-resolution mass spectra were 
obtained fi"om the Durham University Chemistry Department microanalysis 
service. In both cases electrospray (ES), chemical ionisation (CI) and electron 
ionisation (EI) methods were used to generate ions. MALDI-tof spectrum was 
recorded on the Applied Biosystems Voyager-DE STR-MALDI system. 
The numbering system used in reporting/naming the compounds 
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5.2 Compounds from Chapter 2 
5.2.1 N - succinimidyl acrylate (5) 
l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI, 0.82 g, 4.30 mmol) was 
added to a stirred mixture of N hydroxysuccinimide (0.48 g, 4.15 mmol) and 3 -
bromopropionic acid (0.57 g, 3.75 mmol) in dichloromethane (10 mL) at room 
temperature under a nitrogen atmosphere. The mixture was then stirred for 2 h, 
washed with potassium bicarbonate solution (2 x 20 mL), dilute HCl (2 x 20 mL) 
and dried (Na2S04), before being concentrated in vacuo to give the crude 
product. The crude product was then triturated with MeOH to give a colourless 
crystalline solid (0.197 g, 30%). 
5H (CDCI3; 500 MHz) 2.88 (4H, s, br, CH2CH2), 6.18 ( I H , d, JAB = 6.5 Hz, 
C H X = C H B H A ) , 6.32 ( I H , dd, Jex = 11 Hz, C=0CHx=CH2 and JBA - 6.5 Hz, 
C H X = C H B H A ) , 6.71 ( I H , d, JAX = 18.5 Hz, C H X = C H B H A ) . 
m/z (EI) 170 (50 %, M + H) and 56 (100 %) M.P 67 - 69 °C 
5.2.2 3-Hydroxypropanoic acid (6) 
3-Bromopropionic acid (2.5g, 16.3 mmol) was refluxed in water (32 mL) for 6.5 
h. Upon completion, as determined by TLC (Rf = 0.5 in 100 % MeOH) the 
reaction was extracted with ethyl acetate and the organic extracts concentrated 
under reduced pressure. Kulgerohr distillation (2 mbar, 150- 152 °C) furnished 
the product (0.43 g, 30 %) as an orange/pink oil which solidified on standing. 
5H (CDCI3; 400 MHz) 2.66 (2H, t, J = 6.6 Hz, CH2COOH), 4.37 (2H, t, J = 6.6 
Hz, CH2OH) 
8c (CDCI3; 100 MHz) 176.92 (C=0), 37.66 (CH2OH) and 25.23 (CH2COOH). 
m/z (ES -) 89 (40 %, M - H); (CI+) 108 (40 %, M + NH4), 234 (100%); (EI+) 
107 (M + NH4), 91 (100 %, M+H) 
Vmax (liquid film, cm"') 3264 (OH), 2928 (COOH, br), and 1648 (C=0). 
C: H: N. : C3H6O3 Requires C40.45, H5.62 Found C45.66, H5.40. 
M.P 57-58 °C. 
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5.2.3 N-Succinimidyl-(2-bromo-2-methyl)propionate (8) 
l-(3-dimethyl aminopropyl)-3-ethylcarbodiimide iodide (EDCI, 0.82 g, 4.30 
mmol) was added in portions to a stirred solution of 2-bromo-2-methylpropionic 
acid (0.618 g, 3.7 mmol) and N-hydroxysuccinimide (0.48 g, 4.15 mmol) in dry 
dichloromethane (10 mL) at room temperature under a nitrogen atmosphere. The 
mixture was stirred for 8 h before being washed with saturated aq. sodium 
bicarbonate (2 x 20 mL), dil HCl (3 x 20 mL) and water (2 x 20 mL). After 
drying of the organic phase with Na2S04 and concentration in vacuo, the crude 
product was purified by column chromatography (50 % dichloromethane / petrol 
40-50,) to yield the title compound (Rf 0.5, 0.562 g, 55%) as a pale brown syrup. 
5H (CDCI3; 400 MHz) 2.08 (6H, s, (CH3) 2), 2.86 (4H, s, br, CH2-CH2) 
5c (CDCI3; 100 MHz) 169 (C=0), 168 (C=0), 52 (C-Br), 31.5 (Me) and 26 
(CH2). 
(EI) 263 (5%, M +) and 184 (M - Br). 
C: H: N . ; Found C 36.42, H 3.79, N 5.55; Required C 36.39, H, 3.82, N 5.30 
5.2.4 4-l\/lethoxybenzyl-4-hydroxybutanoate (10) 
To a solution of sodium 4-hydroxybutyrate (0.5 g, 4.00 mmol) and tetrabutyl-
ammonium iodide (120 mg, catalytic) in dry tetrahydrofuran (30 mL) was added 
4- methoxybenzyl chloride (0.74 g, 0.64 mL, 4.76 mmol). The reaction mixture 
was heated at reflux for 24 h. The reaction was allowed to cool to room 
temperature before being concentrated in vacuo to a volume of 2 mL and then 
dilute with dichloromethane (30 mL) and washed with water (3 x 20 mL). The 
dichloromethane extracts were combined and the aqueous layer further extracted 
with dichloromethane ( 2 x 1 5 mL). The organic extracts were combined, dried 
MgS04 and filtered. Purification by silica gel column chromatography (20% 
ethyl acetate/hexane) yielded the title compound (0.8 g, 92 %) as a colourless oil. 
5H (CDCI3; 400 MHz) 1.82 (2H, m, CH2), 2.41 (2H, t, J = 7.8 Hz CH2C=0), 3.60 
(2H, m, CH2OH), 3.76 (3H, s, MeO), 5.01 (2H, s, CH2Ph), 6.82 (2H, d, J = 8.5 
Hz, Ph), 7.22 (2H, d, J = 8.4, Ph) 
147 
Compounds from Chapter 2 
5c (CDCI3; 50 MHz) 174.10 (C=0), 159.85 (Ph-C-O), 130.31 (Ph-C), 128.24 (C-
H), 114.17 (C-H), 66.41 (CH2O), 62.08 (CH2OH), 55.49 (MeO), 31.25 (CH2), 
27.91. 
m/z (ES) 247 (M + Na) v^ax (liquid film, cm'') 1712 (C=0) 
5.2.5 4-IViethoxybenzyl 4-(2-bromo-2-
methylpropionyloxy)butanolc acid (11) 
To a solution of 4-methoxybenzyl 4-hydroxybutanoate (2.0 g, 8.93 mmol), and 
triethylamine (1.1 g, 10.71 mmol, 1.2 eqv) in dichloromethane (25 mL) was 
added dimethylaminopyridine (0.22 g, 20 mol %) and the reaction was allowed 
to stir at room temperature for 0.5 h. The mixture was then cooled to 0°C before 
the dropwise addition of 2-bromo-2-methylpropionyl bromide (2.5 g, 1.76 mL, 
1.2 eqv), and stirred for 4 h at 0°C and overnight at room temperature. The 
reaction mixture was washed with dil HCl, water and dried (MgS04) before 
concentration in vacuo and purification by column chromatography (10 % ethyl 
acetate/hexane). The title compound (1.8 g, 54 %) was obtained as a colourless 
oil. 
8H (CDCI3; 200 MHz) 1.92 (6H, s, C [CH3] 2 Br), 2.0 (2H, m, CH2), 2.47 (2H, t, J 
= 7.4 Hz, CH2C=0), 3.80 (3H, s, MeO), 4.20 (2H, t, J = 6.4 Hz, CH2O), 5.06 
(2H, s, PhCH20), 6.87 (2H, d, / = 8.5 Hz, Ph), 7.34 (2H, d, J = 8.5 Hz, Ph). 
5c (CDCI3; 50 MHz) 175.0, 173.0 (C=0), 160.0, 130.0 (Ph-C), 128.0 (CH), 
114.0 (CH), 66.0, 65.0 (CH2O), 55.0 (MeO), 30.0 (CH2) and 24.0 (Me). 
m/z(ES) 395/397 (M + Na). 
HRMS (ES) CifiHzi'^BrOjNa requires 395.0572 found 395.0469 
CieHzi^'BrOsNa requires 397.0552 found 397.0452. 
5.2.6 4-(2-Bromo-2-methylpropionyloxy) butanoic acid (11b) 
A solution of 10 % TFA/ DCM (10 mL) was added slowly with stirring to a 
solution of 4-methoxybenzyl 4-(2-bromo-2-methylpropionyIoxy) butyrate (2.0 g, 
5.4 mmol) in dichloromethane (1 mL) at room temperature. The dark red 
solution was stirred for 4 h at room temperature, and monitored by TLC (25 % 
ethyl acetate/ hexane, Rf = 0.6 of ester). The reaction was diluted with water (5 
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mL) and then saturated aq. NaHCOa (20 mL) was added with stirring. The 
resuhing mixture was stirred for 10 min before being extracted with DCM (3 x 
20 mL) and the aqueous extracts combined, acidified ( I M HCl) and the resulting 
solution fiirther extracted with DCM (3 x 20 mL), concentrated and dried over 
P2O5 under reduced pressure to obtain the title compound (1.33 g, 98 %) as a 
colourless oil, which turned pale brown on standing. 
The compound was analysed and used without further purification. 
6H (CDCI3; 400 MHz) 1.92 (6H, s, C [CH3] 2 Br), 2.11 (2H, m, CH2), 2.51 
(2H, t, y = 7.4 Hz, CH2C=0), 4.24 (2H, t, J = 6.4 Hz, CH2O). 
m/z (+ES) 274/276 (100 %, M + Na). 
HRMS (+ES) C8H,3^^Br04Na requires 275.000 found 274.9912. 
C8Hi3^'Br04Na requires 276.998 found 276.9894 
5.2.7 N-Succinimidyl 4-(2-Bromo-2-methylpropionyloxy) 
butanoate (12) 
A solution of 4-(2-bromo-2-methylpropionyloxy) butyric acid (1.00 g, 4 mmol), 
and Die (0.60 g, 0.56 mL, 1.2 eq.) in DCM (10 mL) was stirred for 1 h at room 
temperature. A solution of N-hydroxysuccinimide (0.55 g, 1.2 eq.) and 
triethylamine (0.80 g, 2 eq.) in DCM (10 mL) was then added. The mixture was 
further stirred at room temperature for 16 h. Upon completion (TLC, 50 % ethyl 
acetate / hexane, Rf = 0.45, KMn04) , dilute HCl (2 x 20 mL) and water (2 x 20 
mL) were used to wash the mixture before drying MgS04. After evaporation, the 
residue was subjected to column chromatography (30 % ethyl acetate / hexane). 
The title compound (1.1 g, 75 %) was recovered as a colourless oil. 
8H (CDCI3; 400 MHz)_1.94 (6H, s, C [CH3] 2 Br), 2.11 (2H, m, CH2), 2.77 (2H, 
m, CH2C=0), 2.84 (4H, s, br, CH2-CH2), 4.27 (2H, m, CH2O). 
5c (CDCI3; 100 MHz)_171.51, 169.00 (C=0), 167.93 (NC=0), 60.41(CH2O), 
55.61 (C-Br), 30.69 (CH2), 27.56, 25.59 (Me), 23.59, 21.06 (CH2). 
m/z(+ES)372 (100%, M + Na) and 374 (80%, M + Na) 
HRMS (+ES) Ci2Hi6'^BrN06Na requires 372.0161 found 372.0064 
Ci2Hi6^'BrN06Na requires 374.0195 found 374.0050 
~IR (liquid film, cm"') 1795 (C-0) , 1784 (C=0). 
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5.2.8 2-Methoxy-2-methyl-propionic acid (13) 
2-Bromo-2-methylpropionic acid (3 g, 18 mmol) was finely ground and added in 
portions to a freshly prepared solution of NaOMe (0.9 g sodium, 39.5 mmol, 2.2 
eqv) in methanol (60 mL) at room temperature. The mixture was then allowed to 
stir overnight at 40 °C under a nitrogen atmosphere. On completion of the 
reaction (TLC, 10 % MeOH / DCM, Rf new 0.25, Rf starting add 0.8, KMn04), the 
mixture was acidified ( I M HCl) to pH 1. The precipitate formed was decanted 
off and the methanolic filtrate concentrated and extracted with dichloromethane 
(3 X 20 mL). The combined dichloromethane extracts were concentrated in vacuo 
and fiirther washed with brine (2 x 25 mL), water (2 x 25 mL) and dried Na2S04. 
The organic phase was then concentrated and dried under reduced pressure 
before being dried over P2O5. The product (2.1 g, 77%) was obtained as a brown 
syrup, which was used in subsequent reactions without fiirther purification. 
8H ( C D C I 3 ; 300 MHz) 1.46 (6H, s, C I C H 3 ] 2 OMe), 3.32 (3H, s, C [ C H 3 ] 2 0Me), 
8.7 ( I H , s, br, COOH). 
5c (CDCI3; 100 MHz) 167.0 (C=0), 72.5 ( ^ [ C H j ] 2}, 61.0 (MeO), 24.0 (Me2). 
m/z (ES) 141 (100 %, M + Na) m/z (CI+) 136 (100 %, M + N H 4 ) 
m/z (EI+) 59 (80 %, M - COOH),Vmax (liquid film, cm'') 2988 (br, OH) and 1724 
(C=0). 
Literature: (see Chap. 2, Ref 4, p80.) 
6H ( C C I 4 ) 1.41 (6H, s), 3.21 (3H, s), 11.6 ( I H , s). v^ax (liquid film, cm"') 3300-
3100 (br), 2985,1735,1715. 
5.2.9 N-Succinimidyl -2-methoxy-2-methyl-propionate (14) 
A solufion of 2-methoxy-2-methyl-propionic acid (1.3 g, 11 mmol), EDCI (2.3 g, 
12 mmol, 1.1 eqv) and A'.A'-dimethylaminopyridine (catalytic) in 
dichloromethane (15 mL) was stirred for 0.5 h at room temperature under an 
atmosphere of nitrogen before the addition of N-hydroxysuccinimide (1.39 g, 12 
mmol, 1.1 eqv). The mixture was then allowed to stir for a fiirther 6 h at room 
temperature. The reaction mixture was washed with I M HCl (3x15 mL), water 
(3 X 20 mL) and dried with MgS04 before being concentrated in vacuo, column 
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chromatography ([1:2] DCM, petrol ether 40/60) before drying over P2O5 under 
reduced pressure to yield the title product (1.76 g, 73 %) as a brown syrup. 
5H (CDCI3; 200 MHz) 1.54 (6H, s, C [CH3] 2 OMe), 2.80 (4H, s, cyclic-
CH2CH2), 3.36 (3H, s, C [CH3] 2 OMe); m/z (ES) 238 (M + Na). 
5.2.10 4-Methoxybenzyl 4-(2-methoxy-2-methyl-
propionyloxy)butanoate (15) 
Triethylamine (90 mg, 0.893 mmol, 0.125 mL) wad added to a solution of 4-
methoxybenzyl 4-hydroxybutanoate (100 mg, 0.446 mmol) and succinamidyl 2-
methoxy-2-methyl-propionate (106 mg, 0.491 mmol, 1.1 eq) in dichloromethane 
(3 mL) at room temperature before being allowed to stir for 6 h at room 
temperature under a nitrogen atmosphere. The reaction mixture was stirred and 
monitored with TLC (50 % ethyl acetate/hexane Rf new 0.8 in KMn04). The 
reaction mixture was diluted with dichloromethane (20 mL) washed with dilute 
HCl (2 X 20 mL) and water (2 x 20 mL), concentrated and dried MgS04 before 
purification by column chromatography (25 % ethyl acetate/hexane). The title 
compound (130 mg, 90 %) was obtained as a colourless oil. 
5H (CDCI3; 200 MHz) 1.41 (6H, s, C [CH3] 2 OMe), 2.00 (2H, m, CH2), 2.42 
(2H, t, J = 7.4 Hz, CH2C=0), 3.26 (3H, s, C [CH3] 2 OMe), 3.82 (3H, s, CH2 
PhOMe), 4.20 (2H, t, J = 6.5 Hz, CH2O), 5.12 (2H, s, PhCH20), 6.87 (2H, d, J 
= 8.5 Hz, Ph), 7.34 (2H, d, J = 8.5 Hz, Ph). 
6c (CDCI3; 50 MHz) 175.0, 173.0 (C=0), 160.0, 130.0 (Ph-C), 128.0 (CH), 
114.2, 114.3 (CH), 66.4, 66.5(CH20), 64.1, 55.0, 52.0 (MeO), 30.9, 30.8 (CH2), 
24.3,24.2 (Me). 
m/z (ES) 347 (M + Na) HRMS (ES) C,7H2406Na requires 347.1573 found 
347.1487. 
Vmax (liquid film, cm'') 1732 (C=0), 1613 (C=0), 1515 (C-0) and 1166 (C-0). 
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5.2.11 Benzyl 4-hydlroxybutanoate (17) 
The sodium salt of 4-hydroxybutyrate (200 mg, 1.59 mmol), 
tetrabutylammonium bromide (0.102 mg, 20 mol%) and benzyl bromide (0.227 
mL, 1.91 mmol) were added to DMF (5 mL) and allowed to stir at room 
temperature. After completion of the reaction (48 h), as monitored by TLC (40 % 
ethyl acetate/hexane Rf new 0.15, UV and KMn04), the mixture was concentrated 
in vacuo, diluted with DCM (15 mL), washed with water (5 x 20 mL) and dried 
over MgS04. The crude compound was further subjected to high vacuum rotary 
evaporation before purification by chromatography (10 % ethyl acetate/hexane) 
to yield the title compound (220 mg, 97%) as a colourless oil. 
6H (CDCb; 400 MHz) 1.65 ( I H , s, OH), 1.92 (2H, m, CH2), 2.52 (2H, m, CH2), 
3.70 (2H, m, CH2), 5.15 (2H, s, PhCH2), 7.28 (5H, m, Ph). 
5c (CDCI3; 100 MHz) 174 (C=0), 136 (Ph-C), 129 (CH), 128 (CH), 67 (CH2O), 
62 (CH2OH), 32 (CH2), 28 (CH2). 
m/z (+ES) 217(80 %, M + Na) 
Vmax (liquid f i lm, cm"') 3279 (OH) and 1736 (C=0). 
HRMS (+ES) CnHnOaNa requires 217.0943 found 217.0823. 
5.2.12 Benzyl 4-(2-methoxy-2-methyl-proplonyloxy)butanoate 
(18) 
A mixture of EDCI (130 mg, 1.2 eqv, 0.680 mmol), 2-methoxy-2-
methylpropionic acid (80 mg, 0.680 mmol, 1.2 eqv) and N , N -
dimethylaminopyridine (85 mg, 1.2 eqv, 0.680 mmol) in DCM (3 mL) was 
stirred for 1 h before a solution of benzyl-4-hydroxybutanoate (110 mg, 0.567 
mmol) in DCM (5 mL) was added dropwise with continued stirring. The reaction 
was monitored by TLC (40 % ethyl acetate / hexane, Rf new 0.75, Rf starting benzyl 
0.3, both UV and KMn04 visible) and left to stir overnight at room temperature 
under a nitrogen atmosphere. The reaction mixture was washed with I M HCl (2 
X 25 mL), water (2 x 25 mL), extracted and concentrated in vacuo before 
purification with silica gel chromatography (10 % and 50 % ethyl acetate / 
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hexane respectively) to yield the title compound (83 mg, 51 %) as a colourless 
oil. 
5H (CDCI3; 400 MHz) 1.40 (6H, s, C [CH3] 2 OMe), 2.0 (2H, m, CH2O), 2.42 
(2H, m, CH2), 3.34 (3H, s, MeO), 4.21 (2H, m, CH2), 5.10 (2H, s, Ph CH2O), 
7.42 (5H, m, Ph). 
5c (CDCI3; 100 MHz) 175.0 (C=0), 173.0 (C=0), 136.0 (Ph-C), 128.7, 128.6, 
128.4, 128.3(CH), 72 ((C_[CH3] 2), 67.0, 65.0 (CH2O), 61 (MeO), 52.0, 31.0 
(CH2), 25.2, 25.0 (Me) 
m/z (ES) 317 (100 %, M + Na) HRMS (ES), Ci6H2205Na requires 317.1467 
found 317.1361, Vmax (liquid film, cm"') 2940 (CH2) and 1738(C=0). 
5.2.13 Benzyl 4-(2-bromo-2-methyl-propionyloxy)butanoate 
(19) 
A solution of benzyl 4-hydroxybutanoate (108 mg, 0.557 mmol) and 
triethylamine (0.09 mL, 0.668 mmol, 1.2 eqv) in DCM (5 mL) was stirred at 
room temperature under a nitrogen atmosphere for 0.5 h. The solution was then 
cooled to 0 °C before the dropwise addition of 2-bromo-2-methylpropionyl 
bromide (0.109 mL, 0.668 mmol 1.2 eqv.). The reaction mixture was fiirther 
stirred at room temperature for 5 h during which some white precipitate formed. 
After completion of the reaction, as determined by TLC (40 % ethyl acetate / 
hexane, Rf new = 0.9 two spots, Rf sm = 0.3 consumed, both UV and KMn04 
visible), the mixture was diluted with DCM (20 mL), washed with I M HCl (2 x 
20 mL), water (2 x 15 mL) and concentrated under reduced pressure. The 
resulting oily mixture was purified by silica gel chromatography (20 % ethyl 
acetate / hexane) to produce the title compound (101 mg, 56 %) as a colourless 
oil. 
5H (CDCI3; 400 MHz) 1.95 (6H, s, C [CH3] 2 Br), 2.05 (2H, m, CH2O), 2.51 (2H, 
m, CH2), 4.22 (2H, m, CH2), 5.18 (2H, s, PhCH20), 7.4 (5H, m, Ph). 
5c (CDCI3; 100 MHz) 173.0 (C=0), 171.0 (C=0), 135.0 (Ph-C), 128.7, 128.6, 
128.4,128.3(CH), 67.0, 65.0 (CH2O), 55.0 (C), 31.0 (CH2), 25.2, 25.0 (Me) 
m/z(ES) 365/367 (M + Na) 
153 
Compounds from Chapter 2 
HRMS (ES) Ci3Hi9^^Br04 requires 365.0467 found 365.0378. 
C,3Hi9^'Br04 requires 367.0446 found 367.0338 
Vmax(liquid f i lm, cm"') 1735 (C=0) 
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5.3 Compounds from Chapter 3 
5.3.1 Methanesulphonyl Azide (18) 
A three-necked flask equipped with a nitrogen inlet and a powder funnel was 
filled with methanesulphonyl chloride (15 mL, 194 mmol) in acetone (Analar 
grade, 100 mL). Sodium azide (18.9 g, 290 mmol) was then added through the 
funnel over 0.5 h under a constant flow of nitrogen at room temperature to the 
solution and stirred for 2 h. The mixture was then filtered, dried over Na2S04 
and concentrated xmder reduced pressure for 2 h. Methanesulphonyl azide (22.3 
g, 94 %) was obtained as a colourless oil which was used without further 
purification. 
Vn,ax(Hquid film, cm-') 2146 (N=N), 1362 and 1174. 
C:H:N : CH3SO2N3 requires C60.27; H5.06; N12.78; found C60.32; H4.65; 
N12.31. 
5.3.2 Toluenesulphonyl Azide (19) 
A solution of sodium azide (10.0 g, 196 mmol) in a mixture of water (28.5 mL) 
and ethanol (57 mL, 90 %) was added to a solution of tosyl chloride (27.2 g, 143 
mmol) in ethanol (143 mL, 90 %) at 45 °C. After 12 h at room temperature, the 
reaction was washed with water, dried over Na2S04 and concentrated under 
reduced pressure. The product (22.76 g, 98 %) was obtained as a colourless oil, 
and was not further purified. 
6H (CDCI3; 400 MHz) 2.42 (3H, s, CHsPh), 7.33 (2H, d, Ph), 7.78 (2H,d,Ph) 
5c (CDCI3; 100 MHz) 146 (C-Me), 135(C-S), 130 (CH), 127 (CH) and 21(Me). 
Vmax (liquid film, cm"') 2132 (N=N). 
C: H: N : S: C7H7N3S requires: C42.63, H3.58, N21.31, S16.26 found: C41.44, 
H3.46, N20.81,815.73. 
5.3.3 Benzyl diazoacetate (21) 
Benzyl acetoacetate (13 mL, 14.5 g, 75.5 mmol) was added to tosyl azide (15 g, 
75.5 mmol, 1 eqv.) in anhydrous acetonitrile (92 mL) in the presence of 
triethylamine (7.6 g, 75.5 mmol, 1 eqv.) over 3 h at room temperature. A solution 
of KOH (9 g) in vvater (7 iriL) Vvas then added and the hiixttire stirred for a 
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fiirther 12 h during which the reaction turned reddish brown in colour. The 
reaction mixture was extracted with ether, washed with a solution of KOH (3 g) 
in water (25 mL) and then with water. After drying (Na2S04), filtration and 
evaporation of the solvent under reduced pressure, the crude product was 
obtained as a reddish brown oil. Purification by silica gel chromatography (90 % 
ethyl acetate / hexane; then 2 % methanol in ethyl acetate) gave the title 
compound (6.0 g, 94 %) as a yellow oil. 
5H (CDCI3; 200 MHz) 4.78 ( I H , s), 5.19 (2H, s, CH2Ph), 7.39 (5H, s, Ph) 
Vmax (liquid film, cm"') 2115 (N=N), 1690 (C=0) 
5.3.4 Benzyl 11-hydroxy-3,6,9-trioxaundecanoate (10) 
Benzyl diazoacetate (5.5 g, 31 mmol) in dichloromethane (20 mL) was added 
slowly to a stirred solution of triethyleneglycol (20 g, 155 mmol, 3 eqv.) and 
boron trifluoride etherate (2 drops, catalytic) at room temperature in 
dichloromethane (10 mL), and a steady evolution of gas was observed The 
colourless reaction mixture was stirred under nitrogen at room temperature for 3 
h, before being diluted with dichloromethane (20 mL) and washed with water (4 
x 30 mL). The aqueous washings were washed with DCM (1 x 20 mL) and the 
combined organic extracts were dried (MgS04) before being concentrated in 
vacuo to give the crude product as a yellow oil. Purification by flash 
chromatography (50 % hexane/ ethyl acetate) then produced the title compound 
(8.2 g, 88 %) as a pale yellow oil. 
5H (CDCI3; 300 MHz) 2.5 ( I H , s, br, OH), 3.6 - 3.8 (12H, m, 5 x OCH2 and 
CH2OH), 4.3 (2H, m, BnOCOCH2), 5.2 (2H, s, CHzPh) 7.32 (5H, s, Ph) 
5c (CDCI3; 75 MHz) 170.0 (C=0), 135.0 (Ph-C), 128.0 (2 x CH), 128.4 (2 x 
CH), 72.0 (PhCH20), 70.9 (2 x OCH2), 70.6 (2 x OCH2), 70.3 (2 x OCH2), 66.0 
(CH2OH). 
m/z (+ES) 321 (100%, M + Na), HRMS (+ES) C, 5H2206Na requires 321.1416 
found 321.1329. 
Vn,ax (liquid film, cm"') 3385 (-0H), 1749 (C=0), 1116 (C-O). 
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5.3.5 Benzyl (11(-2-bromo-2-methylpropionyloxy))-3,6,9-
trioxaundecanoate (7) 
A solution of 2-bromo-2-methylpropionyl bromide (0.92 g, 0.49 mL, 1.2 eq.) in 
dichloromethane (5 mL) previously cooled to 0 °C was introduced to a solution 
of benzyl 1 l-hydroxy-3, 6, 9-trioxaundecanoate (1.00 g. 3.36 mmol) and 
triethylamine (0.72 mL, 1.2 eq.) in dichloromethane (15 mL) at 0 °C. The 
reaction mixture was stirred at 0 °C for 8 h and after a fiirther 8 h at room 
temperature, before being washed successively with saturated aq. NaHCOs (3 x 
20 mL) and water (2 x 20 mL). The extracts were combined and dried (MgS04), 
concentrated in vacuo and the crude material purified by silica gel flash column 
chromatography (20 % ethyl acetate then 50 % ethyl acetate / hexane). The title 
compound (1.2 g, 75 %) was recovered as pale brown oil. 
5H (CDCb; 400 MHz) 1.95 (6H, s, Me2), 3.6 - 3.8 (lOH, m, 5 x OCH2), 4.19 
(2H, s, BnOCOCHz), 4.3 (2H, m, CH2 CH20C=OC[CH3] 2Br), 5.19 (2H, s, 
CH2Ph) 7.38 (5H, m, Ph) 
6c (CDCI3; 100 MHz) 172.0(C=O), 171.0 (C=0), 137.0 (CH), 129.0 - 127.0 (4 x 
Ph-C), 72.5 - 72.0 (6 x OCH2), 69.0 (OCH2), 67.0 (OCH2), 56.0 (C-Br), 32.0 (2 x 
Me). 
m/z (+ES) 469 / 471 (100 %, M + Na) 
HRMS (+ES) Ci9H27''Br07Na requires 469.0940 found 469.0843. 
C,9H27^'Br07Na requires 471.0920 found 471.0826. 
Vmax(liquid film, cm"') 1735 (C=0). 
5.3.6 t-Butyl a-diazoacetate (26) 
A. A mixture of 
anhydrous acetonitrile (110 mL), r-butyl acetoacetate (13.4 g, 84.8 mmol), and 
triethylamine (11.4 mL, 84.8 mmol) was cooled to 0°C. The exothermic reaction 
mixture was stirred for 0.5 h before the dropwise addition of methanesulphonyl 
azide (10 g, 84.8 mmol) in acetonitrile (20 mL) (faster addition of reagents 
resulted in a rapid increase in temperature) over a period of 0.5 h with vigorous 
stirring at 0°C. The resulting yellow reaction mixture was then allowed to warm 
to room temperature and stirred for a fiirther 3.5 h. The solvent was evaporated 
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under reduced pressure and the compound dissolved in ether (100 mL). The 
ethereal solution was washed aq. KOH (23 g in 250 mL, water x 2), KOH (4 g in 
120 mL water, twice) and water (3 x 150 mL, twice). The organic phase was 
dried (Na2S04). and concentrated under reduced pressure to gave the product 
(12.5 g, 80 %) as a yellow oil. 
R A fi-eshly prepared solution of sodium methoxide (3.0 g sodium in 50 mL 
of methanol) was added dropwise with stirring to a solution of /-butyl 
a-diazoacetoacetate (12.5 g) in methanol (50 mL) cooled to 0 °C. The 
temperatvire of the reaction was at 0 °C by regulating the rate of addition of 
sodium methoxide. After the addition, the reaction was stirred at room 
temperature for 0.75 h. The resulting reddish/brown mixture was poured into 
iced water (500 mL), stirred for 0.5 h and extracted with ether (2 x 150 mL). The 
aqueous phase was saturated with sodium chloride and extracted with ether (3 x 
120 mL). The combined organic phase was washed with water (2 x 200 mL) and 
dried (Na2S04). The ether was concentrated using a rotary evaporator and 
slightly reduced pressure at 40 °C water bath temperature. 
The resulting yellow oil was distilled in portions under the same conditions using 
6 mbar/35 °C in a temperature controlled water bath to gave the yellow 
diazoacetate (8 g, 83 %) as a yellow oil. 
5H (CDCI3; 200 MHz) 1.48 (9H, s, \Clhh) and 2.5 ( I H , s, CH=N2) 
Vmax(liquid film, cm'') 2132 (N=N), 1714 (C=0).. 
B.p51-53 °C(12mmHg). 
5.3.7 t-ButyM1-hydroxy-3,6,9-trioxaundecanoate.(27) 
/-Butyl a-diazoacetate (1.49 g, 0.95 g/cm^, 9.43 mmol) in dichloromethane (5 
mL) at room temperature, was added slowly using a syringe to a stirred solution 
of triethyleneglycol (20 g) and boron trifluoride etherate (2 drops, catalytic) in 
dichloromethane (10 mL). A steady evolution of gas was observed. The 
colourless reaction mixture was stirred under a nitrogen atmosphere at room 
temperature for 3 h. The reaction was then diluted with dichloromethane (50 
mL) and washed with water (4 x 30 mL). The aqueous washings were fiirther 
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combined and extracted with dichloromethane (1 x 20 mL) and the combined 
organic extracts were dried (Na2S04) before being concentrated under reduced 
pressure to reveal the crude product as a yellow oil. Purification by flash 
chromatography (50 % hexane/ethyl acetate then 100 % ethyl acetate) fiimished 
the title compound (1.77 g, 71%) as a pale yellow oil. 
5H (CDCI3; 300 MHz) 2.30 ( I H , s, br, OH), 1.5 (9H, s, C [CH3] 3), 3.68 -
3.7(12H, m, 8 X OCH2), 4.0 (2H, s, 0CH2C=0). 
6c (CDCI3; 125 MHz) 170 (C=0), 73 (C-Me), 73.4 - 72.2 (6 x CH2O), 69 
(CH2O), 62 (CH2OH), 28 (2 X Me). 
m/z (ES) 287 (100 %, 264 + Na). HRMS (ES) Ci2H2406Na requires: 287.1573 
found 287.1494. 
Vmax (liquid film, cm"') 3416 (OH) and 1745(C=0). 
5.3.8 t-Butyl 14-hydroxy-3,6,9,12-tetraoxatetradecanoate (28). 
Using the method described for 27 above, a solution of 'butyl a-diazoacetate (2.0 
g, 0.95 g/cm^, 12.7 mmol) in dichloromethane (10 mL) was added slowly over a 
period of 0.25 h to the mixture of tetraethylene glycol (5.0 g) and boron 
trifluoride etherate (2 drops, catalytic) in dichloromethane (10 mL) before being 
stirred for 4h at room temperature under a nitrogen atmosphere. The reaction was 
then diluted with dichloromethane (50 mL) and washed with water (4 x 30 mL). 
The aqueous wash was further extracted with dichloromethane (1 x 20 mL) and 
the combined organic extracts dried over Na2S04, before being concentrated 
under reduced pressure to reveal the crude product as a yellow oil. Purification 
by flash chromatography (50 % hexane/ethyl acetate then 100 % ethyl acetate) to 
furnish the title compound (2.9 g, 87 % based on diazo ester) as a pale yellow oil. 
5H (CDCI3; 300 MHz) 2.50 ( I H , s, br, OH), 1.50 (9H, s, C [CH3] 3), 3.56 - 3.68 
(16H, m, 8 X OCH2), 4.0 (2H, s, OCH2C-O). 
5c (CDCI3; 75 MHz) 170.0 (C=0), 73.5 (C-Mej), 72.0 - 70.7 (8 x CH2O), 69.0 
(CH2O), 61.9 (CH2OH), 28.0 (3 X Me). 
m/z (ES) 331 ( 100 %, M+ Na). HRMS (ES) C,4H2807Na requires 331.1835 
found 331.1725. 
Vmax (liquid film, cm"') 3398 (OH), 1750 (C=0). 
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5.3.9 t-Butyl 17-hydroxy-3,6,9,12,15-pentaoxaheptadecanoate 
(29) 
Using the method described for 27 above, a solution of ?-butyl a-diazoacetate 
(3.6 g, 0.95 g/cm^, 22.9 mmol) in dichloromethane (10 mL) was stirred with 
pentaethyleneglycol (5.0 g) and boron trifluoride etherate (2 drops, catalytic) in 
dichloromethane (10 mL) at room temperature to obtain the title compound (6.3 
g, 71 % based on diazo ester) as a pale yellow oil. 
5H (CDCI3; 400 MHz) 2.40 ( I H , s, br, OH), 1.50 (9H, s, C [CH3] 3), 3.67 - 3.78 
(20H, m, 10 x OCH2), 4.0 (2H, s, 0CH2C=0). 
5c (CDCI3; 100 MHz) 170.0 (C=0), 74.2 - 70.5 (10 x CH2O), 73.8 (C-Me), 69.0 
(CH2O), 61.9 (CH2OH) and 28.0 (3 x Me). 
m/z (+ES) 375 (80 %, M + Na) HRMS (+ES) Ci6H3208Na requires: 375.2097 
found 375.2009. 
Vmax(Hquid film, cm-') 3380 (OH) and 1748 (C=0). 
5.3.10 t-Butyl 11 -(2-bromo-2-methylpropionyloxy)-3,6,9-trioxa 
undecanoate (30) 
To a solution of /-butyl 1 l-hydroxy-3,6,9-trioxaundecanoate (1.75 g, 6.71 
mmol), triethylamine (0.81 mL, 8.05 mmol, 1.2 eqv.) and N , N -
dimethylaminopyridine (200 mg, catalytic) in dichloromethane (10 mL) 
previously stirred for 1 h at room temperature was added dropwise 2 bromo-2-
metiiylpropionyl bromide (0.99 mL, 8.05 mmol, 1.2 eqv.). Following the 
addition, the reaction was stirred for 8 h at 0 °C. The mixture was then washed 
with dilute HCl (2 x 20 mL), and extracted with dichloromethane (3 x 20 mL). 
The organic phase was washed with saturated aq. sodium bicarbonate (2 x 20 
mL) and brine (2 x 20 mL), and dried (Na2S04). Filtration and removal of the 
solvent under reduced pressure resulted in a crude product, which was purified 
by flash chromatography (20 % then 80 % ethyl acetate/hexane) to give the title 
compound (1.86 g, 94 %) as an oil. 
160 
Compounds from Chapter 3 
8H (CDCI3; 300 MHz) 1.47 (9H, s, C [CH3] 3), 1.95 (6H, s, C [CH3] 2 Br), 3.65 -
3.74 (lOH, m, 5 X OCH2), 4.08 (2H, s, 0CH2C=0), 4.28 (2H, m, CH2 
CH20C=0C [CH3]2Br) 
6c (CDCI3; 75 MHz) 170.0 (2 x C=0), 72.0 (C-Me), 70.9 - 70.7 (7 x CH2O), 69.0 
(2 x CH2O), 56.0 (C-Br) and 28.0 (2 x Me), 
m/z (+ES) 435 / 437 (100 %, M + Na) 
HRMS (+ES) C,6H29''^Br07Na requires 435.1097 found 435.0959. 
Ci6H29^'Br07Na requires 437.1097 found 437. 2372 
Vmax (liquid film, cm"') 1742 (C=0). 
5.3.11 t-Butyl 14-(2-bromo-2-methylpropionyloxy)-3, 6, 9,12-
tetraoxatetradecanoate. (31) 
Using the method described above for 30 , a solution of /-butyl 14-hydroxy-3, 6, 
9, 12-tetraoxatetradecanoate (2.90 g, 6.71 mmol) was reacted with 2-bromo-2-
methylpropionyl bromide (3.44 mL, 1.2 eqv.). Filtration and removal of the 
solvent under reduced pressure resulted in a crude product, which was purified 
by flash chromatography (20%, 80% then 100% ethyl acetate/ hexane) to give a 
colourless oily product (4.03 g, 94%). 
6H (CDCI3; 300 MHz) 1.47 (9H, s, C [CH3]3), 1.95 (6H, s, C [CH3]2Br), 3.62 -
3.78 (14H, m, 7 X OCH2), 4.05 (2H, s, 0CH2C=0), 4.38 (2H, m, CH2 
CH20C=0C [CH3]2Br) 
6c (CDCI3; 75 MHz) 171.9, 169.9 (2 x C=0), 72.8 (C-Me), 70.9 - 69.2 (9 x 
CH2O), 68.9 (2 X CH2O), 55.9 (C-Br) and 28.0 (2 x Me), 
m/z (ES) 479 / 481 (30 %, M + Na) 
HRMS (ES) C18H33 ^^BrOgNa requires 479.1359 found 479.1269 
CisHss^'BrOgNa requires 481.1339 found 481.1210 
Vmax (liquid film, cm"') 1750 (C=0). 
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5.3.12 t-Butyl 17-(2-bromo-2-methylpropionyloxy)-3, 6, 9,12, 
15-pentaoxaheptadecanoate (32) 
Using the method described above for 30, a solution of /-butyl 17-hydroxy-3, 6, 
9, 12, 15-pentaoxaheptadecanoate (1.5 g, 4.26 mmol) was reacted with 2- bromo-
2- methylpropionyl bromide (2.20 mL, 1.2 eqv.). Purified of the crude product by 
flash chromatography (50 % ethyl acetate/ hexane, 100 % ethyl acetate then 2% 
methanol/ethyl acetate) gave a colourless oily product (1.72 g, 80 % ) . 
5H (CDCI3; 300 MHz) 1.48 (9H, s, C [CH3] 3), 1.95 (6H, s, C [CH3] 2Br), 3.66 -
3.81 (18H, m, 9 X OCH2), 4.00 (2H, s, 0CH2C=0), 4.28 (2H, m, CH2 
CH20C=OC [CH3] 2 Br 0CH2C=0) 
5c (CDCI3; 75 MHz) 171.0, 169.0 (C=0), 73.9 (C-Me), 70.8 - 69.2 (11 x CH2O), 
68.9 (2 X CH2O), 55.0 (C-Br) and 28.0 (2 x Me), 
m/z (ES) 523 / 525 (100 %, M + Na) 
HRMS (ES) C20H37 '^Br09Na requires 523.1621 found 523.1516. 
C2oH37^'Br09Na requires 525.1620 found 525.1575. 
Vmax (liquid film, cm"*) 1736 (C=0). 
5.3.13 11 -(2-bromo-2-methylpropionyloxy)-3,6,9-trioxa 
undecanoic acid.(4) 
The solution of /-butyl 1 l-(2-bromo-2-methylpropionyloxy)-3,6,9-trioxa 
undecanoate (3.9 g) was added and stirred with a solution of 30 % TFA/ DCM 
(Analar grade; 15 mL), for 3 hours at room temperature, and upon completion 
(TLC, 40 % ethyl acetate/ hexane, Rf = 0.6 of ester), the reaction was diluted 
with water (1 mL) and stirred for 10 min. The mixture was dried (Na2S04) and 
concentrated under reduced pressure, and the resulting oil passed through a silica 
plug. The column was eluted with a gradient of 80 to 100 % ethyl acetate / 
hexane then 5 % methanol / ethyl acetate) and the eluents concentrated and dried 
over P2O5 in vacuo to yield the title compound (2.84 g, 95%) as a colourless oil. 
5H (CDCI3; 300 MHz) 1.95 (6H, s, C [CH3] 2Br), 3.65 - 3.80 (lOH, m, 5 x OCH2), 
4.18 (2H, s, 0CH2C=0), 4.29 (2H, m, OCH2CH20C=0 [CH3]2Br) 4.6 ( I H , br, 
COOH) 
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5.3.14 Succinimidyl 11-(2-bromo-2-methylpropionyloxy)-3,6,9-
trioxa undecanoate.(l) 
A solution of ll-(2-bromo-2-methylpropionyloxy)-3,6,9-trioxaundecanoic acid 
(2.4 g, 6.74 mmol) and EDCI (1.55 g, 8.09 mmol 1.2 eq.) in DCM (10 mL) was 
stirred for 1 hour at room temperature before the addition of a solution of N -
hydroxysuccinimide (0.95 g, 8.09 mmol, 1.2 eq.) and triethylamine (1.0 mL, 1.3 
mmol ) in DCM (10 mL). The mixture was stirred at room temperature for a 
further 16 hours. Upon completion of the reaction (TLC, 80 % ethyl acetate / 
hexane, Rf = 0.5), dilute HCl (3 x 25 mL) and water (2 x 25 mL) was used to 
wash the mixture, before the organic phase was dried with MgS04 and thy 
solvent removed in vacuo. Purification by column chromatography (40 % then 
80 % ethyl acetate / hexane then 5 % methanol / ethyl acetate) produced the title 
compound (1.9 g, 62%) as a colourless oil. 
5H (CDCI3; 300 MHz) 1.91 (6H, s, C [CH3] 2Br), 2.82 (4H, br, s, CH2-CH2) 3.62 
- 3.79 (lOH, m, 5 x OCH2), 4.16 (2H, s, 0CH2C=0), 4.29 (2H, m, OCH2 
CH20C=0 [CH3]2Br) 
5c (CDCI3; 100 MHz) 172.0 - 166.0 (4 x C=0), 72.0 -, 67.0 (7 x CH2O), 56.0 (C-
Br), 31.0 (2 X Me) and 26.0 (2 x CH2). 
m/z (ES) 476 / 478 (100 %, M + Na) 
HRMS (ES) C,6H24^^BrN09Na requires 476.0634found 476.0493 
Ci6H24^'BrN09Na requires 478.0614 found 478.0553 
Vmax (liquid film, cm'') 1790 (C=0), 1738 (C=0). 
5.3.15 Succinimidyl 14-(2-bromo-2-methylpropionyloxy)-3, 6, 9, 
12-tetraoxatetradecanoate. (2) 
Using the method described for 1 above, a solution of /-butyl 14-(2-bromo-2-
methylpropionyloxy)-3,6 9,12-tetraoxa-tetradecanoate. (1.5 g, 4.26 mmol) was 
stirred with N-hydroxysuccinimide. (0.5 g, 1.2 eq) to give the title compound 
(1.72 g, 80%) as an oil. 
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6H (CDCI3; 500 MHz) 1.94 (6H, s, C [CH3] 2Br), 2.92 (4H, br, s, CH2-CH2) 3.65 
- 3.79 (14H, m, 7 X OCH2), 4.18 (2H, s, 0CH2C=0), 4.38 (2H, m, CH2 
Ci^OC=OC [CH3]2Br). 
6c (CDCI3; 125 MHz) 172.0 - 166.0 (4 x C=0), 72.0, - 67.0 (9 x CH2O), 56.0 (C-
Br), 31.0 (2 X Me) and 26.0 (2 x CH2). 
m/z(ES) 520/522 (100%,M + Na) 
HRMS (ES) Ci8H28'^BrNOioNa requires: 520.0897 found 520.0840. 
Ci8H28*'BrNOioNa requires: 522.0876 found 522.0817. 
Vmax (liquid film, cm"') 1787 (C=0), 1744(C=0) 
5.3.16 Succinimidyl 17-(2-bromo-2-methylpropionyloxy)-
3,6,9,12,15-pentaoxaheptadecanoate.(3) 
A solution of r-butyl 14-(2-bromo-2-methylpropionyloxy)-3,6,9 12,15-pentaoxa-
heptadecanoate (3.2 g, 7.64 mmol) was stirred with N-hydroxysuccinimide (1.0 
g, 1.2 eq) according to the method described for 1 above to give the title 
compound (3.2 g, 75 %) as a colourless oil. 
6H (CDCI3; 500 MHz) 1.95 (6H, s, C [CH3] 2Br), 2.82 (4H, br, s, CH2-CH2) 3.62 
- 3.79 (18H, m, 9 X OCH2), 4.16 (2H, s, 0CH2C=0), 4.28 (2H, m, CH2 
CHaOC^OC [CH3]2Br) 
6c (CDCI3; 125 MHz) 172.0 - 166.0 (C=0), 72.0 - 67.0 (11 x CH2O), 56.0 (C-
Br), 31.0 (2 X Me) and 26.0 (2 x CH2). 
m/z (ES) 564 / 566 (50 %, M + Na). 
HRMS (ES) C2oH32 ' 'BrNOiiNa requires: 564.1159 found 564.1033. 
C2oH32^'BrNOiiNa requires: 566.1138 found 566.0961. 
Vmax (liquid film, cm"') 1785 (C=0), 1739 (C=0). 
5.3.17 Benzyl (11(-2-methyl-propionyloxy))-3,6,9-
trioxaundecanoate (47) 
A solution of benzyl 1 l-hydroxy-3,6,9-trioxaundecanoate (80 mg, 0.268 mmol) 
in dichloromethane (5 mL) was stirred with N , N-dimethylaminopyridine (103 
mg, 0.539 mmol, 2 eqv) and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
(EDCI) (103 mg, 0.539 mmol, 2 eqv) for 0.5 h at room temperature. A mixture of 
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isobutyric acid (47 mg, 0.539 mmol, 2 eqv) and N , N-diisopropylethylamine (70 
mg, 0.539 mmol, 2 eqv) in dichloromethane (3 mL) was then added and the 
mixture stirred overnight under a nitrogen atmosphere. The reaction was then 
washed with dil.HCl (3 x 30 mL), water (2 x 25 mL) and the organic phase dried 
(MgS04.) The organic phase was then concentrated under reduced pressure, and 
the crude product purified by silica gel column chromatography (40 % ethyl 
acetate / hexane) to obtain the product (88 mg, 89 %) as a colourless oil 
5H (CDCI3; 500 MHz) 1.15 (6H, d, [CH3]2), 2.60 ( I H , m, CCCHsJaH ), 3.60-3.80 
(lOH, m, 5 x OCH2), 4.20 (4H, m, BnOCOCHj and CH2OCOCH (CH3)), 5.19 
(2H, s, CHzPh), 7.38 (5H, m, Ph) 
5c (CDCI3; 100 MHz) 177.0, 170.0 (C=0), 135.0 (Ph-C), 127.0 - 128.0 (5 x CH), 
71.0 - 72.0 (6 x OCH2), 68.0, 66.0 (OCH2), 34.0 (CH), 19.0 (2 x Me). 
m/z (+ES) 391 (100 %, M+Na^) m/z (CI+) 369 (10 %, M+H^); 386 (20 %, M + 
NH3"). 
HRMS (+ES) C,9H2807Na requires 391.1835 found 391.1749. 
Vn,ax (liquid f i lm, cm^') 1732 (C=0), 1733 (C=0). 
5.3.18 11 (2-methy(propionyloxy)-3,6,9-trioxaundecanoic acid 
(48) 
A suspension of 10 % palladium on charcoal (catalytic) was stirred at room 
temperature with a solution of benzyl (ll(-2-methylpropionyloxy))-3,6,9-
trioxaundecanoate (60 mg, 0.163 mmol) in dry methanol (1 mL), previously 
purged and refilled with hydrogen gas. The reaction completion as determined by 
TLC (100 % ethyl acetate, Rf new = 0.3, KMn04) after 7 h before proceeding to 
diluting the mixture with methanol (5 mL) and filtered through a celite plug, 
dried (MgS04.) and the filtrate concentrated in vacuo to yield the title compound 
(44 mg, 97 %) as an oil. This was used without fiirther purification. 
6H (CDCI3; 400 MHz) 1.15 (6H, d, [CH3]2), 2.60 ( I H , m, C[CH3]2H ), 3.0 - 3.70 
(lOH, m, 5 X OCH2), 4.15 (2H, s, BnO(CO)CH2 ) 4.20 (2H, s, br, 
CH20(CO)C(CH3) H). 
5c (CDCI3; 100 MHz) 177, 170 (C=0), 72.6 - 72.0 ( 6 x OCH2), 68, 63 (OCH2), 
""34 (CH), 19(Me). 
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m/z (-ES) 277 (100 %, M - H). 
Vmax (liquid film, cm'') 3208 (COOH, br), 2876, 1735 (C=0). 
5.3.19 Ethyl(2-methyl-2-thioethyl)propionate (42) 
A solution of sodium ethoxide (1.06 M, 1.2 eqv), prepared by dissolving sodium 
(1.1 g) in dry ethanol (45 mL), was stirred with ethanethiol (5.68 mL, 2 eqv) and 
ethyl (2-bromo-2-methyl) propionate (7.0 g, 36 mmol) at 65 °C for 1.5 h. The 
white precipitate formed was removed by filtration, and the mother liquor 
concentrated to approximately 15 mL in vacuo. Distillation (50 °C at 7 atm) of 
the resulting mixture furnished the title compound (1.96g, 31 %) as a colourless 
oil. 
6H (CDCb; 400 MHz) 1.32 (3H, m, SCH2CH3), 1.45 (3H, m, OCH2CH3), 1-67 
(6H, s, (CH3) 2), 2.78 (2H, m, SCH2), 4.3 (2H, m, OCH2) 
6c (CDCI3; 100 MHz) 174.29 (C=0), 61.11 (OCH2), 46.91 (C-S), 25.72 (2 x 
Me), 23.71 (SCH2), 14.16 (SCH2CH3), 14.12 (OCH2CH3). 
m/z (+ES) 199 (10 %, M + Na) and 469 (100 %) 
Vmax (liquid film, cm'') 1728 (C=0) 
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5.4 Compounds from Chapter 4 
5.4.1 8-(Tetrahydropyranyl-2-oxy)-3,6-dioxaoctanol (19) 
Dihydropyran (19 mL, 18 g, 0.21 mol) was added dropwise into a vigorously 
stirred mixture of /?-toluenesulphonic acid monohydrate (catalytic, 40 mol%) and 
triethyleneglycol (100 mL, 115 g, 0.76 mol) at 70 °C over 2 h under nitrogen. 
The pale brown reaction mixture was then allowed to cool to room temperature, 
diluted with brine (100 mL) and extracted with hexane (2 x 200 mL) and DCM 
(2 X 200 mL) successfully. The DCM extracts were further washed with brine (2 
X 100 mL) and dried with Na2S04 before concentration under reduced pressure. 
Silica gel flash chromatography, using a gradient elution (50 % to 100 % ethyl 
acetate/hexane) gave the pure title compound (35 g, 69%) as a pale brown oil. 
5H (CDCI3; 400 MHz) 1.40 - 1.80 (6H, m, THP), 3.40 - 3.70 (12H, m, 6 x 
CH2O), 3.80 (2H, m, CH2OH), 4.58 ( IH, t, J=3.2 Hz, CH, cyclic). 
6c (CDCI3; 100 MHz) 99.0 (OCH, cyclic), 73.0, 72.0, 71.6, 71.0, 67.0 (CH2O), 
62.0 (CH2O, cycHc), 61.3 (CH2OH), 30.0, 25.0, 19.0 (CH2, cyclic), 
m/z (+ES) 257 (100%, M + Na) 
Vn,ax(liquid film, cm'') 3446 (OH), 2939 (CH2, str)., 2869 (CH2, str). 
5.4.2 11-(Tetrahydropyranyl-2-oxy)-3,6,9-trioxaundecanoi (20) 
Dihydropyran (8.0 g, 95.2 mmol) and tetraethyleneglycol (60 mL) were reacted 
following the method described for 8-(tetrahydropyranyl-2-oxy)-3,6-
dioxaoctanol. The crude product was purified by flash chromatography (gradient 
eluent, 50 % to 100% ethyl acetate/hexane) to yield the title compound (18 g, 64 
%) as pale brovra oil 
5H (CDCI3; 500 MHz) 1.40 - 1.80 (6H, m, THP), 3.40 - 3.70 (16H, m, 8 x 
CH2O), 3.90 (2H, m, HO-CH2), 4.58 ( I H , t, J = 3.2 Hz, CH-0 cyclic-). 
5c (CDCI3; 125 MHz) 99.0 (CH-0, cyclic), 72.8 (CH2O) , 72.0 (overlapping 
signals), 71.6 (CH2O), 71.0 (CH2O), 67.0 (CH2O), 62.0 (CH2O, cyclic), 61.3 
(CH2OH), 31.0 (CH2, cyclic), 25.5 (CH2, cyclic), 20.0(CH2, cyclic). 
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m/z(ES) 301 ( 8 0 % , M + Na) and 217(100%) 
Vmax (liquid f i lm, cm-') 3488 (OH), 2941 (CH/CH2, str), 2870 (CH/CH2, str). 
5.4.3 14-(Tetrahydropyranyl-2-oxy)-3,6,9,12-
tetraoxatetradecanol (21) 
Dihydropyran (2.1 g, 25 mmol) was added dropwise with vigorous stirring to a 
mixture of /?-toluenesulphonic acid monohydrate (40 moI%, catalytic) and 
triethyleneglycol (5.0 g, 4.3 mL; previously dried by azeotropic distillation) and 
over phosphorus pentoxide under reduced pressure. The reaction was then heated 
to 60 °C and gently stirred for 2 h under nitrogen. The resulting dark brown 
reaction mixture was then allowed to cool to room temperature and subsequently 
diluted with brine (25 mL), extracted with hexane (2 x 25 mL) and DCM (2 x 25 
mL) respectively. The DCM extracts were further washed with brine (2 x 25 
mL), dried the organic extracts with Na2S04 and concentrated imder reduced 
pressure. Purification by flash chromatography (gradient eluent, 50 % to 100% 
ethyl acetate/hexane; and a final wash with 10 % methanol/ethyl acetate) gave 
the title compound (4.2 g, 52 %) as a pale brown oil. 
6H (CDCI3; 200 MHz) 1.40 - 1.90 (6H, m, THP), 3.40 - 3.80 (20H, m, 10 x 
CH2O), 3.80 - 3.90 (2H, m, HO-CH2), 4.62 ( I H , t, J= 3.2 Hz, CH-0 cyclic). 
5c (CDCI3; 75 MHz) 99.0 (CH, cyclic), 72.8, 72.0, 71.6, 71.0 (overiapping 
signals), 65(CH20), 62.0 (CH2O, cyclic), 61.3 (CH2OH), 30.0, 25.0, 19.0(CH2, 
cyclic). 
m/z (+ES) 345 (100%, M + Na) HRMS (+ES) dsHsoOyNa requires 345.1992, 
found 345.1889 
Vmax(Iiquidfilm,cm-') 3446 (OH), 2939 (CH/CH2, str), 2869 (CH/CH2, str). 
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General Procedure for preparation of methanesulphonates 
5.4.4 8-(Tetrahydropyranyl-2-oxy)-3,6-methanesulphonate (16) 
Methanesulphonyl chloride (0.75 g, 6.50 mmol, 1.5 eq.) was added in a dropwise 
manner to a stirred mixture of 8-(tetrahydropyrany]-2-oxy)-3,6-dioxaoctanol 19 
(1.0 g, 4.27 mmol), triethylamine (2 mL), and N , N-dimethylaminopyridine (5 
mg, catalyst) in dichloromethane (10 mL) at 0 °C. The resulting clear solution 
was stirred at 0 °C for 5 h under a nitrogen atmosphere, and at room temperature 
for a further 18 h during which a brown solution containing white solids was 
observed. The reaction was diluted with dichloromethane (25 mL), and washed 
with dilute HCl (2 x 25 mL) and water (2 x 25 mL) respectively. The organic 
phase was further dried with magnesium sulphate, concentrated in vacuo and 
purified by flash chromatography [50% to 100% ethyl acetate/hexane] to yield 
the title compound (1.2 g, 89 %) as a pale brown oil. 
5H (CDCI3; 400 MHz) 1.38 - 1.78 (6H, m, THP), 3.0 (3H, s, OMs), 3.40 - 3.90 
(12H, m, 6 X CH2O), 4.21 (2 H, m, CH2O), 4.50 ( I H , t, J = 3.2 Hz, CH-0 cyclic). 
5c (CDCI3; 100 MHz) 99.0 (CH, cyclic), 72.8, 72.0, 71.6, 71.0, 67.0, 63.0 
(CH2O), 62.0 (CH2O, cyclic), 38.0 (S03Me), 31.0,25.5,20.0(CH2, cyclic). 
m/z(+ES) 335 (100%, M + Na). 
HRMS (+ES) Ci2H2407SNa requires 335.1243 found 335.1151. 
5.4.5 11 -(Tetrahydropyranyl-2-oxy)-3,6,9-trioxaundecanyl 
methanesulphonate (17) 
Using method described above for 16, a solution of 1 l-(tetrahydropyranyl-2-
oxy)-3,6,9-trioxaundecanol 20 (13.0 g, 46.8 mmol) and methanesulphonyl 
chloride (11.8 mL, 8 g, 70 mmol) were reacted to yield the title compound (12.8 
g, 77 %)as an oil after chromatography with (50 % to 100 % ethyl acetate/ 
hexane) gradient elution. 
6H (CDCI3; 400 MHz) 1.40 - 1.80 (6H, m, THP), 3.06 (3H, s, OMs), 3.40 - 3.90 
(16H, m, 8 X CH2O), 4.32 (2 H, m, CH2O), 4.46 ( I H , t, J = 3.2 Hz, CH-0). 
6c (CDCI3; 100 MHz) 99.0 (CH, cyclic) 70.0, 70.1, 69.0, 68.0, 68.4, 67.0 (CH2O, 
overlapping), 62.0 (CH2O, cyclic), 38.0 (SOaMe), 31.0,25.0,19.0 (CH2, cyclic) 
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m/z (ES) 379 (M + Na). HRMS (ES) C,4H2808SNa requires 379.1505 found 
379.1414. 
Vmax (liquid film, cm"') 2938 (CH2, str), 2869 ( CH2, str), 1354 (S=0, asym-str), 
1178 (S=0, sym-str). 
5.4.6 14-(Tetrahydropy ranyl-2-oxy)-3,6,9,12-
tetraoxatetradecanyl methanesulphonate (18) 
Using method described above for 16, a solution 14-(tetrahydropyranyl-2-oxy)-
3,6,9,12-tetraoxatetradecanol 21 (3.7 g, 11.5 mmol) and methanesulphonyl 
chloride (2.0 g, 2.9 mL, 17.3 mmol) were reacted to yield the title compound (3.1 
g, 67 %) as an oil. 
5H (CDCI3; 400 MHz) 1.40 - 1.80 (6H, m, THP), 3.10 (3H, s, OMs), 3.40 - 3.90 
(20H, m, 10 X CH2O), 4.40 (2 H, m, CH2O), 4.60 ( I H , t, J = 3.2 Hz, CH-0). 
5c (CDCI3; 100 MHz) 99.0 (CH, cyclic) 70.0, 70.1, 69.0, 69.2, 68.0, 68.4, 67.0 
(CH2O, overlapping), 62.0 (CH2O, cyclic), 38.0 (S03Me), 31.0, 25.0, 19.0 (CH2, 
cyclic). 
m/z(ES) 423 (100%,M + Na). 
Vmax (liquid film, cm'') 2938 (CH2, str), 2869 (CH2, str), 1354 (S=0, asym-str), 
1178 (S=0, sym-str). 
5.4.7 N,N-Domethyl-8-(tetrahydropyranyl-2-oxy)-3,6-
dioxaoctanylamine (10) 
Dimethylamine (40% in water, 10 mL) was added slowly to a solution of 8-
(tetrahydropyranyl-2-oxy)-3,6-dioxaoctanyl methanesulphonate 16 (2.0 g, 6.4 
mmol) in DCM (5 mL) at 0 °C. After the addition, the resulting exothermic 
mixture was then stirred for a further 4 h at room temperature. The reaction was 
then diluted with saturated NaHCOs solution (20 mL), extracted with 
dichloromethane (3 x 25 mL) and the organic phase was washed with saturated 
sodium carbonate solution (2 x 25 mL) before being dried using magnesium 
sulphate and concentrated in vacuo. Purification by flash chromatography ([7: 3] 
ethyr acetate/ hexane) and subsequent flushing of the column with a methanol/ 
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ethyl acetate gradient (maximum 5% methanol/ ethyl acetate) yielded the title 
compound (1.0 g, 60%) as pale brown oil. 
5H (CDCb; 400 MHz) 1.20 - 1.80 (6H, m, THP), 2.26 (6H, s, NMe2), 2.50 (2H, 
t, J = 5.7 Hz, CH2N), 3.20 - 3.70 (lOH, m, 5 x CH2O), 3.90 (2H, m, cyclic 
OCH2), 4.60 ( I H , m, J = 3.1 Hz, CH-0). 
8c (CDCI3; 100 MHz) 99.18 (CH, cyclic), 70.83, 70.77, 70.60, 69.40, (CH2O, 
overlapping), 62.50 (CH2O, cyclic), 58.90 (CH2N), 46.00 (NMe2), 30.80, 25.70 
and 19.70 (CH2, cyclic). 
m/z(+ES) 284 (M + Na, 90%), HRMS (+ES) C13H28NO4 requires 262.1940 
found 262.2034 
IR (liquid film, cm"') 2941, 2868, 2770 (CH2, str) and 1454. 
5.4.8 N,N-Dimethyl-11 -(tetrahydropyranyl-2-oxy)-3,6,9-
trioxaundecanyl amine (11) 
Using the method employed for N, A^-dimethyl-8-(tetrahydropyranyl-2-oxy)-3,6-
dioxaoctanylamine, the solution of 1 l-(tetrahydropyranyl-2-oxy)-3,6,9-
trioxaundecanyl methanesulphonate (6 g, 17 mmol) was treated with 
dimethylamine (25 mL) to yield the title compound (2.3g, 45 %) as a pale brown 
oil. 
5H (CDCI3; 400 MHz) 1.40 - 1.90 (6H, m, THP), 2.27 (6H, s, NMe2), 2.50 (2H, 
t, J = 5.7 Hz, CH2N), 3.40- 3.80 (14H, m, 7 x CH2O), 3.90 (2H, m, cyclic 
OCH2), 4.60 ( I H , m, J = 3.2 Hz, CH-0). 
8c (CDCI3; 100 MHz) 100.0 (CH, cyclic), 72.0, 71.2, 71.0, 69.0 (CH2O, 
overlapping), 62.0 (CH2O, cyclic), 59.0 (CHjN), 46.0 (NMe2), 30.0, 25.0, 19.0 
(CH2, cyclic). 
m/z (+ES) 306 ( M + H^); HRMS (+ES) C13H32NO5 requires 306.2202 found 
306.2297 
IR (liquid film, cm''). 2948, 2872, 2772 (CH2, str) and 1456. 
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5.4.9 N,N-Dimethyl-14-(tetrahydropyranyl-2-oxy)-3,6,9,12-
tetraoxatetradecanylamine.(12) 
Using the method employed for A/, A'^-dimethyl-8-(tetrahydropyranyl-2-oxy) 
-3,6-dioxaoctanylamine, a solution 14-(tetrahydropyranyl-2-oxy)-3,6,9,12-
tetraoxatetradecanyl methanesulphonate (2.1 g, 5 mmol) was treated with 
dimethylamine (12 mL) to yield the title compound (1.3 g, 71 %) as an oil. 
5H (CDCI3; 500 MHz) 1.40 - 1.90 (6H, m, THP), 2.30 (6H, s, NMe2), 2.50 (2H, 
t, J 5.7 Hz, CH2N), 3.35- 3.90 (18H, m, 9 x CH2O), 3.90 (2H, m, cyclic OCH2), 
4.60 ( I H , m, J = 3.2 Hz, CH-0). 
5c (CDCI3; 125 MHz) 99 .0 (CH, cyclic), 72.0, 71.2, 71.0, 69.0 (CH2O, 
overlapping), 63.0(CH2O, cyclic), 59.0(CH2N), 46.0 (NMe2), 31.0, 26.0, 19.0 
(CH2, cyclic) 
m/z(+ES)350 (M+H^") 
IR (liquid film, cm"') 2940, 2868, 2769 (CH2, str) and 1454. 
5.4.10 1-(N,N-dimethylamino)-3,6-dioxa-octan-8-ol (7) 
A mixture of AcOH/water (5 mL, 1:1, v/v) was introduced dropwise into a 
solution of iV,A'-dimethyl-8-(tetrahydropyranyI-2-oxy)-3,6-dioxaoctanylamine 
(0.5 g, 2 mmol) in absolute ethanol (1 mL) and the solution stirred for 4 h at 50 
"C. The reaction was allowed to cool to room temperature before being 
concentrated in vacuo. The product was treated azeotropically with toluene 
before passing through a plug of neutral alumina. The plug was washed 
successively with ethyl acetate (50 mL) and 2 % methanol/ethyl acetate (2 x 20 
mL). The methanolic ethyl acetate wash was then concentrated under reduced 
pressure and the resulting oil further dried in vacuo over phosphorus pentoxide to 
yield the title product (0.23 g, 66%) as colourless oil, which turned brown on 
standing. 
No fiirther purification was attempted. 
5H (MeOD; 300 MHz) 2.81 (6H, s, NMe2), 3.42 (2H, t, J= 5.6 Hz, CH2NMe2), 
3.2 (8H, m, 4 X OCH2), 3.81 (2H, m, CH2OH). 
5C (MeOD; 100 MHz) 71 (OCH2), 66 (CH2OH), 58 (CH2N), 44 (NMe2) 
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mix (+ES) 178 (100%, M + H) HRMS (+ES) C8H20NO3 requires 178.1365 
found 177.9423. 
Vmax (liquid film, cm'') 3409 (OH), 2507, 2243, 2027(CH2) and 1119(C-0). 
5.4.11 1 -(N,N-dimethylamino)-3,6,9-trioxa-undeca-11 -ol.(8) 
Using the method employed for l-(/V,A^-dimethylamino)-3,6-dioxa-octan-8-ol, 
N,N-dimethyl-l l-(tetrahydropyranyl-2-oxy)-3,6,9-trioxaundecanylamine (0.1 g, 
0.33 mmol) was treated with AcOH/ Water (2 mL, 1:1, v/v) to yield the product 
as a pale brown oil (0.7 g, 94 % ) . 
6H (CDCI3; 500 MHz) 2.41 ( IH , s, OH), 2.92 (6H, s, NMe2), 3.21 (2H, t, J = 5.7 
Hz, CH2NMe2) 3.55-3.72 (12H, m, 6 x OCH2), 3.89 (2H, m, CH2OH). 
6c (CDCI3; 125 MHz) 73.0, 71.5, 71.2, 70.0 (CH2O), 66.0 (CH2OH), 58.0 
(CH2N), 44.0 (NMe2). 
m/z (+ES) 222 (100%, M + 1), 224 (50 %, M + Na) 
Vmax (liquid film, cm"') 3376 (OH), 2872,2693,2473 (CH2), and 1118 (C-0). 
5.4.12 1-(N,N-dimethylamino)-3,6,9,12-tetraoxa-tetradeca-14-
ol.(9) 
Using the method employed for l-(N,N-dimethylamino)-3,6-dioxa-octan-8-ol, 
N,N-dimethyl-14-(tetrahydropyranyl-2-oxy)-3,6,9,12-tetraoxatetradecanylamine 
(100 mg, 0.29 mmol) was treated with AcOH/ Water (2 mL, 1:1, v/v) to yield 
the title product (70 mg, 92 %)as a brown oil. 
6H (CDCI3; 400 MHz) 2.40 ( I H , Br, s, OH), 2.82 (6H, s, NMe2), 3.30 (2H, t, J = 
5.7 Hz, CH2NMe2) 3.61 - 3.80 (16H, m, 8 x OCH2), 3.90 (2H, m, CH2OH). 
5c (CDCI3; 100 MHz) 72.7, 72.8, 70.5, 70.5, 70.3, 70.1(CH2O), 65.6 (CH2OH), 
56.0 (CH2N), 43.0 (NMe2). 
m/z(+ES) 266 (100%, M + H) HRMS (+ES) C,2H28N05 requires 266.1889 
found 266.1982 
Vn,ax(liquid film, cm-1) 3406 (OH), 2878, 1472 (CH2) and 1113 (C-0). 
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5.4.13 N-(2-bromoethyl)maleimide (28) 
To a stirred solution of sodium bicarbonate (2.6 g, 31 mmol) in water (30 mL) 
was added 2-bromoethylamine (6.3 g, 31 mmol). As the latter compound 
dissolved, some effervescence was observed. Freshly crushed maleic anhydride 
(3.0 g, 31 mmol) was added slowly with stirring to the clear solution. After an 
increase in the amount of effervescence, it completely dissolved and a white 
precipitate was formed. After stirring for 2 h, the precipitate that had formed was 
removed by filtration and dried over phosphorus pentoxide under reduced 
pressure to obtain the amido-acrylic acid intermediate (5.27 g, 77 %) as a white 
solid without further purification. 
A suspension of sodium acetate (0.69 g) in acetic anhydride (17 mL) and 
was heated to 80 °C for 10 min using an oil bath before 3-(A'^-2-bromoethyl 
carbamoyl) acrylic acid (3 g) was slowly added. The reaction mixture was 
further heated with vigorous stirring at 85 °C for 10 min, after which the mixture 
was poured into a ice-cold water (20 mL) and extracted with chloroform (2x15 
mL). The organic extract was washed with water and dried (MgS04) before 
being concentrated and recrystallised from cyclohexane to yield the product (220 
mg, 14 %) as a white powder/ solid. 
5H (CDCI3; 300 MHz) 3.54 (2H, t, J = 6.71 Hz, CHjBr), 3.96 (2H, t, J = 6.71 Hz, 
CH2N), 6.76 (2H, s, CH=CH) 
6c (CDCI3; 100 MHz) 169.00 (C = O), 134.24 (CH2= CH2), 39.16 (CH2N) and 
28.18 (CH2Br); 
m/z (ES) 227 (40 %, M + Na). M.P 60 - 61 °C 
Vmax (liquid film, cm"') 1770 (C=0), 1710 (C=C, str) and 1406 (C-H, bend). 
Literature. (Chapter 4, Ref 14, pi24) 
5H (CDCI3) 3.53 (2H, t,), 3.95 (2H, t,), 6.75 (2H, s, CH=CH) 
6c (CDCI3) 170.09, 134.22, 39.14 and 28.17. 
Lit (2) 59 - 62 °C. 
v m a x ( , cm-') 3090 (w),1770 (m), 1700 (m), 1580 (m). 
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5.4.14 N= (2-Hydroxyethyl)maleimide (29) 
Solutions of ethanolamine (20.0 g, 0.32 mmol) in acetone (100 mL) and maleic 
anhydride in acetone (100 mL) both at room temperature, were added 
simultaneously using a dropping fimnel over a period of 2 h into a flask charged 
with acetone (200 mL) at 0 °C with vigorous stirring. The reaction was stirred for 
a further 90 min, the volume reduced by half and cooled to 4°C. The precipitate 
formed was washed with chilled acetone and dried under reduced pressure to 
yield the hydroxy maleimic acid intermediate (40.0 g, M.P 99 °C, Lit (1) 98 °C) 
as a white solid. 
10 g (63 mmol) of the maleimic acid was allowed to dissolved in a warm mixture 
of toluene (400 mL) and triethylamine (17.42 mL, 126 mmol) with stirring. The 
flask was then equipped with a Dean Stark condenser, and heating continued for 
2 h. The reaction was then allowed to cool before the toluene phase was decanted 
from the residue and the residue was further extracted with hot toluene (4 x 30 
mL). A l l toluene extracts were combined and concentrated, leaving another 
yellow residue. This residue was extracted with hot ether (3 x 50 mL). The 
extracts were concentrated under reduced pressure and after chromatography (3:1 
ethyl acetate / hexane), the compound (Rf = 0.35, 1.2 g, 14%) was obtain as a 
yellow syrup. 
8H (CDCI3; 300 MHz) 3.73 (2H, t, J = 15 Hz, CH2N), 3.79 (2H, t, J = 17 Hz, 
CH2OH), 6.76 (2H, s, CH=CH) 
8c (CDCI3; 100 MHz) 171 (C=0), 135 (C=C), 61.5 (CH2OH) and 41.8 (CH2N) 
m/z (ES) 115 (10 % ) , 215 (100 %) and 158 (10 %, M + NH4) 
Vmax(liquid film, cm'') 3464 (OH) and 1711(C=0). 
Literature. (Chapter 
4,Ref. 16, p i 26) 
8H (DMS0-d6; 300 MHz) 3.47 (m, 4H, 2 x CH2), 4.07 (br s, I H , OH), 7.01 (2H, 
-s, CH=CH), 8c (CDCI3; 100 MHz) 171 (C=0), 134 (C=C), 57 (CH2OH) and 39 
(CH2N), Ms (EI) 111 (100 %) and 114 (2 %) 
175 
Compounds from Chapter 4 
5.4.15 N- (2-trifluoromethanesulphonyloxy)ethyl 
maleimide.(30) 
To a solution of N-(2-hydroxy) ethylmaleimide (700 mg, 15.0 mmol) and N, N-
dimethylamino pyridine (100 mg, cat.) in dichloromethane (10 mL) at 0 °C, was 
added trifluoromethane- sulphonyl chloride (1.60 mL, 7 eq) and the solution 
allowed to stir for 2 h at 0 °C. The pale yellow solution was allowed to warm to 
room temperature and stirred for a further 8 h. Upon completion of the reaction, 
(TLC, 50 % ethyl acetate / hexane, Rfhew 0.8, KMn04) the reaction was 
concentrated under reduced pressure, diluted with dichloromethane (20 mL), 
washed with water (2 x 20 mL), dil HCl (2 x 20 mL), water (20 mL) and dried 
(MgS04) before being concentrated under reduced pressure. After column 
chromatography (25 % ethyl acetate / hexane) the title product (0.476 g, 63 %) 
was obtained as a white (fluffy) solid. 
5H (CDCI3; 300 MHz) 3.69 (2H, t, J = 6.3 Hz, NCH2), 3.89 (2H, t, J = 6.4 Hz, 
OCH2) and 6.75 (2H, s, CH2=CH2) 
5c (CDCI3; 125 MHz) 170 (C=0), 134 (CH2=CH2), 41 (CH2O) and 39 (CHjN). 
m/z (ES) 274 (M + H) (EI) 293 (25 %) 
Vmax(liquid film, cm'') 1709 (C=0). 
5.4.16 3-(2-Dimethylamino-ethylcarbamoyl)acrylic acid (32) 
To a solution of maleic anhydride (5g, 51 mmol) in dry THF (100 mL) at 0 °C, 
was added A'.A^-dimethylethylamine (5.48 mL, 52 mmol) in THF (100 mL) over 
a period of 2 h. The reaction was stirred for a fiirther 2 h at 0 ° C, the white solids 
removed by filtration and the organic solvent partially reduced in vacuo to induce 
fiirther precipitation by titurating. The combined white solid was washed with 
ice-cold THF and dried under reduced pressure. The product (9.4 g, 99 %) was 
obtained as a white solid, which was used without further purification. 
5H (D2O; 200 MHz) 2.81 (6H, s, N (CH3)2), 3.22 (2H, t, J= 6.6 Hz, NCH2CH2N 
(CH3)2), 3.52 (2H, t, JxA = 5.4 Hz, NCH2CH2N (CH3)2), 5.97 ( I H , d, JAX , = 12 
Hz, =CH (CO) NH), 6.16 ( I H , d, JXA , = 12 HZ, =CHC02H) 
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m/z (ES) 187 (30 %, M + H) and 169 (100 %, M - H2O) 
C: H: N: C8H14N2O3: Requires C 51.05, H 7.58, N 14.88. Found C 51.04, H 
7.47, N 14.67. 
5.4.17 N^-(N,N-djmethylamino)ethyl maleimide.(33) 
The amido-acid (9g, 48.3 mmol) was suspended in THF (50 mL) with 
triethylamine (7.8 mL, 1.2 eqv., 53 mmol) and refluxed for 30 min before 
trimethylsilyl chloride (7.3 mL, 1.2 eqv, 6.3 g, 58 mmol) was added in portions 
and the solution was allowed to reflux for 5 h under a nitrogen atmosphere. After 
cooling to room temperature, the solids were filtered o f f and the mother liquor 
was concentrated (solidifies on standing). The solid was dissolved in 
dichloromethane (10 mL) and washed with cold water (2 x 20 mL) and the 
aqueous wash was further extracted with hexane (20 mL). The organic extracts 
were combined and concentrated in vacuo to yield the product (2.3 g, 80 %) as a 
orange oil which solidified on standing. 
The solid was always re-extracted with dichloromethane before use to reduce 
hydrolysis by-product. 
5H (CDCI3; 500 MHz) 2.25 (6H, s, N (CH3) 2), 2.49 (2H, t, JAX = 6.6 Hz, 
NCH2CH2_N (CH3) 2), 3.64 (2H, t, JXA = 6.63 Hz, NCH2CH2_N (CH3) 2), 6.69 
(2H, s, CH=CH) 
6c (CDCI3; 125 MHz) 171 (C=0), 134.4 (2 x =CH), 57 (NCH2CH2 N (CH3) 2), 
46 (NCH2CH2_N (CH3)2), 37 (NCH2CH2 N (CH3)2) 
m/z(ES) 169(100%,M +1) 
Vmax (liquid film, cm'') 1720 and 1414. 
5.4.18 Tetraethyleneglycol monomesylate (35) 
A solution of methanesulphonyl chloride (8 g, 70 mmol) in dichloromethane (20 
mL) at 0 °C was stringed over a period of 0,5 h into a solution of tetraethylene 
glycol (10 g, 77 mmol), TEA (9.6 mL, 70 mmol) and DMAP (0.8 g, catalytic) 
uiider nitrogen atmosphere in dry dichloromethane (20 mL) at 0 °C. The mixture 
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was then stirred at 0 °C for an additional 18 hours under a nitrogen atmosphere. 
The reaction mixture was then washed with water (2 x 50 mL), brine (2 x 50 mL) 
and dried (MgS04) to give the crude. The crude compound was then column 
chromatographed on silica gel to give the title compound as a pale brown syrup 
(11.6g, 60%). 
6H (CDCI3; 300 MHz) 3.08 (3H, s, OMs), 3.59 - 3.80 (12H, m, 6 x CH2O), 4.20 
(4 H, m, 2 x CH2O), 5c (D2O; 75 MHz) 72.8, 72.0, 71.6, 71.0, 67.0, 63.0 
(overiapping CH2O), 37.6 (Me) 
m/z (ES) 295 (100 %, M + Na), v^ax (liquid film, cm"') 3442 (OH) 
5.4.19 N,N-dimethylammonium-N-ethylmaleimide-N-3, 6, 9-
trioxaundeca-11- octanyl methanesulphonate salt (36) 
Tetraethyleneglycol monomesylate (0.10 g, 0.39 mmol) was dissolved in a 
solution of iV'-(A', jV-dimethyl)ethylmaleimide (0.06 g, 1 eqv) in dry THF (3 mL) 
under argon. The mixture was subjected to microwave radiation (170 watt, 100 
psi) at 150 °C for 1 h. The mixture was allowed to reach room temperature and 
the THF was decanting o f f The brown solid was collected, washed with THF 
and dried with phosphorus pentoxide under a reduced pressure to give the title 
compound (0.052g, 30 %) as a brown solid/syrup. 
5H (D2O; 300 MHz) 2.41 ( I H , s, OH), 2.93 (6H, d, br, CH2N (CH3)2), 3.58 - 3. 
64 (4H, s, br, CH2N (CH3)2 CH2) 3.64 - 3.9 (14H, m, 6 x OCH2 and N (CH3)2 
CH2 CH2_N), 3.95 - 4.15 (2H, m, CH2.N (CH3)2), 6.3 (2H, s, CH= CH). 
6c (D2O; 75 MHz) 170.00 (C=0), 135.00,71.85, 69.56, 69.61(CH20), 
67.99(CH20H), 60.50 (CH2N+), 38.63 (CH3)2N+) and 25.16 (CH2NC=0). 
m/z(ES) 345.2 (100 % , M + ) , HRMS (+ES) C16H29N2O6: requires 345.2020 
found 345.2007. 
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5.4.20 2-Bromo-2-methylpropionyloxy-3, 6, 9 trioxaundecanyl-
11 -pyridinium salt (46) 
To a mixture of 1 l-hydroxy-3,6,9-trioxaundecanyloxy(2-bromo-2-methyl) 
propionate (350 mg, 1.023 mmol) and a suspension of freshly activated 
powdered sieves in dry dichloromethane (5 mL) was added pyridine (81 mg, 1.0 
eqv) at room temperature, and the mixture stirred for 1 h. The reaction was then 
cooled to 0 °C before adding trifluoromethanesulphonyl anhydride (0.207 mL, 
1.2 eqv) and left to stir for 6 h at 0 °C. The mixture was then washed with ice-
cold I M HCl, concentrated in vacuo and chromatographed (10 % to 90 % ethyl 
acetate / hexane eluent) to obtain the title compound (241 mg, 58 %) as a yellow 
oil. 
8H (CDCI3; 400 MHz) 1.96 (6H, s, C [CH3] 2Br), 3.52 - 3.8 (lOH, s, 5 x OCH2), 
4.0 (2H, m, OCH2CH20C=0), 4.36 (2H, m, OCH2CH20C=0), 4.82 (2H, m, 
OCH2CH2, ^%Pyr), 8.05 (2pH, t, J =7.19 Hz, pyr), 8.5 ( ly H, t, J = 7.88 Hz, 
pyridine), 9.02 (2aH, t, J = 5.8 Hz, pyr) 
8c (CDCI3; 100 MHz) 172.00 (C=0), 146.00, 128.00 ( C H , Ar), 70.80,69.86, 
69.92, 69.61 (CH2O), 65.59 CH2O CH2N+, 61.70 (CH2N*), 56.00 (C-Br) and 
31.00 (CMe2). m/z (ES) 404 / 406 (100 %, M + Na). 
HRMS (+ES) Ci7H27^^BrN05^ requires 404.1073 found 404.1086 
Ci7H27^'BrN05^ requires 406.1052 found 406.1044 
Vmax(liquid film, cm"') 2873 (CH), 1731(C=0). 
5.4.21 8-Hydroxy-3, 6-dioxaoctanyloxy (2-bromo-2-
methyl)propionate (37) 
A solution of triethyleneglycol (5.0 g) and triethylamine (1.8 mL, 16 mmol) in 
dichloromethane (30 mL) was stirred for 1 h at room temperature and cooled to 0 
°C. 2-Bromo-2-methylpropionyl bromide (2 mL, 3.72 g, 16 mmol) was added 
dropwise over a 15 min period. The reaction was stirred for a further 8 h at 0 °C. 
The reaction mixture was washed with dilute HCl (2 x 30 mL) and water (2 x 30 
mL), and the organic phase dried (Na2S04). Filtration and removal of the solvent 
in vacuo resulted in a crude product which was purified by flash chromatography 
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(50 % then 100 % ethyl acetate / hexane) to obtain the title compound (4.2 g, 70 
% ) . as a colourless oil. 
5H (CDCI3; 300 MHz) 1.95 (6H, s, C [CH3] 2Br), 3.69 - 3.79 (lOH, m, 5 x OCH2), 
4.29 (2H, m, CH20C=0) 
5c (CDCI3; 75 MHz) 171.9 (C=0), 72.5, 70.7, 70.4, 70, 69.0, 62.0 (CH2OH), 
61.6, 55.9 (C-Br), and 26.9 (Me). 
m/z (+ES) 321/323 (80%, M + Na), v^ax (liquid film, cm"') 3438 (OH), 
1735(C=0) 
5.4.22 11-Hydroxy-3, 6, 9-trioxaundecanyloxy (2-bromo-2-
methyl) propionate (38) 
A solution of tetraethylene glycol (6.0 g) in dichloromethane (30 mL) was 
reacted with 2-bromo-2-methylpropionyl bromide (2.0 mL, 3.72 g, 16 mmol) 
according to the method described above for 37 to obtain the title compound (4.5 
g, 76 %) as a colourless oil. 
5H (CDCI3; 200 MHz) 1.93 (6H, s, C [CH3] 2Br), 3.67 - 3.81 (14H, m, 7 x 
OCH2), 4.34 (2H, m, CH20C=0) 
5c (CDCI3; 100 MHz) 175 (C=0), 72.5, 70.9, 70.7, 70.4, 70, 68.8, 65.1(CH20), 
61.8 (CH2OH), 55.7(C-Br), 57.2 and 28.8 (Me), m/z (ES) 365/367 (M + Na). 
HRMS (+ES) C12H23 '^Br06 requires 365.0678 found 365.0588. 
Ci2H23^'Br06requires 367.0658 found 367.0510 
Vmax (liquid film, cm"') 3441 (OH),, 1735 (C=0). 
5.4.23 14-Hydroxy-3, 6, 9,12-tetraoxatetradecanyloxy (2-
bromo-2-methyl) propionate (39) 
A solution of pentaethylene glycol (5.0 g) in dichloromethane (30 mL) was 
reacted with 2- bromo-2- methylpropionyl bromide (2.0 mL, 3.72 g, 16 mmol) 
according to the method described above for 37 to give the title compound (5.8 g, 
95 %) as a colourless oil. 
180 
Compounds from Chapter 4 
5H (CDCI3; 400 MHz) 1.91 (6H, s, C [CH3] 281), 3.69 (18H, m, 9 x OCH2), 4.30 
(2H, m, CH20C=0) 
6c (CDCI3; 100 MHz) 172.0 (C=0), 73.2, 72.7, 70.9, 70.8, 70.7, 70.5, 68.9, 65.3, 
61.9 (CH2OH),, 56.0 (C-Br) and 28.0 (Me), m/z (+ES) 409 / 411 (80%, M + Na )^ 
HRMS (+ES) C,4H27 ^^ BrOvNa requires 409.0940 found 409.0847 
C14H27 ^ 'Br07Na requires 411.0920 found 411.0825 
vmax (liquid film, cm-') 3454 (OH), 1735(C=0) 
5.4.24 General method for methanesulphonates 
8- Methanesulphonyloxy -3, 6-dioxaoctanyloxy (2-broimo-
2-methyl) propionate (40) 
A solution of 8-hydroxy-3,6-dioxaoctanyloxy (2-bromo-2-methyl) propionate 
(1.2 g, 4.0 mmol) was stirred with methanesulphonyl chloride (0.81 mL, 4.8 
mmol, 1.2 eq) according to the method described below for 41 to give the title 
compound (1.2 g, 78 %) as a colourless oil. 
6H (CDCI3; 400 MHz) 1.94 (6H, s, C [CH3] iBr), 3.07 (3H, s, OSO2CH3), 3.47 
(4H, s, 2 X OCH2), 3.65 (2H, s, OCH2CH2OSO2CH3), 3.72 (2H, m, 
OCH2CH20C=0), 4.35 (2H, m, CH2OSO2CH3), 4.39 (2H, m, OCH2CH20C=0) 
6c (CDCI3; 100 MHz) 172 (C=0), 72, 69,68, 67(CH20), 65 (COSO2), 56 (C-Br), 
38 (S02Me) and 28 (Me).m/z (ES) 399 / 401 (M + Na) 
HRMS (+ES) C11H21 '^ BrOvSNa requires 399.0191 found 399.0093. 
C,iH2i '^ 'BrOvSNa requires 401.0171 found 401.0093. 
Vmax (Hquid film, cm'') 1728 (C-0) 
5.4.25 11-Methanesulphonyloxy-3, 6, 9-trioxaundecanyloxy (2-
bromo-2-methyl)propionate (41) 
ll-Hydroxy-3, 6, 9-trioxaundecanyloxy(2-bromo-2-methyl) propionate (1.0 g, 
3.0 mmol) in dichloromethane (25 mL) was stirred with N, N-
diisopropylethylamine (2.0 mL, 1.48 g, 1.2 eq) for 1 h at room temperature. The 
mixture was then cooled to 0 °C before the dropwise addition of 
methanesulphonyl chloride (1.0 mL, 1.48 g, 1.2 eq) with stirring. The reaction 
was stirred at 0°C for a fiirther 5 h and at room temperature for 1 h under a 
181 
Compounds from Chapter 4 
nitrogen atmosphere. Upon completion of the reaction (TLC, RFnew= 0.9, 50 % 
ethyl acetate/hexane, KMn04), the mixture was washed with I M HCl (3 x 25 
mL), brine (2 x 25 mL) and dried with MgS04. Removal and concentration of the 
organic phase resulted in a crude product, which was purified by flash 
chromatography (30 % ethyl acetate/hexane) to give the title compound (0.95 g, 
78 %) as a colourless oil. 
5H (CDCI3; 500 MHz) 1.94 (6H, s, C [CH3] aBr), 3.05 (3H, s, OSO2CH3), 3.65 -
3.70 (8H, m, 4 X OCH2), 3.64 (2H, s, OCH2CH2OSO2CH3), 3.68 (2H, m, 
OCH2CH20C=0), 4.35 (2H, m, CH2OSO2CH3), 4.39 (2H, m, OCH2CH20C=0) 
8c (CDCI3; 125 MHz) 172 (C=0), 72,69, 68 (CH2O), 65 (COSO2), 56 (C-Br), 38 
(S02Me) and 28 (Me), m/z (ES) 443 /445 (M + Na) 
HRMS(+ES) C,3H25^ ^Br OgS requires 443.0454 found 443.0342. 
Ci3H25 '^Br OgS requires 445.0433 found 445.0241 
Vmax (liquid film, cm'') 1732 (C=0), 1357 (S=0), 1173 (S=0). 
5.4.26 14-Methanesulphonyloxy-3, 6, 9,12-
tetraoxatetradecanyloxy (2-bromo-2-
methyl)propionate.(42) 
14-Hydroxy-3, 6, 9, 12-tetraoxatetradecanyloxy(2-bromo-2-methyl) propionate 
(1.0 g, 2.6 mmol) was stirred with methanesulphonyl chloride (1.2 eq), according 
to the method for 1 l-Methanesulphonyloxy-3, 6, 9-trioxaundecanyloxy (2-
bromo-2-methyl) propionate, purification by flash chromatography (30 % ethyl 
acetate/hexane)to give the title compound (0.80 g, 70 %) as a colourless oil. 
6H (CDCI3; 500 MHz) 1.93 (6H, s, C [CH3]2Br), 3.07 (3H, s, OSO2CH3), 3.62 -
3.70 (12H, m, 6 X OCH2), 3.64 (2H, s, OCH2CH2OSO2CH3), 3.78 (2H, m, 
OCH2CH20C=0), 4.35 (2H, m, CH2OSO2CH3), 4.39 (2H, m, OCH2CH20C=0) 
8c (CDCI3; 125 MHz) 172.0 (C=0), 71.0, 70.8, 70.5, 70.0, 69.5 (CH2O), 65.0 
(COSO2), 56.0 (C-Br), 38.0 (SOjMe) and 31.0 (Me), 
m/z (ES 464 / 466 (70 %, M+) 
HRMS (+ES) CisHzg'^ Br OgSNa requires 487.0716 found 487.0609 
Ci5H29 '^Br 09SNa requires 489.0695 found 489.0572. 
^ m a x (liquid film, cm"') 2870 (CH), 1742 (C=0), 1352 (S=0), 1173 (S=0). 
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5.4.27 General method for trifluoromethanesulphonates 
8-Trifluoromethanesulphonyloxy-3, 6,-dioxaoctanyloxy(2-
bromo-2-methyl)propionate (43) 
A solution of trifluoromethanesulphonyl chloride (0.56 g, 2 eq) in 
dichloromethane (10 mL) at 0 °C was cannulated over a period of 0.5 h into a 
solution of 8- hydroxy -3,6-dioxaoctanyloxy(2-bromo-2-methyl) propionate (300 
mg, 0.1 mmol) and pyridine (80 mg, 1 eq) suspended over activated powdered 
sieves in dichloromethane (10 mL) at 0 °C. The mixture was then stirred at 0 °C 
for an additional 1.5 h under a nitrogen atmosphere. The reaction mixture was 
then filtered through a cotton wool plug then a celite plug before being washed 
with ice-cold water (2 x 20 mL), dried (MgS04) to give the title compound as a 
brown syrup (412 mg, 95 %). The compound was used without further 
purification. 
5H (CDCI3; 400 MHz) 1.94 (6H, s, C [CH3] 2Br), 3.66 (4H, s, 2 xOCH2), 3.71 
(2H, m, OCH2CH20C=0), 3.82 (2H, m, OCH2CH2OSO2CF3), 4.36 (2H, m, 
0CH2CH20C=O), 4.6 (2H, m, CH2OSO2CF3 
5c (CDCI3; 100 MHz) 172.0 (C=0), 76.0, 70.4, 70.2, 69.0, 67.0, 62.0 (CH2O), 
56.0 (C-Br) and 31.0 (Me) 
8F (CDCI3; 188 MHz) -75.08 (3F, s, OSO2CF3) 
m/z (ES) 453/455 (10 %, M + Na), 335/337(65 %), 193/195 (100 %). 
Vmax (Hquid film, cm"') 2932 (CH), 1750 (C=0) 
5.4.28 11-Trlfluoromethanesulphonyloxy-3, 6, 9 -
trioxaundecanyloxy (2-bromo-2-methyl)propionate (44) 
1 l-Hydroxy-3, 6,9-trioxaundecanyloxy(2-bromo-2-methyl) propionate (0.20 g, 
0.59 mmol) was reacted with trifluoromethanesulphonyl chloride (0.20 g, 0.32 
mL, 2 eq) according to the method described above for 43 to give the title 
compound (0.31 mg, 63 %) as a brown syrup. 
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6H (CDCI3; 400 MHz) 1.94 (6H, s, C [CH3] 2 Br), 3.66 (8H, s, 4 x OCH2), 3.71 
(2H, m, OCH2CH20C=0), 3.82 (2H, m, OCH2CH2OSO2CF3), 4.36 (2H, m, 
OCH2CH20C=0), 4.6 (2H, m, CH2OSO2CF3) 
6c (CDCI3; 100 MHz) 172.0 (C=0), 76.0, 70.6, 70.4, 70.2, 70.1, 69.0, 67.0, 62.0 
(CH2O), 56.0 (C-Br) and 31.0 (Me) 
5F (CDCI3; 188 MHz) -75.02 (3F, s, OSO2CF3) 
m/z (ES+) 404/406 (100%, M^ - CF3) 
Vmax (liquid film, cm"') 1750 (C=0). 
5.4.29 14-Trifluoroethanesulphonyloxy-3, 6, 9,12-
tetraoxatetradecanyloxy (2-bromo-2-methyl)propionate 
(45) 
14-Hydroxy-3, 6, 9, 12-tetraoxatetradecanyloxy(2-bromo-2-methyl) propionate 
(0.49 g, 1.27 mmol) was reacted with trifluoromethanesulphonyl chloride (0.43 
g, 0.68 mL, 2 eq) according to the method described above for 43 to give the title 
compound (0.30 g, 45 %) as a brown syrup. 
5H (CDCI3; 400 MHz) 1.94 (6H, s, C [CH3] 2 Br), 3.66 (12H, s, 6 x OCH2), 3.71 
(2H, m, OCH2CH20C=0), 3.82 (2H, m, OCH2CH2OSO2CF3), 4.36 (2H, m, 
OCH2CH20C=0), 4.6 (2H, m, CH2OSO2CF3) 
6c(CDCl3; 100 MHz) 172.0 (C=0), 73.0, 72.0, 70.9, 70.8, 70.7, 70.5, 69.0, 65.0, 
62.0 (CH2O), 56.0 (C-Br) and 31.5 (Me). 
6F (CDCI3; 188 MHz) -75.09 (3F, s, OSO2CF3) 
Vmax (liquid film, cm"') 1754 (C=0) 
5.4.30 N, A/-dimethylammonium-A/-3,6-dioxaoctanyD (8-[2-
bromo-2-methylpropionyloxy])A/-ethylmaleimide 
trifluoromethanesulphonate.(1) 
A solution of2-{N, dimethylamino)ethylmaleimide (70 mg, 0.417 mmol) and 
8-trifluoromethanesulphonyloxy-3,6,-dioxaoctanyloxy (2-bromo-2-methyl) 
propionate (200 mg, 1.12 eqv) in dry THF (2 mL) was stirred for 48 h under a 
nitrogen atmosphere at room temperature. The reaction mixture was then filtered 
through a cotton wool plug and the plug washed with THF (20 mL). The organic 
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washings were combined and concentrated under reduced pressure to produce a 
brown syrup. The syrup was further extracted with cold ethyl acetate. The ethyl 
acetate extracts were evaporated and dried over phosphorus pentoxide in vacuo 
for 8 h to give the product (85 mg, 43 %) as a brown syrup. 
6H (CDCI3; 400 MHz) 1.92 (6H, s, C [CH3]2Br) 3.30 (6H, s, N (^3)2), 3,64 
(4H, s, 2 X OCH2), 3.74 - 3.80 (6H, m, NCH2CH2N (CH3) 2 CH2CH2.O and 
OCH2CH20C=0), 3.84-4.15 (4H, m, NCH2CH2.N (CH3) 2 CH2CH2O), 4.3 (2H, 
m, 0CH2CI^0C=0), 6.8 (2H, s, CH = CH). 
8c (CDCI3; 100 MHz) 172.6,172, 170 (C=0), 135 (C=C), 72, 72.3, 71, 65 
(CH2O),, 65.2 (CH2N+), 56 (C-Br), 44 (NMe), 32 (CH2N) and 31 (C-Me). 
m/z (ES) 449 / 451 (100 %, M + Na*) 
HRMS (+ES) C,8H3o^VN206Na requires 449.1287 found 449.1320 
Ci8H3o '^BrN206Na requires 451.1267 found 451.1318. 
Vmax (liquid film, cm"') 1716 (C=0). 
5.4.31 N,N-dimethylammonium-N-3, 6, 9 -trioxaundecanyl (11 -
[2-bromo-2-methylpropionyloxy])N-ethylmaleimide 
trifluoromethanesulphonate.(2) 
11 -Trifluoromethanesulphonyloxy-3,6,9-trioxaundecanyloxy(2-bromo-2-methyl) 
propionate (57 mg, 1.1 eq) was reacted with 2-(N, N dimethylamino) 
ethylmaleimide (19 mg, 0.11 mmol) in dry THF (2 mL) according to the method 
described above for 1 to give the title compound (47.5 mg, 82 %) as a brovra 
syrup. 
6H (CDCI3; 400 MHz) 1.92 (6H, s, C [CH3] 2 Br), 2.35 (6H, s, N (CH3) 2), 3.64 -
3.8 (8H, m, 4 x OCH2), 3.73 - 3.81 (6H, m, NCH2CH2N (CH3) 2 CH2CH2.O and 
OCH2CH20C=0), 3.95 - 4.15 (4H, m, CH2_N (CH3)2 CH2CH2O), 4.37 (2H, m, 
OCH2CH20C=0), 6.69 (2H, s, CH = CH). 
8c (CDCI3; 100 MHz) 171.01, 170.31, 170.28 (C=0), 134.88, 134.46 (C=C), 
70.96, 70.89, 70.62, 68.97, 67.3, 65.36 (CH2O), 65.25 (CH2N+), 56.95 (C-Br), 
45.24 (NMe), 35.38 (CH2N), 30.97 and 30.85 (C-Me). 
m/z (ES) 493 / 495 (15 %, M*), 405 / 407 (100 %) 
-vsrax(liquid film, cm"') 1712 (C=0) 
185 
Compounds from Chapter 4 
5.4.32 Peptide Synthesis and IVIodification with Initiators 
General methods for the preparation of the peptide/protein 
initiator complex 
5.4.32.1 Peptide Synthesis 
F m o c N H - G R G D S P A S - R E S I N 
Was performed on an Advanced ChemTech peptide synthesiser (36 wells) using 
Fmoc synthesis procedure. The resin, TentaGel-S RAM Fmoc (0.2-0.4 mmol/g 
substitution), Fmoc-protected amino acids and HOBt and PyBOP used to 
facilitate the coupling reactions, were purchased from Advanced ChemTech 
(KY) and used as received. The resin-bound peptide was isolated first treated 
with 20% piperidine/ DMF mixture for 4 h at room temperature to remove the 
terminal Fmoc protected amine. The resin was then washed with DMF (6x15 
mL) and dichloromethane (6x15 mL). The cleavage of solid supported peptide 
for analysis was evoked by treating with 95% TFA (5% TIS and water) for 4 
hours with constant but gentle vortexing under a nitrogen atmosphere. The resin 
was filtered and the filtrate containing the peptide concentrated and the peptide 
precipitated into ice-cold ether at 4°C overnight. The precipitate was analysed by 
TOF MS (+ES) spectroscopy. 
TOF MS (+ES) The parent peptide m/z 745 (100%, M^) 
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5.4.32.2 Preparation of analogue peptide modified with initiator. 
0 
Initiator 3.3 
Init iator—GRGDSP AS—Resin 
The fi-ee (-NH2) was first confirmed by positive ninhydrin test (blue-purple 
colouration) before the activated initiator, N-Succinimidyl 17-(2-bromo-2-
methylpropionyloxy)-3, 6, 9, 12, 15-pentaoxaheptadecanoate 3.3 (Compound 3, 
Chapter 3) (62 mg, 4 eq) was vortexed with resin-bound peptide (0.1 g, 0.029 
mMol, ~30% NH2fiinctionality) and N,N-diisopropylethylamine (0.020 mL, 15.0 
mg, 4 eq) in dry DMF (4 mL, HPLC grade) at room temperature for 6 h under an 
atmosphere of argon. The resin was then washed with DMF (6 x 15 mL), 
dichloromethane (6x15 mL) and dried in vacuo. 
5.4.32.3 The cleavage reaction 
Ini t iator—GRGDSPAS 
The resin was cleaved fi-om the peptide-initiator complex by stirring with a 
mixture of trifluoroacetic acid (TFA, 95%), triisopropylsilane (TIS, 2.5%) and 
water (2.5%) for 4 hours at room temperature under a nitrogen atmosphere. The 
solution was filtered and washed with neat TFA ( 3 x 3 mL) and the resulting 
solution concentrated in vacuo before the peptide was precipitated into ice-cold 
ether at 4°C overnight, to obtain the complex in 20% (7 mg over three steps) 
yield. 
TOF MS (+ES) m/z 1171/1173 (55%, M^). 
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5.4.33 HSA modification with ammonium maleimide salt 
5.4.33.1 Human Serum Albumin (Unmodified) 
Human Serum Albumin (0.5 mL, 2.6 mM) was treated with ethanethiol (20 mM) 
to stir under a nitrogen atmosphere at 4 °C for 24 h in phosphate buffer (pH 7.4, 
200 mM). The mixture was purified by gel filtration on sephadex PD-10 against 
a phosphate buffer eluent. HSA thus prepared had a concentration of 10-50 |j,M 
and typically 0.6 - 0.8 SH/HSA. By observing Ellman's anion''^, the 
concentration of HSA was determined from the absorbance at 412 nm (e =13,600 
M"', cm'') assuming a molecular weight of 66,440 Da .^ 
TOP MS (+ES) expected m/z 1331, found m/z 1328 (48%, M + 50H) 50+ 
• 
l O O 
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5.4.33.2 Human Serum Albumin (modified) 
A solution of A';A^-dimethylammonium-N-3,6-dioxaoctanyl(8-[2-bromo-2-
methyl-propionyloxy] )A'^ -ethylmaleimide trifluoromethanesulphonate 
(1.4) (compound 1, Chapter 4, 4 eqv., 2.6 mM) in phosphate buffer (pH 7.4, 200 
mM) was gently vortexed with HSA (2.6 mM.) under a nitrogen atmosphere at 
room temperature. Upon completion (UV analysis of Ellman's anion) the 
reaction mixture was treated with gel filtration on sephadex PD-10 at room 
temperature. 
TOF MS (+ES) expected m/z 1423, found m/z 1425 (100%, M + 47H) 47+ 
ISIS ? 
Wi ' igg:---" laoo t4bo moo 1000 itstoo ssloo mm 
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